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Abstract 
Central hemodynamic evaluation during exercise testing provides critical information for 
the clinical classification of reduced (HFrEF) or preserved ejection fraction (HFpEF) 
heart failure (HF) patients. Recent and encouraging observations suggest that non-
traditional indices of central hemodynamics can robustly describe cardiac function and 
pulmonary vascular hemodynamics in healthy individuals and in HF. Therefore, because 
of emerging evidence in favor of non-traditional indices to describe central 
hemodynamics in HF, it is unclear what index or indices best describe cardiac function 
and the heart–lung hemodynamic interaction in HF. Moreover, contributing to the 
complexity of the pathophysiology underlying the HF syndrome, it is becoming more 
recognized that neural mechanisms originating within skeletal muscle likely contribute to 
impaired cardiovascular function and symptoms of these patients. However, it remains 
unclear what role this neural feedback from skeletal muscle ergoreceptors has in the 
impaired central hemodynamic response frequently observed during exercise in HF. 
Therefore, the aims of this dissertation focused on investigating factors to better 
understand the central hemodynamic response to exercise in HF. In this series of studies 
we observed that non-traditional measurement of cardiac and pulmonary hemodynamics 
could describe the central hemodynamic response to exercise in HF. Also, experimental 
manipulation of neural feedback from skeletal muscle ergoreceptors resulted in 
observations which suggest pulmonary hemodynamics could be influenced by this 
mechanism, whereas cardiac function may not be similarly influenced by this pathway in 
HFrEF. Equally important and relevant to both clinical and research settings, it was 
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observed that non-invasive measurement of stroke volume at peak exercise could be 
reliably estimated using echocardiography, acetylene rebreathe, and oxygen pulse in HF.   
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Chapter 1  
Introduction 
Chronic heart failure (HF) is associated with an estimated $34 billion healthcare cost in 
the United States and accounts for 55,000 deaths per year as a primary cause and 
contributes to more than 280,000 deaths annually (Heidenreich et al., 2011; Roger et al., 
2012). Heart failure contributes to dysfunction of organ systems, which include renal, 
pulmonary, skeletal muscle, vascular, and nervous systems; and, in parallel, dysfunction 
of these organs further contributes to the deterioration of health, increasing HF- and non-
HF related hospitalizations, and augmenting the risk for premature mortality (Dickstein et 
al., 2008; Forman et al., 2004; Haldeman, Croft, Giles, & Rashidee, 1999; Komajda et al., 
2011; Lee et al., 2003; Paulus et al., 2007; Roger et al., 2012; Vasan et al., 1999). 
The etiology of HF is commonly the result of an underlying myocardial and/or 
cardiovascular disease, of which, coronary artery disease and hypertension together 
account for an estimated 70–80% of cases (Dickstein et al., 2008; Fox et al., 2001; Paulus 
et al., 2007; Roger et al., 2012). Despite the current understanding of HF, diagnosis and 
prognosis of HF are not discernable by a single methodology or approach. Confirmation 
of HF and therapeutic regimen are reliant on clinical judgment based on a combination of 
medical and familial history, overt signs and symptoms, and objective tests (Dickstein et 
al., 2008; Paulus et al., 2007).  
Despite the heterogeneity in HF phenotypes, common to the clinical diagnosis of systolic 
HF, frequently referred to as reduced ejection fraction HF (HFrEF), is left ventricular 
(LV) dysfunction which is closely associated with an abnormal LV ejection fraction 
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percentage (EF%) typically <35–40% (Dickstein et al., 2008). In contrast, diastolic HF 
which is commonly referred to as HF with preserved ejection fraction (HFpEF) 
demonstrates a clinical phenotype with normal EF% with characteristic impaired LV 
relaxation, high LV stiffness, and high LV- and- left atrial pressures (Paulus et al., 2007). 
However, most importantly, HFpEF is now estimated to account for nearly 50% of HF 
cases while the mortality risk is comparable to HFrEF (Paulus et al., 2007; Vasan et al., 
1999). 
Despite differentiating phenotypic characteristics between HFrEF and HFpEF, diagnoses 
are not mutually exclusive. Individuals with HFrEF or HFpEF frequently share similar 
non-cardiac specific symptoms and signs, which include dyspnea, fatigue, fluid retention, 
or exertional intolerance (Aronson, Eitan, Dragu, & Burger, 2011; Dickstein et al., 2008; 
Ghio et al., 2001; McDonagh et al., 1997; Paulus et al., 2007; Roger et al., 2012; Rubin & 
Brown, 1984). Cardiac-specific signs of HF including measures of atypical structure and 
function closely relate with hemodynamic and pressure abnormalities in both HFrEF and 
HFpEF (Dickstein et al., 2008; Grothues et al., 2002; Paulus et al., 2007). In particular, 
low cardiac output (Q) and stroke volume (SV) at rest are common in both HFrEF and 
HFpEF despite contrasting EF% between conditions. Therefore, clinical assessment of 
cardiac as well as non-cardiac specific factors at rest are routinely used to assist in 
identifying the presence of HF, describing syndrome severity, and predicting prognosis in 
patients (Dickstein et al., 2008; Olson, Denzer, Sinnett, Wilson, & Johnson, 2013; Paulus 
et al., 2007).  
Scientists now commonly recognize that despite the importance of resting clinical 
evaluation of HF at rest, patients demonstrate exacerbation of both signs and symptoms 
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during physical activity (Dickstein et al., 2008; Kao et al., 1997; Mancini et al., 1991; 
Osada et al., 1998; Sullivan, Higginbotham, & Cobb, 1988; Weber & Janicki, 1985). 
Moreover, and perhaps most importantly, information attained from objective 
measurement of cardiac function during clinical exercise testing has been closely 
associated with robust prognostic power in HF (Cohn et al., 1993; Guazzi, Reina, 
Tumminello, & Guazzi, 2005; Lang, Agostoni, & Mancini, 2007; Lang, Karlin, Haythe, 
Lim, & Mancini, 2009; Lavie, Milani, & Mehra, 2004; Mancini et al., 1991; Williams, 
Jackson, et al., 2005). Thus, because of the importance of clinical exercise testing and 
assessing cardiac hemodynamics for evaluating syndrome severity and prognosis in HF, 
this dissertation will address the following gaps in the literature to improve our 
understanding of the need for increased emphasis of exercise assessment of central 
hemodynamics for the clinical classification of HF.  
Project 1: To study the technical factors which potentially influence the non-invasive 
measurement of cardiac hemodynamics in HFpEF; and, identify the extent of 
relationships between measurements of SV during exercise using three non-invasive and 
readily available techniques. We will use linear regression to study relationships between 
non-invasive echocardiography (ECHO), acetylene rebreathe, and oxygen pulse 
(O2pulse) for the assessment of stroke volume during exercise in HFpEF. In addition to 
coefficient of determination (R2), we will assess slopes and intercepts of linear 
regressions in order to describe relationships and potential biases associated with each of 
these techniques. 
H1: We hypothesized that acetylene rebreathe and O2pulse would compare favorably to 
ECHO when measuring SV at rest and at peak exercise in HFpEF.  
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H2: We hypothesized that gas transfer capacity within lungs would not directly influence 
SV measured using acetylene rebreathe at peak exercise in HFpEF. 
Project 2: To study the influence of metabolite-sensitive group IV neural feedback 
associated with locomotor muscle on central hemodynamics in HFrEF. We will study in 
this cross-over experiment both circulatory power (CircP) and pulmonary vascular 
capacitance (GXCAP) responses to stimulation of the metaboreflex immediately following 
submaximal locomotor exercise in comparison to a normal recovery condition in HFrEF. 
H1: We hypothesized that activation of the skeletal muscle metaboreflex would attenuate 
both CircP and GXCAP in HFrEF. 
Project 3: To study the influence of neural feedback from group III/IV locomotor 
muscles during submaximal exercise on central hemodynamics in HFrEF. This placebo-
controlled cross-over study will assess the influence of inhibiting locomotor muscle 
group III/IV neural feedback with lower lumbar intrathecal fentanyl injections on CircP 
and GXCAP in comparison to an exercise condition with placebo inhibition in HFrEF. 
H1: We hypothesized that selective μ-opioid blockade of neural feedback from group 
III/IV afferents using intrathecal fentanyl at the lower-lumbar level during submaximal 
constant-load exercise would be influential in increasing CircP and GXCAP in HFrEF. 
This dissertation begins with Chapter Two and an introduction to the commonly used 
New York Heart Association (NYHA) classification system in HF. Following, we present 
an in-depth review of the literature focusing on central hemodynamics, which includes 
the assessment of traditional measurements of central at rest and during exercise in HF. 
Next, we will introduce newer non-traditional indices of central hemodynamics and 
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discuss outcomes of both resting and exercise evaluation in HF. Finally, we will discuss 
the clinical implications of using central hemodynamic assessment during exercise in HF.  
Chapter Three of this dissertation will describe and interpret the central hemodynamic 
response to exercise in HF using observations from the three dissertation projects.  
Chapter Four will discuss in detail the observations, overall interpretations, and clinical 
implications from the three projects comprising the body of this dissertation. 
Chapter Five will provide a brief discussion of the potential limitations which may have 
influenced the interpretability of the current findings.  
Chapter Six will detail future directions for this area of research, as well as providing 
overall concluding remarks which together lay the framework for advancing the 
understanding of central hemodynamics in HF.     
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Chapter 2  
Background and literature review 
2.1 Introduction 
The clinical classification of HF commonly calls into use the NYHA functional 
classification system which is mainly derived from measures of symptom severity and 
perception of exercise tolerance (Broek et al., 1992; Dickstein et al., 2008; Scrutenid et 
al., 1994). Heart failure patients are typically stratified into one of four (I-IV) classes 
based on a comprehensive examination of both subjective and objective factors 
administered by the clinician. Class I HF patients are suggested to have the mildest form 
of HF while demonstrating no symptoms at rest or functional limitations. In contrast, the 
progressive increase in NYHA class number corresponds with HF patients who 
demonstrate more frequent and severe occurrences of the signs and symptoms during 
exertion. Upon categorization into NYHA class IV, HF patients typically demonstrate 
symptoms at rest in addition to severe functional limitations. However, in addition to 
being descriptive of syndrome severity, objective factors which are not considered in the 
NYHA classification of patients have demonstrated the capability to closely associate 
with prognosis in HF (Broek et al., 1992; Lang et al., 2009; Roul, Germain, & Bareiss, 
1998; Roul et al., 1995; Scrutenid et al., 1994). 
Individuals who are suspected of having HF, perhaps because of familial history and/or 
concurrent comorbidities (Table 1), are routinely recommended for comprehensive 
clinical evaluation, which includes examination of symptoms related to dyspnea and 
fatigue in addition to objective outcomes. Although valuable in the clinical setting, the 
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reliability of the NYHA classification system is highly dependent on both the outcomes 
of clinical testing and judgement of the clinician. Also, because symptoms of HF have 
been observed to correlate poorly with the magnitude of cardiac dysfunction, it is critical 
that clinical evaluation of patients includes objective assessment of cardiac function 
(Stevenson & Perloff, 1989). Overall, however, combined subjective and objective 
outcomes are closely involved in assessing parameters related to signs or symptoms of 
HF which frequently mirror cardiovascular system dysfunction (Lipkin, Canepa-Anson, 
Stephens, & Poole-Wilson, 1986; Lipkin & Poole-Wilson, 1986; Lipkin, Scriven, Crake, 
& Poole-Wilson, 1986; Spiteri, Cook, & Clarke, 1988). 
 
One of the most common indices to support the diagnosis of HF is abnormal cardiac 
structure and function that may include a low resting EF%, which is specific to HFrEF. 
Although, despite a normal EF%, there are several distinct cardiac abnormalities which 
can be useful in the diagnosis of HFpEF (Table 2). 
Table 1. Common causes of heart failure 
Etiology 
Coronary artery disease* 
Hypertensive heart disease/aortic stenosis* 
Myocardial infarction 
Dilated cardiomyopathy/myocarditis 
Hypertrophic cardiomyopathy 
Incessant tachycardia 
Cor pulmonale 
Pericardial effusion/tamponade 
*Combined to account for the etiology in ~ 70 – 80% of cases (adapted from Dickstein et al., 
2008; Fox et al., 2001; Paulus et al., 2007; Roger et al., 2012) 
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Equally important in the clinical classification of HF are non-cardiac hemodynamic 
specific signs and symptoms (Table 3). The evaluation of non-cardiac hemodynamic 
specific signs and symptoms of HF enables the clinician to make judgements based on 
both subjective and objective measures. For example, dyspnea and fatigue are commonly 
recognized subjective measures that are well-regarded as valuable measures in the 
clinical classification of HFpEF and HFrEF (Remes, MlEttinen, Reunanen, & Pyörälä, 
1991). In contrast, measurements related to ventilatory function and cardiac structure for 
example, which can be measured via objective data recording, also demonstrate clinical 
value in the evaluation of HF (Chua et al., 1997; Cohn et al., 1993; Corra et al., 2002; 
Francis et al., 2000). 
Table 2. Cardiac structure and function abnormalities common in heart failure 
Systolic Heart Failure Diastolic Heart Failure 
Ejection fraction % <35 – 40% Ejection fraction % >50% 
Low cardiac output Low cardiac output 
Eccentric hypertrophy Concentric hypertrophy 
High left ventricular filling pressures  Impaired left ventricular relaxation  
Deceleration time <115 – 150 ms Time constant of relaxation >48 ms 
E/E’ >15 High left ventricular filling pressure  
High ventricular diameters E/E’ >15 
End-diastolic >55 – 60 mm Left ventricular end-diastolic pressure >16 mm Hg 
End-systolic >45 mm Left atrial volume >32 – 40 mL/m2 
Atrial fibrillation Atrial fibrillation 
Left atrial diameter >40 mm Pulmonary capillary wedge pressure > 12 mm Hg 
Global or regional loss of left ventricular function Global or regional loss of left ventricular function 
Structure and function thresholds were determined with echocardiography in most cases. ms, milliseconds; 
mm, millimeters; mm Hg, millimeters mercury; mL, milliliters; m, meters (adapted from Dickstein et al., 
2008; Komajda et al., 2011; Paulus et al., 2007; Roger et al., 2012) 
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In addition to clinical assessment of HF at rest, it is becoming more common to include 
an evaluation of many of the indices listed in Tables 2 and 3 during exercise to improve 
the strength of association between signs, symptoms, and severity with prognosis in HF. 
The emergence of cardiopulmonary exercise testing in HF has produced an ample body 
of evidence which suggests that ventilatory function and gas-exchange responses during 
exercise may be strongly indicative of syndrome severity and prognosis in HF (Chua et 
al., 1997; Francis et al., 2000; Weber & Janicki, 1985; Weber, Kinasewitz, Janicki, & 
Fishman, 1982). The value of cardiopulmonary outcomes during exercise testing are 
important foremost because of their associations with prognosis in HF, but also because 
cardiopulmonary testing can be performed routinely, non-invasively, and with little risk 
to the individual (Chua et al., 1997; Cohn et al., 1993; Corra et al., 2002; Francis et al., 
2000). 
Table 3. Non-cardiac hemodynamic specific symptoms and signs common in heart failure 
Symptoms Signs 
Dyspnea at rest or exercise Fluid retention  
Fatigue Pulmonary edema and/or 
Exercise intolerance Peripheral edema 
Peak oxygen consumption <18 mL/kg/min Raised jugular venous pressure 
6-minute walk test <300 m Cachexia 
Nausea Hypertension (pulmonary/peripheral) 
Confusion Impaired functional sympatholysis 
Erectile dysfunction Left ventricular hypertrophy 
Persistent coughing or wheezing Wall thickness >11 – 12 mm 
 Ventilatory inefficiency 
 VE/VCO2 slope >34 
 Tachypnea 
 Tachycardia 
 Atrial fibrillation 
 High natriuretic peptide levels 
 BNP >400 pg/mL 
 NT-proBNP >2000 pg/mL 
 Dysrhythmia on electrocardiogram 
 QRS >120 ms 
mL, milliliters; kg, kilogram; min, minute; m, meters; mm, millimeters; BNP, brain natriuretic peptide; pg, 
picograms; NT-proBNP, N-terminal pro b-type natriuretic peptide; ms, milliseconds (adapted from Dickstein 
et al., 2008; Komajda et al., 2011; Paulus et al., 2007; Roger et al., 2012). 
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The information attained during cardiopulmonary exercise testing in HF and subsequent 
interpretation is commonly cross-referenced with the Weber-Janicki Classification 
system, which assesses functional impairment based on objective physiological responses 
during incremental treadmill testing in HF (Weber & Janicki, 1985; Weber et al., 1982). 
The Weber-Janicki Classification system for HF patients relies primarily on 
measurements of peak oxygen uptake (VO2peak), VO2 at anaerobic threshold, and peak 
cardiac index (QI) during treadmill exercise testing. As such, stratification of HF severity 
considers specific thresholds for all three indices with the resultant assessment of 
syndrome severity ranging from none/mild (class A)- to- very severe (class E) (Weber & 
Janicki, 1985; Weber et al., 1982).  
Despite the valuable information garnered from ventilatory and gas-exchange responses 
during exercise testing in HF, encouraging observations from notable studies which 
examined cardiac hemodynamic responses during exercise in HF suggest that exercise 
assessment of cardiac hemodynamics may be the strongest indicators of syndrome 
severity and prognosis in these patients (Chua et al., 1997; Francis et al., 2000; Lang et 
al., 2009; Weber & Janicki, 1985; Weber et al., 1982; Williams, Jackson, et al., 2005; 
Williams et al., 2001). Several observations suggest that cardiac hemodynamic 
assessment via non-invasive techniques may provide more robust clinical value compared 
to more traditional outcomes such as ventilatory responses (Lang et al., 2009; Williams, 
Jackson, et al., 2005; Williams et al., 2001). Moreover, a growing body of evidence 
suggests that non-traditional indices of cardiac hemodynamics may add value to cardiac 
hemodynamic measurements beyond traditional assessment of Q and SV (Lang et al., 
2009; Williams, Jackson, et al., 2005; Williams et al., 2001). However, to date, the body 
11 
 
of evidence supporting the use of non-traditional indices of cardiac hemodynamics during 
exercise for augmenting the strength of the clinical classification of HF is small in 
number. Although, observations thus far suggest that indices, which include cardiac 
power (CP), CircP, O2pulse, and/or GXCAP warrant further examination in the context of 
exercise testing for augmentation of the clinical classification of HF (Cohen-Solal et al., 
2002; Lang et al., 2009; Roul et al., 1995; Taylor, Olson, Chul Ho, Maccarter, & 
Johnson, 2013; Williams, Jackson, et al., 2005),           
2.1.1 Overview of traditional and non-traditional central hemodynamics 
The heart is a four chamber pumping organ that has a primary function to continuously 
match the delivery of nutrients and gases with the transient metabolic demands of the 
cardiovascular system. As an integral component of the cardiovascular system, the heart 
receives and then expels blood at high volumes (EF% ~ 50–75%) into the circulation in a 
rhythmic manner.  
Integrated with the heart both in proximity and functional purposes, the pulmonary 
circulation serves to deliver deoxygenated blood received by the right side of the heart to 
gas-exchange sites at the alveoli-pulmonary capillary membrane barrier where blood can 
be oxygenated and then transported to the left side of the heart to be propelled to the 
systemic circulation. Propulsion of oxygenated blood toward metabolically active tissue 
(e.g. skeletal and smooth muscle, kidneys, neural) requires a contrasting degree of 
vascular structure, tone, and distensibility of the peripheral branch of the circulation in 
comparison to the vasculature comprising the pulmonary circulation since pulmonary 
vasculature receives the entire Q of the RV and does not need to distribute blood over 
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long distances or multiple organ systems (Hughes, Glazier, Maloney, & West, 1968; 
Permutt, Bromberger-Barnea, & Bane, 1962; West, Dollery, & Naimark, 1964).  
The pulmonary vasculature has thin walls with high distensibility and develops on 
average markedly less pressure (~20 millimeters of mercury [mm Hg]; mean pulmonary 
arterial pressure (mPAP) ~15 mm Hg, systolic/diastolic pulmonary arterial pressure ~ 
25/8 mm Hg) compared to that of the thicker walled peripheral vasculature which is 
purposefully structured for less distensibility and averages nearly five times the pressure 
of the pulmonary circulation (~100 mm Hg; 120/80 mm Hg systolic/diastolic) (Galie et 
al., 2009; Simonneau et al., 2009). Because of differences in pulmonary and peripheral 
vascular structure and function, adjustments in Q can differentially influence marked 
changes in pulmonary versus peripheral circulatory hemodynamics and pressures.          
Hemodynamic homeostasis of the cardiovascular system depends on the continuous 
maintenance of blood flow and pressure gradients which facilitate circulation of blood 
toward (veins) and from (arteries) the heart (Pirofsky, 1953; Washburn, 1921). Integral to 
the process of hemodynamic regulation at the level of the heart are local interactions 
which include the segmental interrelationships the heart shares with the peripheral and 
pulmonary vascular systems and can be described using Ohm’s Law: 
𝐹𝑙𝑜𝑤 =  ∆ 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒/𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒    (equation 1) 
Ohm’s Law describes blood flow out of the heart as being mediated by the pressure 
difference between the circulation (pulmonary or systemic) and the atria (left or right) 
divided by the resistance of the circulation, respectively.  
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Moreover, to describe the capacity of a specific sector of the circulation to contain blood 
at a given pressure the following relationship is derived (e.g. RV SV → pulmonary 
artery) (Guyton, Armstrong, & Chipley, 1956; Guyton, Polizo, & Armstrong, 1954; 
Mahapatra, Nishimura, Oh, & McGoon, 2006; Mahapatra, Nishimura, Sorajja, Cha, & 
McGoon, 2006): 
𝑉𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝑐𝑎𝑝𝑎𝑐𝑖𝑡𝑎𝑛𝑐𝑒 =  Δ𝑣𝑜𝑙𝑢𝑚𝑒/Δ𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒  (equation 2) 
The relationship between volume and pressure of the circulation is generally positive in 
healthy individuals, but the magnitude of linearity can be heterogeneous throughout the 
systemic vasculature. Because of the structural and functional differences of arterial 
versus venous vasculature, capacitance of the venous circulation is markedly greater 
compared to the arterial circulation (Guyton et al., 1956). This is an important difference 
as low capacitance of the arterial circulation assists in maintaining perfusion pressure to 
the most distal regions of the body while also providing a gradient in which the venous 
circulation uses to drive blood back to the central circulation.  
The direct Fick equation can be used to describe the overall systemic hemodynamic, 
pressure, and gas-exchange relationships during exercise (Fick, 1870; Hsia, Herazo, 
Ramanathan, & Johnson, 1995; Johnson et al., 2000; Lipkin & Poole-Wilson, 1985; 
McMichael & Sharpey-Schafer, 1944; Werko, Berseus, & Lagerlof, 1949): 
𝑄 = 𝑉𝑂2/𝐶𝑎−𝑣𝑂2    (equation 3) 
The factors of the direct Fick equation are: VO2 as oxygen uptake from alveoli of lungs 
into the circulation per minute, arteriovenous difference in oxygen content (Ca-vO2) as the 
total uptake of oxygen (O2) by the peripheral tissues, and Q as the sum and propulsion 
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strength of blood flow to peripheral tissues or the pulmonary circulation per unit of time 
(Hsia et al., 1995). 
Accordingly, because of the close anatomical and physiological relationships the heart 
shares with the pulmonary and peripheral vascular systems, and because individuals with 
HF demonstrate dysfunction of nearly all components of the cardiovascular system, it is 
critical to understand the implications of these interactions in this population. From a 
clinical perspective, it is already well-known that cardiac hemodynamic evaluation in HF 
is important. However, determining cardiac pumping capability as a direct interaction 
with vascular hemodynamics is central to evaluating syndrome severity and predicting 
prognosis in HF. 
2.1.2 Cardiac hemodynamics 
2.1.2.1 Traditional measurements   
Cardiac pumping capability has been traditionally assessed using measurements of Q and 
SV. Cardiac output and SV have proven useful for describing cardiac health because 
these indices are suggested to be direct estimates of myocardial contractility and 
rhythmicity separately or together under various conditions of metabolic demand and/or 
health status (Chomsky et al., 1996; Sullivan, Knight, Higginbotham, & Cobb, 1989a; 
Wilson, Rayos, Yeoh, & Gothard, 1995). Also important to note, in healthy individuals 
who are not elite-level athletes, the O2 cost of breathing is consistent at approximately 3-
5% of the total VO2 and thus it has been suggested that Q is directly proportional 
metabolic rate (Beck et al., 2006; Bhambhani, Norris, & Bell, 1994; Crisafulli, Piras, et 
al., 2007; Stringer, Hansen, & Wasserman, 1997; Whipp, Higgenbotham, & Cobb, 1996). 
Therefore, even though respiratory muscles can demand upwards of 15% of Q during 
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exercise, because of the close dependence VO2 has on the cardiac hemodynamic response 
to exercise, it is suggested that VO2 may approximate cardiac function in healthy 
individuals (Bhambhani et al., 1994; Crisafulli, Piras, et al., 2007; Whipp et al., 1996). 
For example, in using mathematical modeling in healthy individuals, Stringer et al. 
(1997) demonstrated that direct Fick measurements of Q closely related to Q predicted 
from linear regression between percentage of maximal oxygen consumption (VO2MAX) 
and measured Ca-vO2 during exercise (coefficient of determination, R
2 = 0.97, p<0.05) 
(Stringer et al., 1997).  
However, VO2 is suggested to be highly influenced by non-cardiac factors (e.g. age, 
muscle deconditioning, motivation, or abnormal pressor reflexes) as well as cardiac 
hemodynamics during exercise in HF (Becklake, Frank, Dagenais, Ostiguy, & Guzman, 
1965; Chomsky et al., 1996; Chua, Clark, Amadi, & Coats, 1996; Ponikowski et al., 
2001; Weber et al., 1982; Wilson et al., 1995). As an example, by using a low Q response 
threshold previously defined as <0.5 × VO2 + 3 Liters (L)/minute (min) (Higginbotham et 
al., 1986), it was demonstrated in HFrEF who were classified as having mild (normal Q 
and ≤20 mm Hg pulmonary wedge pressure during exercise), moderate (normal Q and 
>20 mm Hg pulmonary wedge pressure during exercise), or severe (low Q and >20 mm 
Hg pulmonary wedge pressure during exercise) cardiac dysfunction, that VO2peak did not 
differ between groups nor did it correlate with cardiac hemodynamics during exercise 
(p>0.05) (Wilson et al., 1995). These authors attributed this disconnect to potential 
differences in non-cardiac factors including skeletal muscle deconditioning and/or 
motivational differences amongst HF patients (Wilson et al., 1995). Thus, despite 
observations suggesting a close correlation between VO2 and Q in HF (Lang, Karlin, 
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Haythe, Tsao, & Mancini, 2007; Mancini, Katz, Donchez, & Aaronson, 1996; Szlachcic, 
Masse, Kramer, & Tubau, 1985), caution should be applied when interpreting 
independent measurements of VO2 as the surrogate for cardiac pumping capacity in these 
patients (Chomsky et al., 1996; Griffin, Shah, Ferguson, & Rubin, 1991; Lang et al., 
2009; Roul et al., 1995; Wilson et al., 1995). 
Stroke Volume    
Stroke volume is the volume of blood ejected by the heart per cardiac cycle and is 
measured as the absolute difference between ventricular filling and ventricular emptying, 
with the volume entering the pulmonary and systemic circulations typically being 
identical. The range for SV at rest is 60–80 milliliters (mL) per beat in healthy 
individuals. Stroke volume can be influenced by lean body mass and therefore indexing 
to body surface area (BSA, meters2) is appropriate when body size (e.g. patients or 
athletes) could influence measurement of cardiac function (Carlsson et al., 2012; Collis et 
al., 2001; de Simone et al., 1997).  
Stroke volume is mainly dependent on preload, contractility, and afterload (Braunwald et 
al., 1969; Frank, 1895; Gleason & Braunwald, 1962; Patterson & Starling, 1914; Starling, 
1918). In brief, preload occurs during diastole and reflects the stretch of the myocardium 
in response to the total blood volume within ventricles but is highly influenced by 
numerous factors including venous return, atria, or skeletal muscle pump function for 
example. In contrast, contractility refers to the capacity of the heart to generate systolic 
tension which is analogous to the ability of the myocardium to develop force at a given 
rate of muscle shortening (inverse relationship) and, hence, is related to the number and 
integrity of actin and myosin relationships within heart muscle at a given preload and 
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afterload. Lastly, afterload refers to the magnitude of impedance to the ejection of blood 
from the LV through the aortic valve. Afterload is related to systemic vascular resistance 
and reflects both the pressure within the ventricle and ventricular wall tension needed 
during systole to open the aortic valve. Afterload can be influenced by changes in 
ventricular wall thickness, ventricular dilation, or aortic compliance for example. 
However, in healthy individuals with normal sized hearts without abnormal wall 
hypertrophy (concentric), increased preload (i.e. volume → pressure = ↑ myocardial 
stretch) permits stronger myocardial actin and myosin interactions and thus the potential 
for higher myocardial systolic wall tension, contractility, and SV.  
The overall significance of the integrative relationships between preload, contractility, 
and afterload can be described by the principles governing the Frank—Starling Law of 
the heart which serve to maintain SV homeostasis (Figure 1) (Frank, 1895; Gleason & 
Braunwald, 1962; Patterson & Starling, 1914; Schnabel Jr, Sacker, Allen, & Lewis, 1961; 
Starling, 1918; Villars, Hamlin, Shaw, & Kanusky, 2004). 
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Briefly, the Frank—Starling Law of the heart suggests that due to the myocardium’s high 
sensitivity to venous return with associated pressure (i.e. preload), increased end-diastolic 
volume (EDV) can lead to high pressure within ventricles and, hence, increased 
 Figure 1: Top: Frank-
Starling curve. The 
myocardial work capacity at 
any given ventricular end-
diastolic pressure. Increases 
in contractility (e.g. beta 
agonist) of the myocardium 
shift this relationship 
upward and to the left. 
Decreases in contractility 
(e.g. heart failure) shift this 
relationship downward and 
to the right. Adjustments in 
these curves suggest that an 
equal quantity of 
myocardial work up to a 
given point can be 
generated at different 
conditions of contractility; 
but, perhaps at the expense 
of abnormal loading (i.e. 
end-diastolic 
pressure)(adapted from 
Schnabel et al., 1961). 
Bottom: Ventricular 
pressure-volume (P-V) 
relationships for a single 
cardiac cycle in a healthy 
individual. Point A 
represents end-systolic 
volume (ESV) just before 
opening of the mitral valve. 
Point A to B represents 
early and late filling of 
diastole. Point B represents 
end-diastolic volume 
(EDV). Point B to C represents the isovolumic contraction period. Point C represents opening of 
the aortic valve. Point C to D represents rapid ejection of blood through the aortic valve. Point D 
to E represents reduced ejection of blood through aortic valve. Point E represents closure of 
aortic valve. Point E to A represent the isovolumic relaxation period. Accordingly, stroke volume 
(SV) is calculated as the absolute difference between EDV and ESV (adapted from Villars et al., 
2004).  
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myocardial stretch that maximizes actin—myosin interactions which can contribute to 
higher contractility and lead to increased SV in healthy individuals (Frank, 1895; Gleason 
& Braunwald, 1962; Patterson & Starling, 1914; Starling, 1918). Large increases in Q 
(e.g. ~ magnitude of 5–7 compared to normal range reported at rest) could not occur 
without intact normal ventricular relaxation and contractile capabilities concurrent with 
adequate venous return to stimulate RV and LV filling and loading, particularly during 
high-intensity exercise when increased HR decreases ventricular filling time (Holmgren, 
1956; Horwitz, Atkins, & Leshin, 1972; Poliner et al., 1980; Sullivan, Cobb, & 
Higginbotham, 1991). For example, Poliner et al. (1980) demonstrated that during both 
upright and supine exercise at low, medium, and peak intensities that EDV progressively 
increased while end-systolic volume (ESV) was maintained (supine) or trended 
downward (upright) in healthy individuals, which were accompanied by progressive 
increases in SV from rest to peak exercise despite significant concurrent increases in HR 
from rest to peak exercise (Poliner et al., 1980). Thus, although many factors contribute 
to changes in SV, it could be suggested that the Frank—Starling mechanism in the 
presence of normal cardiac relaxation and contractility is a primary influence on increases 
in SV.  
Cardiac Output 
Cardiac output represents the total volume of blood pumped by the ventricles per unit of 
time and theoretically accounts for the rate of pumping and the contractile capability of 
myocardial tissue. Because Q is a product of heart rate (HR) and SV, this measure is 
subject to the variable influences of each factor, which together can share either a direct 
(e.g. high-intensity exercise) or an indirect (e.g. low- to moderate-intensity exercise) 
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relationship with one another (Holmgren, 1956; Horwitz et al., 1972; Poliner et al., 1980; 
Rodeheffer et al., 1984; Sullivan et al., 1991). Cardiac output should be indexed to BSA 
when lean body mass would be expected to influence cardiac function (Carlsson et al., 
2012; Collis et al., 2001; de Simone et al., 1997; Poliner et al., 1980). The normal range 
of Q is 4.0–8.0 L/min in healthy individuals, whereas the QI range at rest is 
approximately 2.6–4.2 L/min/m2.  
In a study of HR, SV, and Q at rest and during exercise in healthy individuals, Sullivan et 
al. (1991) demonstrated that Q and QI increased in direct relationship with increasing 
work-load (Sullivan et al., 1991). Moreover, in examining HR and SV responses during 
exercise in these individuals, it was apparent that the Frank—Starling mechanism was 
highly influential in contributing to adjustments in cardiac hemodynamics in these 
individuals. Evidence of this is noted by the progressive increase in HR from rest to peak 
exercise which paralleled the pattern of increase in Q and QI from rest to peak exercise; 
yet, SVI mirrored by EDV, remained constant for the duration of exercise following their 
initial increase from rest to the first stage of exercise (Sullivan et al., 1991). Indeed, these 
observations suggest that increases in QI and maintenance of SVI during exercise are 
highly dependent on the Frank—Starling mechanism in healthy individuals, with 
enhanced relaxation and contractility occurring shortly thereafter the onset of exercise 
and continuing throughout higher-intensities of exercise.  
2.1.2.2 Non-traditional direct measurements  
All four chambers of the heart are integral in maintaining cardiac hemodynamic 
homeostasis, with this interaction being particularly important during excessive loading 
of the heart (e.g. exercise). The atria serve well to increase the pumping capability of the 
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ventricles by contributing to the augmentation of the Frank—Starling effect. This occurs 
because atria accommodate blood from venous return and, therefore, can facilitate 
preload and pressure development within ventricles. The Law of Laplace can be used to 
describe the influence of concurrent changes in blood volume with pressure and the 
impact these factors have on the force generating capabilities of the heart (or the 
myocardial energy required for contraction in response to changes in loading conditions 
of the heart) (Shipley & Wilson, 1951; Tallarida, Rusy, & Loughnane, 1970): 
𝑇𝑒𝑛𝑠𝑖𝑜𝑛 = (𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 × 𝑟𝑎𝑑𝑖𝑢𝑠)/2   (equation 4) 
The Law of Laplace implicates, although not a perfect cylindrical shape, theoretically, 
pressure is that within a ventricle, the radius is that of the transverse cross-section of a 
ventricle, 2 is a numerical constant, and tension being equivalent to the quantity of energy 
required to generate systolic pressure required to eject blood from a ventricle.   
As such, it is important to point out that the right side of the heart is highly sensitive to 
blood volume changes (i.e. preload dependent volume pump), whereas the left side of the 
heart although being both preload and afterload sensitive, perhaps may be particularly 
sensitive to pressure changes (i.e. afterload dependent pressure pump) and is usually 
larger and thicker in wall structure compared to the right side because of the systemic 
circulation it needs to supply blood to.  
Although the measurement of Q and SV may account for venous return (i.e. volume 
pump), these indices do not directly assess the influence of the relationship arterial 
pressure (i.e. pressure pump) shares with cardiac function. Observations in animal models 
clearly indicate that adjustments in Q are integral in supporting systemic arterial pressure 
and, hence, perfusion pressure to capillary beds of metabolically active tissue (e.g. 
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contractile-active skeletal muscle) (Ichinose et al., 2010; Spranger et al., 2013). As a 
pumping organ, the heart relies on the contributions of the kinetic energy imparted from 
rhythmic blood flow and concurrent pressure generation within cavities to generate 
hydraulic power. Hydraulic power can be converted by the heart to mechanical power for 
propulsion of blood out of the LV with the strength to not only overcome the resistance 
of the circuit (i.e. systemic vasculature); but, more importantly, to provide continuous 
perfusion of the cardiovascular system relative to metabolic demands (Lang et al., 2009; 
Williams, Jackson, et al., 2005; Williams et al., 2001). Indeed, it is crucial for a measure 
of cardiac function aimed at describing cardiac pumping capability to account for both 
blood flow (i.e. preload → Q) and pressure (i.e. Q → MAP) generating capacity.  
Cardiac Power 
The integrative relationship that depicts the hemodynamic and pressure generating 
capability of the heart pump is CP. The direct components of this index are Q as a 
product with MAP to estimate hydraulic power (Lang et al., 2009; Tan, 1986; Williams, 
Jackson, et al., 2005). To further illustrate the utility of CP as a direct indicator of cardiac 
pumping capability, when Q and total peripheral resistance (TPR) are known the 
following relationship can be derived: 
𝑀𝐴𝑃 = 𝑄 × 𝑇𝑃𝑅     (equation 5) 
Thus, if it is assumed that TPR is close to the true resistance to blood flow offered by the 
peripheral vasculature (i.e. not including the pulmonary vasculature), and that the 
contribution of central venous pressure to resistance is negligible, it is clear that Q is 
directly related to MAP. Indeed, MAP represents the pressure generating capacity of Q 
and, therefore, CP is conceptually a direct measure of cardiac pumping capability: 
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𝐶𝑃 = 𝑄 × 𝑀𝐴𝑃    (equation 6)   
Cardiac power can be expressed as the absolute volume of blood per minute as a pressure 
product (L/min ∙ mm Hg), it can be normalized for power generated in units of watts by 
multiplying by a correction factor of 2.22 × 10-3 or dividing by 451 (Cooke et al., 1998; 
Lang, Agostoni, et al., 2007), or it can be indexed to BSA (L/min/m2 ∙ mm Hg) or body 
weight (watts/kg).  
Early examination of CP in healthy individuals demonstrated resting values of 1.11 ± 
0.05 watts (Marshall et al., 2001). More recently, it was observed that CP did not differ at 
rest in healthy individuals compared to HFpEF (271 ± 53 versus 254 ± 107 L/min/m2 ∙ 
mm Hg, respectively; p = 0.624) (Bhella et al., 2011). Although, it was observed by 
Bromley et al. (2006) in healthy individuals that men demonstrated significantly higher 
peak exercise CP in comparison to women, older men demonstrated significantly lower 
peak CP in comparison younger men, there appeared to be no age effects in women, and 
body weight did not appear to have an influence on this measure (Bromley, Hodges, & 
Brodie, 2006). These observations by Bromley et al. (2006) were consistent with another 
study of healthy men and women which similarly reported a significantly higher CP in 
men versus women at peak exercise (Bromley et al., 2006; Jakovljevic et al., 2012). Also 
important, these recent observations suggest that peak CP is directly related to peak Q, 
SV, and VO2 in healthy individuals (Jakovljevic et al., 2012). In contrast, but perhaps 
related to the age (34 ± 9 years) and training status of the participants, Schlader et al. 
(2010) observed the mean CP at peak exercise in well-trained healthy men to be nearly 
two times higher compared to previous observations in recreationally active men 
(Schlader, Mundel, Barnes, & Hodges, 2010). Nevertheless, despite being a less studied 
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cardiac hemodynamic parameter compared to Q and SV in HF, these encouraging 
observations in healthy individuals provide useful information in interpreting CP in 
patients (Bromley et al., 2006; Jakovljevic et al., 2012; Schlader et al., 2010).  
2.1.2.3 Non-traditional Indirect Measurements 
Because of the hemodynamic dependence of VO2 as well as the physiological principles 
supporting the direct Fick equation (equation 3) (Fick, 1870; Johnson et al., 2000; 
McMichael & Sharpey-Schafer, 1944; Stringer et al., 1997; Werko et al., 1949), it has 
been suggested that VO2 in parallel with other cardiovascular factors can estimate cardiac 
pumping capability. The assumption of exact associations between hemodynamics and 
factors of the cardiovascular system are the framework for the use of indirect 
cardiovascular based metrics for the estimation of cardiac function. 
Oxygen Pulse 
Mathematically, if the physiological associations of the direct Fick equation remain 
constant, the quotient of VO2 and HR yields the following cardiovascular index, O2pulse 
(Crisafulli, Piras, et al., 2007; Kasch, Phillips, Carter, & Boyer, 1973; Saltin, 1964; 
Whipp et al., 1996): 
𝑂2𝑝𝑢𝑙𝑠𝑒 = 𝑉𝑂2/𝐻𝑅     (equation 7) 
Oxygen pulse is theoretically an estimate of the product of SV with Ca-vO2 when Ca-vO2 
remains invariable, details which are explained in greater detail in studies 1 – 3 of this 
dissertation. In brief, the units for O2pulse reported in the literature have been in absolute 
terms (mL/beat), relative to BSA (mL/beat/m2), or relative to body weight (mL/beat/kg) 
(Kasch et al., 1973; Mahler, Parker, & Andresen, 1985; Saltin, 1964; Whipp et al., 1996). 
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Also, and important to note, our group recently observed that O2pulse correlated closely 
with direct Fick measurements of SV during exercise in HFrEF with or without 
pulmonary hypertension (PH) (r = 0.91, p<0.01) (Taylor, Olson, et al., 2013). Although, 
despite these recent observations by our group in addition to evidence which suggests 
that O2pulse demonstrates prognostic strength in HF, further testing is needed to confirm 
whether O2pulse estimates SV during exercise in HF (Cohen-Solal et al., 1997; 
Laukkanen, Kurl, Salonen, Lakka, & Rauramaa, 2006; Lavie et al., 2004; Taylor, Olson, 
et al., 2013).  
Circulatory Power 
Circulatory power imparts the assumptions which O2pulse is supported, but may be a 
better indicator of cardiac pumping capability compared to O2pulse because CircP also 
accounts for arterial pressure which is consistent with CP (equation 6). Circulatory power 
is a gas-exchange based parameter calculated per unit of time: 
𝐶𝑖𝑟𝑐𝑃 = 𝑉𝑂2 × 𝑀𝐴𝑃    (equation 8) 
The principles and theory supporting CircP as an indicator of cardiac pumping capacity 
similar to CP are explained in detail within studies two and three of this dissertation. 
Therefore, in brief, the units for CircP have been expressed in absolute terms (mL/min ∙ 
mm Hg) or adjusted for body weight (mL/kg/min ∙ mm Hg) (Cohen-Solal et al., 2002; 
VanIterson, Snyder, Joyner, Johnson, & Olson, 2014; Williams, Jackson, et al., 2005; 
Williams, Tzeng, Barker, & Tan, 2005). Also, in a recent study by Williams et al., it was 
demonstrated that CircP correlated closely (r = 0.93, p<0.0001) with CP (via CO2 
rebreathe technique) during exercise testing in 219 NYHA class I-IV HFrEF (Williams, 
Tzeng, et al., 2005). Our group also recently demonstrated CircP closely relates with 
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invasive assessment of CP at peak exercise in both HFrEF and HFpEF (r = 0.82 and 0.74, 
respectively; both p<0.05) (unpublished data from our lab). Thus, based on these 
promising, yet limited in number experimental evidence, cardiac pumping capacity 
during exercise may be estimated using CircP.  
2.1.3 Vascular capacitance 
Capacitance can be described in general as the magnitude of the total contained blood 
volume of the vasculature in relation to the transmural pressure imposed on or by the 
vessels (Guyton et al., 1956; Guyton et al., 1954; Mahapatra, Nishimura, Oh, et al., 2006; 
Mahapatra, Nishimura, Sorajja, et al., 2006). However, it is important to note that even 
though this relationship is expressed as a quotient depicting a positive relationship 
between volume and pressure (equation 2), due to differences in arterial versus venous 
wall structure as well as the pulsatile nature of blood flow within the arterial circulation, 
it should not be assumed that these variables are systemically nor constantly inversely 
related in human or animal systems. As an example, by carefully controlling arterial and 
venous pressure by acute maximal stimulation of vagus nerves in dogs to control cardiac 
function, Guyton et al. (1956) found that there was a 60 mL increase in arterial blood 
circulation when the heart was actively pumping versus when circulation was arrested; 
and, in parallel, there was 60 mL less blood in the venous circulation when the heart was 
pumping versus when circulation was at a stand-still (Guyton et al., 1956). Moreover, and 
of further interest, when capacitance of the arterial circulation (thick-walled low 
distensibility) was compared to capacitance of the venous circulation (thin-walled high 
distensibility), it was found that the venous circulation has a capacitance 18-30 times 
greater than capacitance of the arterial circulation. The differences in capacitance 
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between the two components of the systemic circulation in dogs suggests that blood flow 
through the arterial circulation could be expected to generate 18-30 times the pressure 
(i.e. hydraulic power) as that of blood flowing through the venous circulation (Guyton et 
al., 1956). These findings of Guyton et al. (1956) illustrate that peripheral capacitance 
can influence cardiac hemodynamics; but, perhaps more telling, there appears to be a 
strong influence of cardiac hemodynamics on peripheral capacitance (Guyton et al., 
1956; Guyton et al., 1954). This further supports the hypothesis that in the assessment of 
cardiac pumping capability it is essential to evaluate the influence that cardiac 
hemodynamics have on arterial pressure generation associated with blood flow. In 
contrast, it is also important to assess the influence of attenuated peripheral arterial 
capacitance on cardiac hemodynamics, particularly because HF patients LV dysfunction 
and changes in Q which suggest a high degree of afterload dependence. 
Pulmonary Vascular Capacitance 
The importance of vascular capacitance may be highlighted further when studying the 
capacitance of pulmonary arterial vasculature and its relationship with cardiac function. 
Understanding this relationship could be critical because it has previously been reported 
that low peripheral vascular capacitance was strongly related to survival in HF 
(Domanski et al., 1999; Mitchell et al., 1997). In addition, it is now well-recognized that 
individuals with HF are predisposed to in increased risk for pulmonary disease concurrent 
with HF (i.e. PH) which further increases the mortality risk in patients (Aronson et al., 
2011; Butler, Chomsky, & Wilson, 1999; Moraes, Colucci, & Givertz, 2000). Pulmonary 
hypertension may also be related to the development of interstitial lung fluid 
accumulation (i.e. pulmonary edema) which is a common symptomatic marker in HF; 
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although, pulmonary edema in HF is commonly traced back to initial high diastolic filling 
pressure concurrent with systolic dysfunction and systemic hypertension, which are 
antecedent events to the onset of “passive and/or mixed” forms of PH in HF (Dickstein et 
al., 2008; Galie et al., 2009; Lewis, Houssay, Haynes, & Dexter, 1953; Paulus et al., 
2007; Pietra et al., 2004; Simonneau et al., 2009). 
In early studies of vascular capacitance within the lungs of anesthetized dogs, Sarnoff and 
Berglund reported several noteworthy findings concerning the relationships between 
changes in lung blood volume with corresponding pulmonary arterial pressure (Sarnoff & 
Berglund, 1952). Upon emptying the lungs of blood, these authors observed that when 
blood was incrementally reinfused into the main pulmonary artery that after reaching a 
threshold of 15-30 mm Hg, further infusion of blood resulted in a progressive decline in 
pressure, with the magnitude of decrease being the largest at the highest blood volume. 
This shift in relationships between blood volume and pressure past 30 mm Hg was 
suggested to be caused by a relaxation mechanism due to excessive wall stress because it 
was also shown that when fluid was incrementally withdrawn in the same quantities as 
injected, pressure decreased in an exaggerated curvilinear pattern (Sarnoff & Berglund, 
1952). Moreover, and perhaps relevant to a potential risk for pulmonary edema in HF, 
these authors noted that fluid losses of 10–20 mL occurred during 10 second pauses 
between injections and 40–50 mL were lost during 30 second pauses between injections. 
It is therefore apparent based on these observations that highly variable pulsatile blood 
flow of persistently elevated volumes from the RV into the pulmonary artery could cause 
high pulmonary arterial pressure and subsequent interstitial fluid accumulation within 
lungs of humans. Although, it is also apparent that with intact vessel distensibility and 
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pressor reflex pathways (e.g. baroreflex), a drop in vascular tone in the presence of high 
blood volume could occur (i.e. increase in capacitance) (Sarnoff & Berglund, 1952). 
These novel findings have been subsequently supported by the observations of others 
using similar animal model techniques (Coleridge & Kidd, 1963).        
More recently, the direct relationship between RV hemodynamics and pulmonary arterial 
hemodynamics has been studied in various cardiopulmonary patients (Friedberg, 
Feinstein, & Rosenthal, 2007; Mahapatra, Nishimura, Oh, et al., 2006; Mahapatra, 
Nishimura, Sorajja, et al., 2006; Taylor, Olson, et al., 2013). This is important because 
traditional assessment of pulmonary vascular resistance (PVR) is not entirely indicative 
of the direct relationship between pulmonary arterial pressure and RV hemodynamics, it 
is simply: 
𝑃𝑉𝑅 =  ∆𝑃/𝑄    (equation 9) 
Where ΔP is the pressure difference across the entire pulmonary circulation and Q is flow 
of blood through the entire pulmonary circulation per unit of time (i.e. ≈Q). 
Importantly, PVR primarily reflects pressure within smaller peripheral pulmonary 
arterioles (diameter, 100–300 μm) which are high resistance vessels that can narrow and 
lose compliance prior to late stage remodeling of larger arteries of the pulmonary 
circulation in PH or in individuals with PH secondary to HF (Aronson et al., 2011; 
Horsfield, 1978; McGoon et al., 2004; McLaughlin et al., 2009; Moraes et al., 2000). 
Therefore, PVR is not sufficient to describe the integrity nor direct interaction of large 
pulmonary arterial segments most proximal to the RV. To describe the segmental 
interaction between the RV and the main pulmonary artery (diameter, 2.72 ± 0.3 
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centimeters) (Edwards, Bull, & Coulden, 1998), pulmonary vascular capacitance (PVCAP) 
is useful (equation 2) (Taylor, Olson, et al., 2013). 
Focused studies of PVCAP in humans are limited and have mainly centered on individuals 
with PH likely because of the influence PH has on RV workload and RV SV (Holverda et 
al., 2006). Although, PVCAP has been successfully assessed using invasive and non-
invasive techniques in PH (adults and children), HF, and HF with PH (Friedberg et al., 
2007; Mahapatra, Nishimura, Oh, et al., 2006; Mahapatra, Nishimura, Sorajja, et al., 
2006; Taylor, Olson, et al., 2013). It was recently observed that PVCAP assessed using 
cardiac catheterization versus ECHO demonstrated a correlation coefficient r = 0.74 in 
adolescents with PH (p<0.0001) (Friedberg et al., 2007).  
In one of the first studies of PVCAP, Mahapatra et al. (2006) demonstrated that invasive 
assessment of this index was the strongest indicator of prognosis versus traditional 
pulmonary function indices in adults with PH (>2.0 mL/mm Hg predicted 100% survival 
at 4-years) (Mahapatra, Nishimura, Sorajja, et al., 2006). Mahapatra et al. (2006) 
demonstrated PVCAP at rest could range from 0.40 to 3.77 mL/mm Hg
 in PH (mean, 1.43 
± 0.73 mL/mm Hg), with higher values indicating better prognosis. Subsequent studies in 
adolescent PH, HF, or HF with PH demonstrated PVCAP values that compared reasonably 
with measures of PVCAP in adult PH (Friedberg et al., 2007; Mahapatra, Nishimura, 
Sorajja, et al., 2006; Taylor, Olson, et al., 2013). 
The validity of non-invasive assessment of PVCAP, called GXCAP, has recently been 
demonstrated by our group to closely correlate with direct cath lab measures of PVCAP 
during exercise in HFrEF (r = 0.86, p<0.01) and are explained in further detail in studies 
two and three of this dissertation (Taylor, Olson, et al., 2013). Briefly, to estimate PVCAP 
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non-invasively using gas-exchange methods, the product of these cardiovascular derived 
parameters is required (Taylor, Olson, et al., 2013): 
𝐺𝑋𝐶𝐴𝑃 =  𝑂2𝑝𝑢𝑙𝑠𝑒 ×  𝑃𝐸𝑇𝐶𝑂2         (equation 10) 
Summary 
The human studies described in this section of central hemodynamics have presented 
traditional and non-traditional indices proven to be useful in describing the blood flow 
and pressure generating potential of the heart in HF. Newer indices of central 
hemodynamics offer several feasible interpretations of the hydraulic power generating 
capability of the heart. Equally important, many of these indices have been validated 
against invasive and non-invasive methodology, and the evidence would suggest that 
non-invasive determination of central hemodynamics can be accomplished with similar 
accuracy, precision, and repeatability comparable to invasive techniques but without the 
added risk to the individual or need for additional resources (Friedberg et al., 2007; 
Johnson et al., 2000; Taylor, Olson, et al., 2013; Whipp et al., 1996; Williams, Tzeng, et 
al., 2005). Still, despite encouraging evidence which favors newer non-traditional indices 
(e.g. CP or CircP) for describing central hemodynamics during exercise in HF, the 
current field remains divided and thus further study is warranted (Cohen-Solal et al., 
2002; Lang et al., 2009; Metra et al., 1999).     
2.2 Central hemodynamic responses to exercise 
2.2.1 Introduction 
Irrespective of health condition, the main function of the heart as it pertains to the 
cardiovascular system is to ensure adequate blood flow (nutrient and O2 delivery) to 
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match metabolic demand at rest as well as under all conditions of physiological stress 
(e.g. cold/heat exposure, gravitational changes, exercise, etc.). Fundamental to this 
understanding is to point out that the heart does not pump independently. Cardiac 
pumping capability is influenced by factors of the cardiovascular system (e.g. veins and 
arteries) which exert their influence on circulation to a great extent during exercise. As 
such, it is not surprising that independent measurements of cardiac function at rest do not 
robustly describe cardiac pumping capability in healthy individuals during exercise 
(Rerych, Scholz, Newman, Sabiston Jr, & Jones, 1978; Stratton, Levy, Cerqueira, 
Schwartz, & Abrass, 1994). Similarly, in the instance of HF patients, resting measures of 
cardiac function are not strong indicators for quantifying the overall magnitude of heart 
pump dysfunction.    
2.2.2 Healthy individuals 
Overview of cardiac hemodynamics 
The total blood volume in humans is approximately 5 L, which, assuming normal cardiac 
function is intact, this entire volume is pumped through the circulation approximately 
once per minute at rest. However, as healthy adults transition from rest to dynamic 
exercise, the rate of VO2 and Q increase beyond resting ranges, upwards of 20 and 7 
times that reported at rest, respectively (Saltin, 1964; Saltin & Astrand, 1967). These 
specific changes in cardiovascular function which occur during exercise in healthy 
individuals are particularly evident when examining the early works of Saltin (Saltin, 
1964). Saltin observed that both Q and SV changed in near linearity from rest to maximal 
exercise in healthy individuals performing upright bicycle ergometer exercise (Saltin, 
1964). The range of Q and SV for participants was 3.8–6.7 L/min and 54.0–98.0 mL/beat 
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at rest, respectively. Whereas, the range of Q and SV was 16.0–29.9 L/min and 80.0–
166.0 mL/beat at maximal exercise, respectively. Further interesting, the mean Q (18.5 
versus 24.1 L/min, significance not reported) and SV (100 versus 134 mL/beat, 
significance not reported) were lower in women compared to men at maximal exercise 
which was consistent with differences reported at rest between genders, respectively 
(Saltin, 1964). Also noted, the linearity between Q and VO2 throughout exercise became 
significantly more variable as participants neared maximal exercise (Saltin, 1964), which 
may have been attributable to body mass (e.g. heart size) and/or more efficient O2 
transport and O2 utilization related to relationships between hemoglobin (Hb) and arterial 
blood O2 content. These observations of Saltin and others subsequently are likely due to 
Frank—Starling mechanism (Hermansen, Ekblom, & Saltin, 1970; Saltin, 1964; Sullivan 
et al., 1991); however, additional factors influential to the relationship between Q and 
VO2 should be considered (Becklake et al., 1965; de Simone et al., 1997; Freedson, 1981; 
Ogawa et al., 1992; Salton et al., 2002; Sandstede et al., 2000).    
Observations from more recent studies support previous findings in healthy individuals, 
while providing additional evidence to suggest that there may be a profound influence of 
diastolic function on the Frank—Starling mechanism for maintenance or even increases 
in SV at high exercise intensities in highly-trained endurance athletes. Studies of 
Warburton et al. (2002) and Zhou et al. (2001) have shown that highly trained cyclists or 
elite-level runners demonstrate continuous linear increases in SV from rest to maximal 
exercise (Warburton et al., 2002; Zhou et al., 2001). Further, Warburton et al. (2002), 
using the radionuclide ventriculography method, demonstrated that increases in SV 
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during exercise were associated with improvements in diastolic function during exercise 
(Warburton et al., 2002). 
In summary, it remains clear that apart from the attenuating influences of aging on 
cardiac structure and function (Brandfornbrener, Landowne, & Shock, 1955; Gleason & 
Braunwald, 1962; Hagberg et al., 1985; Sandstede et al., 2000), the cardiac hemodynamic 
response to exercise via primary influences of the Frank—Starling mechanism could be 
expected to adequately adjust relative to systemic metabolic demands in healthy 
individuals. 
Overview of pulmonary hemodynamics 
Exercise and accompanying increases in Q allows for elevated perfusion of pulmonary 
capillaries for VO2 as well as for enhanced release of CO2. As Q can increase during 
exercise up to 5–7 times that of resting conditions (Saltin, 1964), the increase in 
pulmonary arterial hemodynamics and pressure contribute to increases in vascular driving 
pressure (i.e. difference between pulmonary artery pressure and pulmonary venous 
pressure) of oxygenated blood to the left atria (Banchero et al., 1966). In contrast, 
although the pulmonary venous circulation by itself offers little resistance to flow during 
exercise, increases in left atrial hemodynamics and pressure can cause marked decreases 
in vascular driving pressure by facilitating increases in pulmonary venous as well as 
arterial pressures (Eldridge, Braun, Yoneda, & Walby, 2006; Eldridge et al., 1996). 
However, in the absence of pulmonary vascular disease (e.g. mixed PH), it is suggested 
that the normal pulmonary arterial hemodynamic response to exercise is suggested to be 
reflected by a mPAP less than 30 mm Hg in younger (i.e.<50 years age) healthy 
individuals (~2 × magnitude at rest) in addition to an attenuated rise in pulmonary 
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capillary wedge pressure (PCWP) and PVR (Eldridge et al., 1996; Galie et al., 2009; 
Riley, Himmelstein, & et al., 1948; Saltin, 1964; Simonneau et al., 2009). 
The overall decrease and/or attenuated rise in PVR during exercise was observed early on 
by Damato et al. (1996) who noted that PVR decreases in parallel with moderate 
increases in mPAP as exercise intensity increases (i.e. ↑ Q) (Damato, Galante, & Smith, 
1966). Damato et al. (1966) demonstrated that PVR could drop to nearly 70 dynes ∙ 
sec/cm5 ∙ m2 in the presence of an increase in mPAP upwards of 47 mm Hg (mean 29 ± 8 
mm Hg) during the highest level of exercise in young-adult healthy individuals (Damato 
et al., 1966). However, in the absence of a decrease and/or attenuated rise in PVR during 
exercise, exaggerated increases in both PVR and mPAP could suggest the presence of 
abnormal left heart function (i.e. ↑ left atrial pressure related to impaired LV diastolic 
function), which over-time could contribute to exaggerated resistance of arterioles, poor 
pulmonary vascular recruitment and dilation, the risk for pulmonary congestion, or PH 
(Banchero et al., 1966; Fishman, Fritts, & Cournand, 1960; Reeves et al., 1990).      
2.2.3 Heart failure 
In healthy individuals it has been demonstrated that independent measurements of cardiac 
function at rest do not robustly describe full cardiac pumping capability (Rerych et al., 
1978; Stratton et al., 1994). Similarly, in patients with impaired cardiac function, resting 
measures of cardiac function are not strong indicators for quantifying the overall 
magnitude of heart pump dysfunction.  
Franciosa et al. (1981) observed in HFrEF that resting measurements of cardiac function 
or structure correlated poorly with total exercise duration (Franciosa, Park, & Barry 
Levine, 1981). In contrast, Szlachcic et al. (1985) observed that cardiac index during 
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exercise closely related with VO2peak in HFrEF (Szlachcic, Masse, et al., 1985). Also, in 
HFpEF, Borlaug et al. (2006) demonstrated that exercise capacity (i.e. exercise duration 
and VO2peak) was significantly associated with exercise mediated changes in Q (Borlaug 
et al., 2006). Indeed, because of these and other observations in HF, it could be suggested 
that objective measurement of cardiac function during exercise is critical in assessing 
cardiac pump dysfunction in HF (Borlaug et al., 2006; Borlaug, Nishimura, Sorajja, Lam, 
& Redfield, 2010; Franciosa et al., 1981; Francis, Goldsmith, & Cohn, 1982; 
Higginbotham, Morris, Conn, Coleman, & Cobb, 1983; Kronenberg et al., 1998; 
Szlachcic, Masse, et al., 1985).    
Overview cardiac hemodynamics 
Much of our understanding of the cardiac hemodynamic response to exercise in HF can 
be explained by factors which prohibit normal functioning of the Frank—Starling 
mechanism in patients (e.g. impaired contractility and/or relaxation) (Gleason & 
Braunwald, 1962; Ross & Braunwald, 1964). In contrast to healthy individuals, there is a 
large disconnect in the relationships between blood flow and pressure of the central 
circulation, and secondarily of the peripheral circulation.    
Because of gross anatomical (e.g. ischemic/necrotic tissue) and bio-cellular (e.g. 
desensitized/downregulated β-adrenergic receptors) dysfunctions of the myocardium in 
HF, the agreement between preload and blood ejected into the systemic circulation 
cannot always be assumed to be equal (Bristow et al., 1982; Bristow et al., 1986; 
Dickstein et al., 2008). The disconnect between ventricular filling and emptying as a 
result of impaired cardiac function and high intracavity filling pressures can be observed 
at rest, which is then exacerbated further during exercise. This abnormal cardiac 
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hemodynamic response during physical exertion is frequently associated with the 
triggering of signs and symptoms that are common in HF. 
Lewis et al. (1953) in comparing observations from cardiac patients with LV dysfunction 
to previous findings in healthy individuals suggested that QI and SVI could be similar in 
HF versus healthy individuals at rest (Dexter et al., 1951; Lewis et al., 1953). In contrast, 
the similarities between groups at rest did not persist during exercise, demonstrating that 
differences in QI and SVI were due to a lack of increase in the HF population (Dexter et 
al., 1951; Lewis et al., 1953). Increases in QI during exercise appeared to be largely 
mediated by adjustments in HR, and changes in SVI seemed to occur at the expense of 
abnormally high LV filling pressure in HF. This suggests the presence of abnormal 
relaxation (i.e. impaired diastolic function) concurrent with an inability to develop 
adequate wall tension during systole in these patients (Lewis et al., 1953). These findings 
are supported by the observations of Epstein et al. (1967) and Ross et al. (1966) who 
examined cardiac hemodynamic responses at rest and during exercise in healthy 
individuals and in cardiac patients with LV dysfunction (Epstein, Beiser, Stampfer, 
Robinson, & Braunwald, 1967; Lewis et al., 1953; Ross, Gault, Mason, Linhard, & 
Braunwald, 1966). Similarly, these authors also observed that patients did not 
demonstrate increases in QI and SVI to a similar degree as healthy individuals during 
exercise despite both groups having comparable QI and SVI at rest (Epstein et al., 1967; 
Lewis et al., 1953; Ross, Gault, et al., 1966).  
Epstein et al. (1967) also found that adjustments in QI during exercise appeared to be 
sensitive to adjustments in pulmonary arterial O2 saturation in patients (Epstein et al., 
1967). The relationship between QI and pulmonary arterial O2 saturation was normal until 
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pulmonary arterial O2 saturation approached a threshold of approximately 30% (i.e. 
moderate intensity exercise), whereby any further decrease in saturation (i.e. increasing 
exercise intensity) did not correspond to adequate adjustments in QI (Epstein et al., 1967). 
The authors found this relationship between QI and pulmonary arterial O2 saturation 
down to and below 30% useful for identifying LV dysfunction and a potential reason for 
exercise limitation in cardiac patients.  
In contrast, when Epstein et al. (1967) compared exercise QI responses to exercise 
intensity (i.e. VO2) there was no discernable trend in relationships between QI and 
exercise intensity that could be used to indicate at what point, if any, cardiac function was 
at its true pumping capacity (Epstein et al., 1967). Thus, even at the highest VO2 
measurement it was suggested that the corresponding QI should not be assumed to be the 
absolute limit of cardiac function. As such, with incremental increases in exercise 
intensity, even with a drop in VO2, it is not unreasonable to suggest that corresponding 
increases in Ca-vO2 and QI could occur to prolong exercise beyond the point of the highest 
VO2 in HF (Epstein et al., 1967; Katz et al., 2000; Sullivan, Knight, Higginbotham, & 
Cobb, 1989b). It has been observed previously that as VO2 drops it is possible for parallel 
increases in O2 extraction from arterial blood to occur during exercise in both HFrEF and 
HFpEF (Katz et al., 2000). Moreover, because symptomology (e.g. dyspnea, fatigue, 
peripheral factors, or discomfort) typically limits exercise capacity in HF prior to 
reaching a VO2 limitation, in most instances it would not be accurate to conclude that 
exercise capacity is commonly limited by VO2 in HF (Chomsky et al., 1996; 
Higginbotham et al., 1986; Lipkin, Canepa-Anson, et al., 1986; Piepoli et al., 1999; 
Wilson et al., 1995). Therefore, Epstein et al. (1967) observed that Q, as it related to 
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pulmonary arterial O2 saturation was distinctly identifiable at a given threshold of work 
(i.e. 30% O2 saturation) whereby upon reaching this threshold, Q increased no further 
despite the intensity of exercise continuing to increase (Epstein et al., 1967). Therefore, it 
is reasonable to suggest that the cardiac hemodynamic response relative to pulmonary 
arterial O2 saturation during exercise could be effective for objectively describing the 
limit of cardiac pumping capability in cardiac patients with LV dysfunction.       
Included in the study of Ross et al. (1966) was the observation that during exercise, the 
changes in LV end-diastolic pressure in relation to changes in SVI during exercise were 
variable and could be considered abnormal in most cardiac patients with LV dysfunction 
(Ross, Gault, et al., 1966). These observations relate to the functionality of the Frank—
Starling mechanism in regulating the blood flow and pressure generating capacity of the 
heart in patients. In healthy individuals LV end-diastolic pressure could be assumed to be 
commensurate with LV end-diastolic volume which is directly related with preload and 
hence SV (Hagberg et al., 1985; Mason, Spann, Zelis, & Amsterdam, 1971; Ross, 
Morrow, Mason, & Braunwald, 1966; Sandstede et al., 2000). However, the finding of a 
disconnect between SVI and LV end-diastolic pressure during exercise in patients 
foremost suggests that there may be an abnormal disconnect between hemodynamics and 
appropriate pressure adjustments within the heart. This points to the likelihood that 
abnormal compliance and relaxation with low contractility could in fact be present in HF 
and causal for low exercise QI and SVI observed in patients (Braunwald & Ross, 1963). 
This unique relationship between LV end-diastolic pressure and SVI that was uncovered 
during exercise in cardiac patients is significant because many of the patients with LV 
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dysfunction demonstrated what would be considered normal LV function at rest (Ross, 
Gault, et al., 1966).  
In an extension of these early observations in cardiac patients with LV dysfunction, more 
recently, investigators have looked to better understand the response of alternative 
metrics of cardiac function or the hydraulic power generating capacity of the heart (e.g. 
CP or CircP) during exercise in HF (Cohen-Solal et al., 2002; Lang et al., 2009; 
Williams, Jackson, et al., 2005). However, in studying CP or CircP for example, it is 
important to note that these indices do not impart differential mechanisms of action 
versus Q and SV, rather, it is suggested that they better represent the coordinated 
influences of venous return, preload, contractility, and afterload (all components which 
comprise the Frank—Starling mechanism) in describing cardiac hemodynamics (Griffin 
et al., 1991; Lang et al., 2009; Williams, Jackson, et al., 2005; Williams et al., 2001). 
Observations from exercise studies which have tested these alternative indices of cardiac 
hemodynamics have been consistent with studies of Q and SV in HF (Epstein et al., 
1967; Lewis et al., 1953; Ross, Gault, et al., 1966), demonstrating that the hydraulic 
power of the heart in HF does not increase during exercise as would be expected in 
healthy individuals (Cohen-Solal et al., 2002; Griffin et al., 1991; Lang et al., 2009; 
Williams, Jackson, et al., 2005; Williams et al., 2001). 
Heart failure patients with reduced ejection fraction have been observed to demonstrate 
CP values upwards of 6.79 watts at peak exercise (lowest = 1.2 watts); although, the 
average peak exercise CP in this sample of HFrEF patients was markedly lower at 2.96 ± 
1.2 watts (resting mean = 0.99 ± 0.29 watts) (Williams et al., 2001). This response of CP 
to peak exercise testing is consistent with the hypothesis of impaired pump function in 
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HF, given these patients also demonstrated low Q and VO2 at peak exercise (12.0 ± 3.4 
L/min and 23.1 ± 9.23 mL/kg/min, respectively). Further, Lang et al. (2009) recently 
observed that peak exercise CP appears to track with severity of HF, in that NYHA class 
I and II patients have nearly 1–1.5 units higher CP compared to patients in NYHA class 
III and IV (Lang et al., 2009). The differences in peak exercise CP observed between 
these studies are likely attributable to the larger number of NYHA class II patients in the 
former study versus a larger number of NYHA class III and IV patients in the latter study 
(Lang et al., 2009; Williams et al., 2001). Nevertheless, despite differences in CP 
between studies, the CP response at peak exercise in both studies still suggests 
impairment of cardiac hydraulic power generating capacity in HFrEF. 
The interpretation of impaired cardiac pumping capacity from observations of peak 
exercise CP in HFrEF are further supported by observations of CP at peak exercise in 
healthy individuals which have been observed to reach upwards of 7.94 watts with an 
average of 4.5 ± 1.2 watts (Bromley et al., 2006). Also, in healthy men and women (>45 
years old), average CP at peak exercise has been demonstrated to be 4.85 ± 0.79 watts 
and 3.69 ± 0.68 watts, respectively (Bromley et al., 2006). Thus, the impaired cardiac 
hemodynamic rise during exercise in HF likely contributes to symptoms since blood flow 
demands to metabolically active tissue (e.g. respiratory and skeletal muscles) are 
augmented during exercise (Olson, Joyner, Dietz, et al., 2010).  
Accompanying CP observations in HFrEF are newer evidence which extend this area of 
study to HFpEF. Bhella et al. (2011) recently demonstrated that despite no differences in 
CP at rest between HFpEF and healthy individuals (254 ± 107 versus 271 ± 53 L/min/m2 
∙ mm Hg, p = 0.624), at peak exercise there was a significant difference between groups 
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(893 ± 174 versus 1136 ± 240 L/min/m2 ∙ mm Hg), respectively (Bhella et al., 2011). 
Indeed, these observations of Bhella et al. (2011) provide encouraging evidence which 
suggests that the hydraulic power generating capabilities of the heart likely related to 
mechanisms governing the Frank—Starling mechanism (i.e. diastolic dysfunction, poor 
relaxation, and high intracavity filling pressure) are impaired in HFpEF, perhaps in a 
manner which supports the likelihood that diastolic dysfunction is more influential in 
HFrEF than previously thought (Bhella et al., 2011).  
Studies of CP during exercise in HF have been followed-up by examinations of CircP 
during exercise in HF (Cohen-Solal et al., 2002; VanIterson et al., 2014; Williams, 
Jackson, et al., 2005). Because CircP is suggested to be the surrogate of CP it could be 
assumed that like CP, CircP would also demonstrate an attenuated rise during exercise in 
HF. However, using CircP during exercise in HF may have additional benefits because 
this surrogate uses VO2 in place of Q in its calculation. Although, as mentioned 
previously, VO2 may be highly influenced by non-cardiac factors (e.g. obesity, 
motivation, skeletal muscle deconditioning) in HF, and consequently it cannot be 
assumed that VO2 can always estimate Q in these individuals (Becklake et al., 1965; 
Chomsky et al., 1996; Chua et al., 1996; Ponikowski et al., 2001; Weber et al., 1982; 
Wilson et al., 1995).  
Nevertheless, observations in HF have indicated that the behavior of CircP during 
exercise is closely associated with that of CP (Cohen-Solal et al., 2002; Williams, 
Jackson, et al., 2005; Williams, Tzeng, et al., 2005). Circulatory power assessed at peak 
exercise is consistently higher in healthy individuals compared to the sickest HF patients 
(e.g. 3573 ± 1273 versus 2567 ± 984 mL/kg/min ∙ mm Hg, p<0.001) (Cohen-Solal et al., 
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2002). To help support these previous findings, our group has demonstrated that CircP is 
indeed lower in HFrEF compared to healthy individuals during submaximal exercise 
(2721 ± 618 versus 1413 ± 257 mL/kg/min ∙ mm Hg, respectively; p<0.05) (VanIterson 
et al., 2014). Thus, the strength of CircP as a cardiac hemodynamic surrogate in HF is 
further strengthened when also considering the closeness of relationships observed 
between CircP and CP during peak exercise testing in HF (HFrEF, r = 0.93, p<0.0001 
(Williams, Tzeng, et al., 2005), and HFpEF, R2 = 0.68, p<0.05 (unpublished research 
from our lab)). 
Consistent with the observations of CircP during exercise in HF, the rise of O2pulse has 
been observed to be attenuated in HF (Cohen-Solal et al., 1997; Cohen-Solal et al., 2002). 
This could be expected since this parameter is derived from assumptions which suggest 
that VO2 changes in parallel with cardiac hemodynamics during exercise (Crisafulli, 
Piras, et al., 2007; Whipp et al., 1996). In a comparison study of O2pulse at peak exercise, 
Cohen-Solal et al. (1997) demonstrated that peak O2pulse was markedly lower in HF 
compared to healthy individuals (Cohen-Solal et al., 1997). Cohen-Solal et al. (1997) 
reported mean O2pulse values of 8.8 ± 3.0 mL/beat in NYHA class II-IV HF (Cohen-
Solal et al., 1997), whereas Bhambhani et al. (1994) previously demonstrated mean 
maximal O2pulse values in trained and untrained healthy individuals to be 23.8 ± 5.1 
mL/beat and 20.8 ± 3.9 mL/beat, respectively (Bhambhani et al., 1994). Thus, although 
O2pulse is considered an indirect measurement of cardiac pumping capability, 
observations of O2pulse at peak exercise in HF are consistent with traditional (i.e. SV) 
assessment of cardiac hemodynamics in these patients. Low O2pulse suggests that the 
ability to generate blood flow from the heart is impaired.   
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In summary, observations of traditional and non-traditional cardiac hemodynamic 
responses to exercise in HF indicate that the heart is incapable of generating the proper 
blood flow and perfusion pressure to accommodate the increased metabolic demands of 
exercise. It is likely that a significant contribution to impaired pump function in HF is 
attributable to an unknown degree of both diastolic and systolic dysfunction (Kitzman, 
Higginbotham, Cobb, Sheikh, & Sullivan, 1991; Ross & Braunwald, 1964). Impaired 
diastolic function disrupts the ascending arm of the Frank—Starling curve by inhibiting 
the ability to generate end-diastolic pressure at an appropriate volume of blood (i.e. 
causing excessive loading and myocardial stretch) and therefore causing a rightward shift 
in the curve while also causing large end-diastolic and systolic volumes (Ross & 
Braunwald, 1964). Whereas, systolic dysfunction also in the presence of diastolic 
impairment could further shift the Frank—Starling curve rightward and downward due to 
the additional loss of contractility and wall tension development during systole (Ross & 
Braunwald, 1964). Still, even with impaired systolic and/or diastolic function, it remains 
possible for HF to generate blood flow with the Frank—Starling mechanism during 
exercise. Although, in comparison to healthy individuals, in HF this is believed to occur 
on the descending arm (i.e. less myocardial distension) of the Frank—Starling curve in 
addition to the fact that any increase in Q and SV from resting levels comes at the 
expense of abnormal intracavity blood volume and pressure throughout diastole and 
systole (Ross & Braunwald, 1964).            
Overview of pulmonary hemodynamics 
Briefly mentioned earlier, it is now well-recognized that the pulmonary hemodynamic 
response to exercise in HF is not consistent with responses demonstrated in healthy 
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individuals (Butler et al., 1999; Epstein et al., 1967). In general, there appears to be a 
severe increase in mPAP (>30 mm Hg) and attenuated decreases in PVR with increasing 
exercise workload in HF. Epstein et al. (1967) demonstrated that mPAP was 53 ± 25 mm 
Hg in HF at maximal exercise, which was over two times the values demonstrated in 
healthy individuals (29 ± 5 mm Hg, p<0.05) (Epstein et al., 1967). These findings were 
extended by Butler et al. (1999) who observed that elevated levels of mPAP (28 ± 11 
versus 40 ± 13 mm Hg), PCWP (18 ± 9 versus 23 ± 10 mm Hg), and PVR (2.45 ± 1.57 
versus 2.41 ± 1.52 wood units) at rest were exacerbated during exercise in HFrEF (Butler 
et al., 1999). Additionally, it was observed that severity of pulmonary hemodynamic 
dysfunction appeared to directly relate with the degree of cardiac hemodynamic 
impairment in HF. Individuals with HF who had resting PVR greater than 3.5 wood units 
demonstrated significantly worse peak exercise mPAP, PCWP, Q, and VO2 compared to 
patients with a PVR less than 1.5 wood units (Butler et al., 1999). Together, these 
observations of abnormal pulmonary hemodynamic responses during exercise suggest 
that dysfunctional regulation of pulmonary pressures should be considered a serious 
concern in HF; and, that the magnitude of cardiac impairment during exercise may be 
related to the severity of pulmonary hemodynamic impairment in these patients (Butler et 
al., 1999; Epstein et al., 1967; Franciosa, Baker, & Seth, 1985). 
Pulmonary hemodynamic responses during exercise in HF have been reported by 
Franciosa et al. (1985) to average 50.4 ± 12.9 mm Hg while reaching nearly 60 mm Hg in 
certain individuals (Franciosa et al., 1985). Also, consistent with the sharp rise in mPAP 
observed from rest to maximal exercise was the finding that PVR failed to drop 
significantly at maximal exercise. Somewhat surprising, however, despite abnormal 
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mPAP at maximal exercise, these parameters did not appear to correlated with exercise 
capacity (i.e. VO2MAX) in HF. In contrast, QI, which is attenuated in HF appears to be a 
rather strong correlated of VO2MAX (Franciosa et al., 1985). However, it is possible that 
the abnormal pulmonary hemodynamic responses to maximal exercise was secondary to 
the primary influences of impaired cardiac function; and, perhaps related to combined 
diastolic and systolic dysfunction in these patients (Franciosa et al., 1985). An elevated 
PCWP at maximal exercise is suggestive of elevated left atrial pressure (related to poor 
LV relaxation) which likely leads to back pressure toward the pulmonary venous 
circulation and contributes to the pulmonary hemodynamic responses that are observed in 
HF (Franciosa et al., 1985). 
In support of the potential role of diastolic dysfunction in contributing to abnormal 
pulmonary hemodynamics during exercise in HF, more recent evidence suggests that 
mPAP and systolic pulmonary arterial pressure (SPAP) at peak exercise are nearly two-
fold higher in HFpEF compared to healthy individuals (Borlaug, Nishimura, et al., 2010). 
Heart failure with preserved ejection fraction patients are known to have impaired LV 
relaxation at rest which is exacerbated during exercise. Moreover, in comparing cardiac 
with pulmonary hemodynamic responses between HFpEF and controls at rest and peak 
exercise, the evidence strongly suggests that exercise exacerbates abnormal cardiac and 
pulmonary hemodynamic function in HFpEF (Borlaug, Nishimura, et al., 2010). Thus, 
HFpEF patients demonstrate abnormal pulmonary hemodynamic responses to exercise 
which, despite differences in HF classification, appear to be similar to HFrEF (Borlaug, 
Nishimura, et al., 2010; Butler et al., 1999; Franciosa et al., 1985).   
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In summary, there is more than a negligible interaction between left sided HF, abnormal 
pulmonary hemodynamics, and impaired right heart function during exercise in patients 
with chronic HF. In addressing the latter consequence of chronic LV diastolic 
dysfunction, with or without concurrent systolic dysfunction,  it is crucial to understand 
pulmonary hemodynamic responses to exercise as direct interactions with cardiac 
function given SV is received by the pulmonary circulation and this appears to occur 
under exaggerated pulmonary pressures during exercise in HF (Borlaug, Nishimura, et 
al., 2010; Butler et al., 1999; Epstein et al., 1967; Franciosa et al., 1985).       
2.3 Peripheral neural factors influencing central hemodynamics during exercise 
2.3.1 Introduction 
Input to the brain originating from peripherally located sensory neurons can facilitate 
adjustments in cardiovascular function in all individuals. This afferent signal transduction 
comes from pathways of several types of receptors which includes contraction and/or 
metabolically activated skeletal muscle ergoreceptors—mechanoreceptors and 
metaboreceptors (Batman et al., 1994; Hayes, Kindig, & Kaufman, 2005; Herr, 
Imadojemu, Kunselman, & Sinoway, 1999; Kaufman, Longhurst, Rybicki, Wallach, & 
Mitchell, 1983; Kniffki, Mense, & Schmidt, 1978; MacLean, Imadojemu, & Sinoway, 
2000; McCloskey & Mitchell, 1972; Piepoli, Clark, & Coats, 1995; Piepoli, Dimopoulos, 
Concu, & Crisafulli, 2008; Rotto & Kaufman, 1988). More recently it has been suggested 
that the strength of activity originating from these reflexes and others (e.g. baroreceptors 
and chemoreceptors) changes depending on health status (e.g. HF versus healthy 
individuals) as well as resting versus exercising conditions (Crisafulli et al., 2011; 
Crisafulli et al., 2006; Crisafulli, Salis, et al., 2007; Dibner-Dunlap & Thames, 1992; 
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Hammond et al., 2001; Hansen, Thomas, Jacobsen, & Victor, 1994; Johnson, Joyner, & 
Olson, 2014; Leshnower, Potts, Garry, & Mitchell, 2001; Mitchell & Schmidt, 1983; 
Olson, Joyner, & Johnson, 2010; Piepoli et al., 1995; Piepoli et al., 1996; Piepoli et al., 
1999; Scott et al., 2000; Scott et al., 2004). Studies examining the function of the 
ergoreflex suggests that changes in efferent neural drive during exercise can be 
influenced by neural feedback originating within skeletal muscle (Amann et al., 2010; 
Asmussen & Nielsen, 1964; Coote, Hilton, & Perez-Gonzalez, 1971; Daley, Khan, 
Hogeman, & Sinoway, 2003; Freund, Rowell, Murphy, Hobbs, & Butler, 1979; Mark, 
Victor, Nerhed, & Wallin, 1985; McCloskey & Mitchell, 1972; Mitchell, Kaufman, & 
Iwamoto, 1983; Sinoway & Prophet, 1990; Vorluni & Volianitis, 2008). Studies 
examining the influence of afferent feedback from skeletal muscle suggests this feedback 
may lead to beneficial adjustments of the autonomic nervous system (ANS) by enhancing 
the exercise responses of the central circulation and cardiac tissue (i.e. ↑ sympathetic 
drive, ↓ parasympathetic drive, and ↑ Q) and vasculature of the peripheral circulation in 
an attempt to regulate homeostasis of the circulation (Crisafulli et al., 2011; Crisafulli et 
al., 2006; Fisher et al., 2010; Floras, 1993; McDaniel et al., 2010; Spranger et al., 2013; 
Tsuchimochi, Matsukawa, Komine, & Murata, 2002; White, Lykidis, & Balanos, 2013). 
In HF, however, evidence suggests this peripheral neural feedback is dysfunctional and 
contributes to exercise intolerance and exertional symptoms characteristic of the 
syndrome (Piepoli, 1998; Piepoli et al., 1999). Dysfunction of this neural feedback in HF 
is closely related to impaired ANS function, skeletal muscle myopathy (e.g. cachexia), 
and cardiovascular dysfunction (Coats, Clark, Piepoli, Volterrani, & Poole-Wilson, 1994; 
Minotti et al., 1991; Piepoli et al., 1996; Piepoli et al., 2006; Piepoli et al., 1999; 
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Szlachcic, Massie, Kramer, Topic, & Tubau, 1985; Wilson, Martin, & Ferraro, 1984). 
Moreover, it has been suggested that the ergoreceptor pathway is tonically dysfunctional 
in HF and a main contributor to chronic sympathoexcitation and symptomology observed 
at rest and during exercise in these patients (Crisafulli, Salis, et al., 2007; Floras, 1993; 
Hammond et al., 2001; Johnson et al., 2014; Olson, Joyner, & Johnson, 2010; Piepoli et 
al., 1999; Scott et al., 2004; Smith, Mitchell, Naseem, & Garry, 2005; Smith, Williams, 
Mitchell, Mammen, & Garry, 2005). Nevertheless, despite convincing observations with 
regard to the negative influence of the ergoreceptor pathway on cardiovascular function 
(i.e. ventilation and peripheral hemodynamics) in HF, it remains unclear what influence 
this pathway has on cardiac and pulmonary vascular hemodynamic function associated 
with exercise in HF.  
2.3.2 Anatomy and physiology of the ergoreceptor pathway 
The ergoreceptor pathway is a reflex arc linking the peripheral nervous system to the 
central nervous system. Ergoreceptors are unencapsulated afferent nerve endings found 
within the interstitium and around the vasculature and connective tissue and skeletal 
muscle. Upon stimulation, the neural feedback from skeletal muscle ergoreceptors 
synapse at cells located within the laminae of the dorsal horn of the spinal cord at which 
point signal transduction converges and is relayed toward the brainstem via second-order 
spinal neurons for organization, integration, and eventual modulation at higher-brain 
centers (Ciriello & Calaresu, 1977; Coote et al., 1971; Iwamoto, Parnavelas, Kaufman, 
Botterman, & Mitchell, 1984; Iwamoto, Kaufmann, Botterman, & Mitchell, 1982; Mark 
et al., 1985; McCloskey & Mitchell, 1972; Mitchell & Schmidt, 2011; Piepoli et al., 
1995; Randle Adair, Hamilton, Scappaticci, Helke, & Gillis, 1977; Sato, 1973; Strange et 
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al., 1993; Victor, Seals, & Mark, 1987). The brainstem houses neurons responsible for 
processing and integrating afferent input to regulate respiration, heart rhythm, and blood 
pressure; but, more specifically, contained within this medullary region are the 
ventrolateral medulla and dorsal caudal nucleus tractus solitarius (NTS) which are critical 
sites for sensory processing of somatic and cardiorespiratory neural feedback related to 
ergoreceptors. The ventrolateral medulla and caudal NTS are the terminals for afferent 
neural traffic from ergoreceptors, however, after convergence and organization, the 
resultant integrated neural signaling is relayed to higher brain centers (e.g. central 
command—hypothalamus, motor cortex, and cerebellum) for further modulation at 
which point appropriate efferent neural signals are sent to facilitate cardiovascular 
pressor responses (Ciriello & Calaresu, 1977; Iwamoto et al., 1984; Iwamoto et al., 1982; 
Iwamoto et al., 1985; Mark et al., 1985; McCloskey & Mitchell, 1972; Potts, Fuchs, Li, 
Leshnower, & Mitchell, 1999; Randle Adair et al., 1977; Sato, 1973). 
Ergoreceptors—Metaboreceptors and Mechanoreceptors   
Two specific types of sensory nerve fibers make up the umbrella term ‘ergoreceptors’. 
These polymodal muscle afferents have been identified as having high sensitivity to 
mechanical and/or metabolite specific stimuli related to skeletal muscle contraction. 
More specifically, group III myelinated C-fibers are considered mechanoreceptors and 
demonstrate a primary sensitivity to non-noxious mechanical deformation and pressure 
changes of skeletal muscle fibers with secondary responsiveness to metabolic byproducts 
of muscle contraction (Hanna, Hayes, & Kaufman, 2002; Hanna & Kaufman, 2004; Li & 
Sinoway, 2002; Middlekauff et al., 2004; Middlekauff et al., 2001; Smith, Mammen, 
Mitchell, & Garry, 2003; Smith, Mitchell, et al., 2005). In contrast, group IV 
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unmyelinated A-δ fibers are termed metaboreceptors and are primarily sensitive to 
ischemic metabolites, metabolic byproducts, and acidosis as a function of muscle 
contraction (e.g. H+, pH, capsaicin, bradykinin, prostaglandins, K+, lactic acid, or 
arachidonic acid) (Clark, Piepoli, & Coats, 1995; Hanna et al., 2002; Kaufman, Iwamoto, 
Longhurst, & Mitchell, 1982; Kaufman et al., 1983; Kaufman & Rybicki, 1987; 
Kaufman, Rybicki, Waldrop, & Ordway, 1984; Li & Sinoway, 2002; McCord, 
Tsuchimochi, & Kaufman, 2009; Piepoli et al., 1995; Rotto, Stebbins, & Kaufman, 1989; 
Rybicki, Kaufman, Kenyon, & Mitchell, 1984; Scott, Wensel, et al., 2003; Stebbins, 
Maruoka, & Longhurst, 1986; Victor, Bertocci, Pryor, & Nunnally, 1988). Although it 
may be commonly recognized that metaboreceptors and mechanoreceptors function in 
two distinct mechanistic pathways, the associated reflex pathways of these afferents are 
not mutually exclusive in that both types of ergoreceptors can lead to adjustments in ANS 
activity and sympathoexcitation in humans (exercise pressor reflex, EPR). The 
stimulation of mechanoreceptors (mechanoreflex) or metaboreceptors (metaboreflex) 
have been closely associated with ventilatory, cardiac, and peripheral hemodynamic 
adjustments which occur in healthy individuals during and immediately following 
exercise (Amann et al., 2010; Coote et al., 1971; Fisher et al., 2010; Mark et al., 1985; 
McCloskey & Mitchell, 1972; Spranger et al., 2013).  
The earliest evidence demonstrating muscle contraction could evoke a pressor reflex was 
by Alam and Smirk (1937). These authors demonstrated that direct increases in blood 
pressure could be elicited using circulatory occlusion of the leg (via sphygmomanometer 
cuffs around the upper thigh) during seated dynamic calf exercise. This study also 
showed that increases in blood pressure which occurred during exercise were augmented 
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at the cessation of exercise by maintaining suprasystolic cuff pressure for an additional 
3–4 min post-exercise (Alam & Smirk, 1937). Because of the exaggerated blood pressure 
response demonstrated individual using this technique it was speculated that the 
heightened response during post-exercise with occlusion was caused by retention of the 
byproducts from muscle contraction (e.g. H+, lactic acid, K+) within the muscle which 
facilitated a pressor reflex (i.e. ↑ sympathetic drive) via afferent signal transduction 
(Alam & Smirk, 1937). 
2.3.2.1 Metaboreflex 
Metaboreceptors are stimulated by the accumulation of metabolites as opposed to the act 
of contracting muscle. Therefore, it is suggested that rapidity of firing of group IV 
afferents is consistent with time needed for the accumulation of byproducts of skeletal 
muscle metabolism, however, these afferents may also fire in direct proportion to 
magnitude of metabolite buildup (Kaufman et al., 1983; Kaufman, Rybicki, et al., 1984; 
Kaufman, Waldrop, Rybicki, Ordway, & Mitchell, 1984).  
The laboratory of Coote et al. (1971) was one of the first to directly confirm the pressor 
response of the metaboreflex by using isolated electrical stimulation of lumbar and sacral 
ventral roots to simulate hind-limb exercise in cat preparations (Coote et al., 1971). 
Observations from this novel study suggested that increases in arterial blood pressure, 
HR, and ventilation were reflex responses which originated within contracting muscle. 
Also demonstrated was that when vascular occlusion to the contracting limb was induced 
to attenuate arterial blood flow, the rise in arterial blood pressure was augmented 
compared to contractions during non-ischemia, suggesting that the origin of the 
metaboreceptor pressor response was chemical in nature and caused by the accumulation 
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of metabolites from skeletal muscle metabolism (Coote et al., 1971; Coote & Perez-
Gonzalez, 1970; Mark et al., 1985; Piepoli et al., 1995). Moreover, to confirm the 
muscular origins of the metaboreflex response, these authors further demonstrated that 
increases in arterial blood pressure were abolished when muscular contraction was 
inhibited by cholinergic blockade using gallamine triethiodide, as well as when sensory 
input to the spinal cord was eliminated via transection of dorsal roots of lumbar and 
sacral regions (Coote et al., 1971).   
McCloskey and Mitchell subsequently demonstrated, in a similar feline model, that 
anodal blockade of the L7–S1 dorsal roots did not influence cardiovascular responses to 
muscle contraction, whereas applying a topical anesthetic to dorsal roots of this same 
region did not inhibit group I and II sensory nerves but did attenuate cardiovascular 
responses to muscle contraction (McCloskey & Mitchell, 1972). Thus, it was suggested 
that skeletal muscle group IV and to a lesser extent group III nerve afferents stimulated 
by exercise, ischemic exercise (arterial and venous occlusion), and post-exercise ischemia 
(PEI) could unequivocally evoke chemically mediated pressor reflex response increases 
in arterial blood pressure, HR, and ventilation (Coote et al., 1971; McCloskey & 
Mitchell, 1972). Further, in a more recent study in humans using adrenergic or 
cholinergic blockade, Fisher et al. (2010) observed that the blood pressure response to 
isometric handgrip exercise (i.e. 25.0% and 40.0% of maximum voluntary contraction, 
MVC) or PEI was dependent on metaboreflex feedback (Fisher et al., 2010). 
Additionally, these authors found that during PEI, the engagement of the metaboreflex 
resulted in an augmented HR response which paralleled blood pressure changes (Fisher et 
al., 2010). Thus, these newer data in healthy individuals suggest that the intensity of the 
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metaboreflex response may be workload dependent and that this may influence cardiac 
sympathetic drive while contributing to adjustments in central hemodynamics (i.e. ↑ Q 
and SV) in addition to its known impact on peripheral hemodynamics. There is 
substantive evidence to suggest that the metaboreflex initiated during exercise in healthy 
individuals contributes to ANS activity directed toward central and peripheral vascular to 
benefit cardiovascular function.   
2.3.2.2 Mechanoreflex 
Mechanoreceptors are abundant within and around skeletal muscle of humans and 
animals. Yet, despite the similarity in anatomical origin of these receptors, the polymodal 
mechanoreceptor is unique because of its rapid and preferential sensitization by non-
noxious mechanical (e.g. stretch/contraction) and to a lesser extent chemical stimuli 
(Adreani & Kaufman, 1998; Batman et al., 1994; Hayes et al., 2005; Herr et al., 1999; 
Kaufman, Waldrop, et al., 1984; McDaniel et al., 2010). Observations from studies in 
both healthy individuals and animals suggest that the mechanoreflex is particularly active 
during periods of passive and/or low- to- moderate intensity rhythmic exercise (Batman 
et al., 1994; Gladwell & Coote, 2002; Hayes et al., 2005; Herr et al., 1999; McDaniel et 
al., 2010). Upon sensitization, the mechanoreflex has the capacity to influence 
adjustments in ANS activity (↑ sympathetic drive) in order to facilitate changes in 
cardiovascular function which can result in beneficial adjustments to HR, blood pressure, 
and ventilation in order meet the metabolic demands of the cardiovascular system during 
exercise in healthy individuals (Gladwell & Coote, 2002; McCloskey & Mitchell, 1972; 
McDaniel et al., 2010; Mitchell et al., 1983; Vorluni & Volianitis, 2008; White et al., 
2013). 
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Initial findings by McCloskey and Mitchell and later of Adreani and Kaufman and 
Tsuchimochi et al. (2002) indicate that mechanoreceptors in addition to metaboreceptors 
within cat skeletal muscle during PEI and ischemic and non-ischemic static and/or 
dynamic exercise can facilitate reflex responses of cardiac, cardiovascular, and 
ventilatory systems (Adreani & Kaufman, 1998; McCloskey & Mitchell, 1972; 
Tsuchimochi et al., 2002). Moreover, to extend the observations of McCloskey and 
Mitchell (1972) (McCloskey & Mitchell, 1972), in a similar feline model in which 
ventral root stimulation was used to facilitate static hind-limb exercise, Kaufman et al. 
(1983) quantified the relative activity and pattern of responses of group III and IV nerve 
afferents required to elicit cardiovascular responses (Kaufman et al., 1983). Kaufman et 
al. (1983) demonstrated that both groups of nerve afferents contributed to reflex 
responses, but also that there was contrasting and preferential activity of group III and IV 
nerve afferents specific for mechanical and chemical stimuli, respectively, elicited from 
contracting skeletal muscle (Kaufman et al., 1983). In more recent studies of healthy 
individuals during exercise, there is evidence which suggests that sensitized skeletal 
muscle mechanoreceptors contribute to augmented sympathetic drive during exercise that 
can contribute to normal cardiac, vascular, and ventilatory function which is observed 
during exercise (Batman et al., 1994; Gladwell & Coote, 2002; Herr et al., 1999; 
McDaniel et al., 2010; Vorluni & Volianitis, 2008, 2010; White et al., 2013).   
Herr et al. (1999) measured muscle sympathetic nerve activity (MSNA) of non-
exercising legs of eight healthy men during 12-repetitions (each lasting 20.0 seconds of 
duration) of static left-leg quadriceps exercise at 25.0% of relative MVC (Herr et al., 
1999). These authors suggest that mechanoreflex mediated increases in MSNA occurred 
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within 4-6 seconds of the onset of low-intensity intermittent quadriceps contractions. 
Also observed, beginning with repetition number three, it was apparent that significant 
increases in MSNA occurred as a function of exercise repetition number and, hence, the 
mechanoreflex is potentially related to exercise intensity or work performed. Stimulation 
of the mechanoreflex was also observed to be closely related to adjustments in 
cardiovascular outcomes, with both HR and MAP increasing with each successive 
exercise repetition starting from baseline (Herr et al., 1999). In contrast to the findings of 
Herr et al. (1999), metaboreceptor-mediated elevation of MSNA has been demonstrated 
to take upwards of 30–60 seconds (Mark et al., 1985).  
To extend the observations of Herr et al. (1999) (Herr et al., 1999), White et al. (2013) 
found that stretch activation of skeletal muscle mechanoreceptors could influence 
significant increases in SPAP, peripheral blood pressures, Q, SV, and HR in healthy 
individuals during ischemic plantar-flexor exercise (White et al., 2013). Moreover, SPAP 
during PEI (i.e. metaboreflex activation alone) was not associated with changes in Q 
during this condition (White et al., 2013). Whereas, when PEI combined with passive-
stretch was present (i.e. chemical and mechanical stimuli present), it was demonstrated 
that significant increases in Q (via ↑ in HR and SV) occurred in the absence of significant 
changes in SPAP (White et al., 2013). Thus, importantly, these observations suggest that 
the mechanoreflex has the capacity to influence metaboreflex-mediated pulmonary 
vasodilation and/or attenuation of metaboreflex-mediated increases in PVR. This 
potentially could occur via mechanoreflex-mediated increases in cardiac sympathetic 
drive and parasympathetic-vagal withdrawal, as would be suggested by the increases in 
HR and SV during PEI + passive-stretch (White et al., 2013). As such, the observations 
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of this study in healthy individuals as well as those of others in animals and humans 
clearly indicate that the mechanoreflex is excitable with deformation of skeletal muscle 
(i.e. passive, static, and/or dynamic exercise) which likely contributes to increases in 
MSNA that are closely associated with cardiac, vascular, and ventilatory reflex responses 
(Adreani & Kaufman, 1998; Batman et al., 1994; Hayes et al., 2005; Herr et al., 1999; 
Kaufman, Waldrop, et al., 1984; Lykidis, White, & Balanos, 2008; Mark et al., 1985; 
McCloskey & Mitchell, 1972; White et al., 2013). It also remains possible that 
stimulation of the mechanoreflex may occur prior to that of the metaboreflex and 
therefore an earlier contributor to adjustments in MSNA than the metaboreflex. Lastly, 
the strength of the mechanoreflex pressor response may be augmented in accordance with 
exercise intensity or skeletal muscle work output as well as in the presence of additional 
chemical stimuli (Adreani & Kaufman, 1998; Gladwell & Coote, 2002; Hayes et al., 
2005; Herr et al., 1999; Kaufman et al., 1983; Leshnower et al., 2001; McDaniel et al., 
2010; Tsuchimochi et al., 2002; White et al., 2013). 
2.3.2.3 Exercise pressor reflex and central hemodynamics 
Cardiac hemodynamics 
In contrast to the evidence supporting the association between the EPR and ventilatory 
and peripheral vascular control during exercise, our understanding of the magnitude of 
association between the EPR and the adjustments which occur to central hemodynamics 
during or immediately following exercise in healthy individuals is less clear. In this light, 
a few studies have demonstrated evidence to suggest an association between the EPR and 
cardiac hemodynamics during exercise in an attempt to regulate circulation in healthy 
individuals.  
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In a recent study on the influence of the metaboreflex on Q in the canine model during 
treadmill running, Ichinose et al. (2010) observed that when the metaboreflex was 
activated by an acute reduction in hindlimb blood flow there was a significant increase in 
Q (↑ HR and SV) which was sustained during the course of ischemia (Ichinose et al., 
2010). Moreover, when Q was not permitted to increase beyond the level that observed 
during non-metaboreflex activated exercise, the metaboreflex mediated a significant 
increase in peripheral vascular resistance and decreased vascular conductance in non-
ischemic limbs (Ichinose et al., 2010). This reduction in vascular conductance was 
significant compared to the condition where Q was freely able to adjust. Thus, these 
contrasting responses of hemodynamics in response to metaboreflex activation during 
exercise in canines suggest that metaboreflex-mediated adjustments in Q occur in an 
attempt to restore blood flow to hypo-perfused metabolically active tissue (Ichinose et al., 
2010). Whereas, when cardiac reserve is impaired (e.g. HF), metaboreflex stimulation 
leads to increases in peripheral vascular resistance. These findings suggest that 
stimulation of the metaboreflex can increase cardiac contractility (i.e. SV) in non-failing 
hearts, and that Q is an important mediator of arterial pressure which reaffirms the role of 
the heart as a hydraulic power generator. 
In a similar experimental set-up to study the association between the metaboreflex and Q 
responses in canines, observations by Spranger et al. (2013) support the relationship 
between Q and the metaboreflex demonstrated by Ichinose et al. (2010) (Ichinose et al., 
2010; Spranger et al., 2013). However, to extend these findings and attempt to isolate the 
metaboreflex to a greater extent versus the potential influences of the mechanoreflex, 
Spranger et al. (2013) also studied the Q response during post-exercise recovery with 
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metaboreflex activation (Spranger et al., 2013). These authors found significantly higher 
Q (via HR and lesser SV) and MAP during post-exercise recovery with metaboreflex 
activation compared to recovery without metaboreflex stimulation (Spranger et al., 2013). 
This was accompanied by no significant differences in vascular conductance between 
conditions which could be expected since Q was freely able to adjust and no central 
command was present as these canines were in a state of static rest. Also, although not 
significant, SV was still higher during recovery with metaboreflex activation versus 
normal recovery (Spranger et al., 2013). These observations during and immediately 
following exercise suggest that there is a strong influence of the metaboreflex on 
contributing to increased HR, SV, and Q in a condition where cardiac function is not 
impaired. It is likely that adjustments in factors (e.g. MAP and vascular conductance) 
influencing perfusion pressure to metabolically active tissue are closely associated with 
the ability of cardiac hemodynamics to adjust at rest and during exercise healthy 
individuals. 
To extend these observations to healthy individuals, Crisafulli et al. (2011) recently 
observed  that Q responses to metaboreflex activation during exercise and post-exercise 
were consistent with the observations of Ichinose et al. (2010) and Spranger et al. (2013) 
in healthy canines (Crisafulli et al., 2011; Fisher et al., 2010; Spranger et al., 2013). It 
was shown that increased Q during hand-grip exercise with an metaboreflex stimulation 
(via upper arm suprasystolic cuffing) was significantly higher versus hand-grip exercise 
without metaboreflex stimulation. Alternatively, during post-exercise recovery with 
suprasystolic cuffing, Q was significantly higher versus rest, whereas Q during normal 
recovery was no different from rest (Crisafulli et al., 2011). Additionally, the SV 
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response during post-exercise recovery with metaboreflex augmentation was significantly 
higher versus rest as well as that of normal recovery. These differences in SV between 
recovery conditions contrasted the HR response which recovered to resting values with 
and without metaboreflex stimulation. These observations suggest that metaboreflex 
stimulation increases in HR and Q in healthy individuals (Crisafulli et al., 2011). 
Whereas, because of observations during post-exercise recovery with sustained 
augmentation of the metaboreflex, it is possible that increases in Q via elevated SV are 
significantly influenced by group IV metabolite-sensitive neural feedback. Accordingly, 
although it is difficult to interpret during exercise whether metabo- or mechano-reflexes 
are the primary mediators of this reflex, it would appear as a result of post-exercise 
responses of SV that the metaboreflex can contribute to increased cardiac contractility 
(i.e. SV) in healthy individuals. 
Pulmonary hemodynamics 
Contrasting what would appear to be a favorable influence of the EPR on cardiac 
hemodynamics in healthy individuals, recent findings from studies suggest that 
pulmonary hemodynamics may be impaired by the EPR in healthy individuals. It was 
observed that sustained isometric exercise of handgrip muscles followed immediately by 
upper arm regional circulatory occlusion (RCO) during recovery was associated with 
elevated SPAP versus a resting condition immediately followed by RCO (control) 
(Lykidis et al., 2008). This elevation in SPAP during exercise and recovery with RCO 
was significantly higher versus resting values of SPAP, while also demonstrating that 
SPAP did not return to baseline until the second minute of recovery following release of 
the upper arm cuff. These adjustments in SPAP appeared to relate with changes in Q and 
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SV which also may have been associated with adjustments in peripheral blood pressure 
(i.e. MAP, SBP, and DBP). Cardiac output and peripheral blood pressure were 
significantly higher compared to rest during exercise and recovery with RCO, whereas 
SV was higher in these same comparisons albeit not significantly (Lykidis et al., 2008). It 
was also apparent that exercise and recovery with RCO was associated with higher HR, 
SV, and Q versus the control condition. Thus, the metaboreflex may play a role in 
regulating the pulmonary vasculature as well in healthy individuals. Alternatively, it is 
possible that because of the higher distensibility of pulmonary vasculature compared to 
that of the peripheral arterial vasculature, metaboreflex-mediated increases in SPAP are 
protective to the pulmonary vasculature to assist in increasing pulmonary capillary 
perfusion while also preventing over distension of vessels during periods of increasing 
pulmonary blood flow (Lykidis et al., 2008). 
This same group subsequently studied the combined influence of metabo- and mechano-
reflex activation on pulmonary hemodynamics in healthy individuals (White et al., 2013). 
In a unique study design using active plantarflexion exercise or passive dorsiflexion 
stretch of calf muscles, it was shown that ischemic exercise results in significantly higher 
SPAP compared to rest and that this significance persisted during ischemic recovery and 
then during ischemic dorsiflexion of muscles. The changes in SPAP also appeared to be 
markedly higher versus the control condition of no exercise followed by ischemic rest 
and ischemic dorsiflexion. Similar to previous observations with hand-grip exercise 
(Lykidis et al., 2008), changes in SPAP appeared coincide with changes in HR, SV, and 
Q during plantarflexor exercise and ischemic recovery (White et al., 2013). However, in 
extending earlier observations, it was observed during ischemic dorsiflexion in the 
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exercise condition that HR, SV, and Q were significantly higher compared to rest, 
whereas this did not occur in the control condition. Moreover, changes in SV and Q 
during ischemic recovery and ischemic stretch following exercise appeared to mirror 
adjustments in blood pressure (i.e. MAP and DBP). These findings corroborate previous 
observations to suggest that active mechanoreflex stimulation with augmentation of the 
metaboreflex can contribute to increases in SPAP which parallel Q, HR, and peripheral 
blood pressure in healthy individuals (Lykidis et al., 2008; White et al., 2013). These 
observations of the central and peripheral hemodynamic response to metabo- and 
mechano-reflex activation shed light on the integrated role each of these pathways has on 
circulatory regulation during exercise in healthy individuals.  
In summary, the metaboreflex contributes to elevations in SPAP in healthy individuals 
(Lykidis et al., 2008; White et al., 2013); however, the highest level of SPAP achieved in 
these individuals would not typically be considered abnormal in comparison to the level 
reached at rest or during exercise in the disease conditions such as HF or PH (Aronson et 
al., 2011; Galie et al., 2009; Simonneau et al., 2009). Therefore, although unclear, it is 
unlikely that the elevation in SPAP in response to metaboreflex activation is indeed a 
harmful response in healthy individuals. Rather, this stiffening of pulmonary arteries 
would appear to be a normal mechanism to protect the pulmonary vasculature in response 
to increased Q and SV, which could evoke excessive distention of pulmonary vessels due 
to augmented vascular loading related to augmented pulmonary blood flow.      
2.3.3 Exercise pressor reflex and the “muscle hypothesis” in heart failure 
Despite the capacity of the EPR to beneficially influence cardiac, cardiovascular, and 
ventilatory function during exercise in healthy individuals (Amann et al., 2010; Crisafulli 
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et al., 2011; Fisher et al., 2010; Mark et al., 1985; McDaniel et al., 2010; White et al., 
2013), mounting evidence suggests that EPR pathways are dysfunctional in HF and that 
these pathways are associated with tonic neurohumoral hyperexcitation, ergoreceptor 
hyper- or hypo-sensitization, and impaired cardiovascular function; which, suggests that 
peripheral neural mechanisms may be closely associated with symptoms and prognosis in 
HF (Crisafulli, Salis, et al., 2007; Dibner-Dunlap & Thames, 1992; Johnson et al., 2014; 
Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999; Ponikowski et al., 2001; Scott et al., 
2000; Smith, Williams, et al., 2005). However, it remains unclear whether cardiac 
hemodynamics are influenced by afferent feedback in HF, whereas observations in 
healthy individuals clearly indicate that cardiac hemodynamics are favorably influenced 
by group III/IV neural feedback associated with exercise (Crisafulli, Salis, et al., 2007; 
Dibner-Dunlap & Thames, 1992; Johnson et al., 2014; Jondeau et al., 1992; Olson, 
Joyner, & Johnson, 2010; Piepoli et al., 2008; Ponikowski et al., 2001; Scott, Davies, 
Coats, & Piepoli, 2002; Smith, Williams, et al., 2005). 
Exercise intolerance, dyspnea, and fatigue are hallmark symptoms of HF have 
traditionally been attributed to dysfunction of central hemodynamics and/or pulmonary 
congestion. More recently, an emerging body of evidence suggests that peripheral factors 
may play a larger role than once believed (Coats et al., 1994; Johnson et al., 2014; 
Jondeau et al., 1992; Middlekauff et al., 2004; Minotti et al., 1991; Olson, Joyner, & 
Johnson, 2010; Piepoli et al., 1999; Smith, Mitchell, et al., 2005; Szlachcic, Massie, et al., 
1985). This alternative explanation for symptoms of HF suggests that exercise 
intolerance, dyspnea, and fatigue are likely attributable to impaired mechanisms in the 
periphery and explainable by the “muscle hypothesis” (Coats et al., 1994; Middlekauff et 
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al., 2004; Minotti et al., 1991; Olson, Joyner, & Johnson, 2010; Piepoli et al., 2006; 
Piepoli et al., 1999; Smith, Mitchell, et al., 2005). The muscle hypothesis suggests that 
increased neural feedback from locomotor muscle is most striking during times of 
physical exertion likely because increased contractile activity of poorly functioning 
skeletal muscle causing exaggerated neural feedback from already dysregulated 
ergoreceptors in these patients (Clark, Poole-Wilson, & Coats, 1996; Li et al., 2004; 
O'Leary et al., 2004; Shoemaker, Kunselman, Silber, & Sinoway, 1998; Smith, Mitchell, 
et al., 2005; Smith, Williams, et al., 2005). 
2.3.3.1 Metaboreflex in heart failure 
In contrast to the observations in healthy animals and humans, the effects of the 
metaboreflex in HF appear paradoxical. Hammond et al. (2000) observed in the pacing-
induced HF canine model that during exercise with graded aortic ischemia, skeletal 
muscle metaboreflex pathways are not only sensitized by these conditions, but the 
cardiovascular responses are markedly different compared healthy individuals 
(Hammond et al., 2000). Hammond et al. (2000) demonstrated that the metaboreflex 
contributes to exaggerated increases in sympathetic drive to cause peripheral 
vasoconstriction (Hammond et al., 2000). Further, the Q response to stimulation of the 
metaboreflex was negligible in the HF condition. These observations and those of others 
help to support the hypothesis that in the presence of HF, the metaboreflex is active but 
dysfunctional and associated with abnormal pressor reflex responses of the central and 
peripheral circulation during exercise in comparison to non-HF (Hammond et al., 2000; 
Hammond et al., 2001; O'Leary et al., 2004). 
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In the rat model of HF, complimentary studies of Li et al. (2004) and Smith et al. (2005) 
demonstrated that the EPR was dysfunctional (Li et al., 2004; Smith, Williams, et al., 
2005). However, because capsaicin administered to the neonate rat is known to destroy 
unmyelinated (i.e. metaboreceptors) but not myelinated (i.e. mechanoreceptors) neural 
afferents in rats (Jancso, Kiraly, & Jancso-Gabor, 1977; Nagy & van der Kooy, 1983), by 
treating neonatal rats with capsaicin, Smith et al. (2005) observed an enhanced 
cardiovascular (i.e. HR and MAP) pressor response to muscle contraction which was 
comparable to pressor response of rats with HF (Smith, Williams, et al., 2005). Thus, 
because mechanoreceptors and hearts of capsaicin treated neonatal rats were determined 
to be fully functional, in addition to the similarities in cardiovascular responses to muscle 
contraction in HF rats, the observations of Smith et al. (2005) suggested that the 
abnormal HR and MAP responses to muscle contraction were likely due to the removal 
of metaboreceptors (Smith, Williams, et al., 2005). These observations suggest that part 
of the link between abnormal cardiovascular responses in HF may be related to blunted 
sensitivity of metaboreceptors due to desensitization and/or downregulation of these 
nerve afferents. 
Similar to the interpretations of Smith et al. (2005) (Smith, Williams, et al., 2005), 
although using a different methodology, Li et al. (2004) observed that the sensitivity of 
metaboreceptors could be blunted in HF (Li et al., 2004). Previous observations suggest 
that when capsaicin is injected into the intra-arterial circulation of contracting hindlimbs 
that this can be used to selectively stimulate metaboreceptors and evoke a pressor 
response of the cardiovascular system in rats (Guo, Vulchanova, Wang, Li, & Elde, 1999; 
Michael & Priestley, 1999). Therefore, following the injection of capsaicin into the 
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arterial circulation of hindlimbs in healthy rats and rats with HF, in the absence of muscle 
contraction, it was observed that blood pressure was significantly increased in healthy 
rats versus rats with HF. Thus, similar to the conclusions of Smith et al. (2005) (Smith, 
Williams, et al., 2005), it could be possible based on the blood pressure response to intra-
arterial capsaicin injection that the sensitivity of metaboreceptors are blunted in HF and 
related to abnormal cardiovascular responses that are commonly observed in HF.       
To extend the findings of animal models to human HF our group recently examined the 
influence of the metaboreflex on ventilatory responses during post-exercise recovery in 
NYHA class I and II HF compared to healthy individuals (Olson, Joyner, & Johnson, 
2010). We observed that a four-minute bout of moderate intensity (60.0% VO2peak) 
steady-state cycling-exercise results in an attenuated return of ventilation to resting levels 
during metaboreflex stimulation (via bilateral supra-systolic blood pressure cuffing 
around upper thighs) This finding suggest that the metaboreflex pathway is stimulated by 
exercise and also that this reflex is abnormally augmented in HF in comparison to healthy 
individuals. 
Subsequently, we have demonstrated that the exercise blood pressure response is also 
associated with heightened metaboreflex activity (Keller, Johnson, Joyner, & Olson, 
2014). It was observed that significantly elevated MAP and SBP during exercise 
persisted during post-exercise recovery with RCO-mediated metaboreflex stimulation in 
HF. In contrast, MAP and SBP did not continue to increase during recovery in healthy 
individuals. Overall, the contribution of these respiratory and peripheral blood pressure 
observations in response to metaboreflex stimulation help to support the body of evidence 
which suggests that the mechanisms regulating the influence of metabolite-sensitive 
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neural feedback on cardiovascular and ventilatory function are dysfunctional in HF 
(Keller et al., 2014; O'Leary et al., 2004; Olson, Joyner, Dietz, et al., 2010; Shoemaker et 
al., 1998).          
2.3.3.2 Mechanoreflex in heart failure 
In addition to the pathophysiologic changes noted in the metaboreflex a outlined above, 
studies have suggested that the mechanoreflex is also abnormal in HF (Middlekauff et al., 
2001; Smith et al., 2003). In revisiting the observations in rats with HF from the group of 
Li et al. (2004), in addition to evidence suggesting decreased responsiveness of the 
metaboreflex in HF, these authors further suggest that the augmented afferent feedback in 
HF could be due to hypersensitivity of mechanoreceptors (Li et al., 2004).  
In describing the potential hypersensitivity of the mechanoreflex in HF, it is important to 
note that adenosine triphosphate (ATP) accumulation within the muscle interstitium has 
been previously demonstrated to occur during muscle contraction in decerebrate cats (Li, 
King, & Sinoway, 2003); and, that the mechanoreflex has been observed to be augmented 
in the presence of ATP as well as intra-arterial injections of α,β-methylene ATP via 
purinergic (P2X) receptors which can be found on group III afferent fibers (Hanna et al., 
2002; Hanna & Kaufman, 2003; Li et al., 2003; Li & Sinoway, 2002). Previous 
observations suggests a significant pressor response (i.e. MAP and HR) when α,β-
methylene ATP is injected into the intra-arterial circulation of hindlimbs in rats with HF 
prior to manual stretch in comparison to rats with HF that received saline and rats without 
HF receiving α,β-methylene ATP or saline (Li et al., 2004). These data suggest that HF 
may be associated with an augmented sensitivity of mechanoreceptors to mechanical 
stretch as well as to by-products of metabolism (e.g. ATP). 
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To complement the observations of Li et al. (2004) and to further understand the 
contribution of mechanoreceptors to the abnormal EPR in HF (Li et al., 2004), Smith et 
al. (2005) studied rat hindlimbs using various techniques to isolate the mechanoreflex 
pathway (Smith, Mitchell, et al., 2005). By selectively activating or blocking group III 
neural afferents using electrical stimulation of lumbar ventral roots to simulate static 
muscle contractions, gadolinium injectate (blocks mechanoreceptors), passive stretching, 
and/or treatment with capsaicin. These authors have found that mechanoreceptor activity 
is augmented in the presence. In response to both passive stretch and static contraction of 
hindlimbs prior to and following gadolinium administration, relative and absolute 
measures of HR and MAP were significantly higher in both rats with HF and neonatal 
rats treated with capsaicin compared to rats without HF further suggesting that 
mechanoreflex-mediated EPR pathways are dysfunctional in HF (Smith, Mitchell, et al., 
2005). Moreover, although passive and static contraction during gadolinium exposure 
contributed to increases in the pressor response that were significantly less than pre-
gadolinium contractions in all rats, the magnitude of increase remained significantly 
higher in both rats with HF and neonatal capsaicin rats compared to rats without HF 
(Smith, Mitchell, et al., 2005). In contrast, this pressor response was not seen when saline 
was used in place of gadolinium during contractions in all rats. These observations and 
those of others provide evidence that the sensitivity of mechanoreceptors may be 
heightened in HF which likely contributes to the augmented pressor reflex during 
exercise in HF (Li et al., 2004; Middlekauff et al., 2004; Smith, Mitchell, et al., 2005; 
Wang, Li, Gao, Zucker, & Wang, 2010).  
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Consistent with the observations in animal models of HF, testing of the mechanoreceptor 
in humans with HF supports that the mechanoreflex is abnormally augmented in HF (Li 
et al., 2004; Middlekauff et al., 2004; Middlekauff et al., 2001; Smith, Mitchell, et al., 
2005; Smith, Williams, et al., 2005). Middlekauff et al. (2004) in a mechanistic study was 
one of the first to directly confirm the abnormal activity of mechanoreceptors in 
individuals with HF (Middlekauff et al., 2004). Middlekauff et al. (2004) demonstrated 
that passive wrist exercise coupled with microneurography could be used to isolate, 
excite, and quantify the activity of mechanoreceptors, which indicated accentuated 
MSNA in NYHA class II–III HF but not in healthy individuals. These authors also 
observed that low-level (20.0% of relative MVC) rhythmic (30 contractions/min for 
three-minutes) handgrip exercise could be used to isolate and excite mechanoreceptors in 
HF and healthy individuals (Middlekauff et al., 2004). Although both groups 
demonstrated mechanoreceptor-mediated elevations in MSNA attributable to low-level 
rhythmic exercise; perhaps more importantly, increased MSNA was significantly 
exaggerated and occurred earlier in HF compared to healthy individuals. These data 
suggest a heightened sensitivity and level of activity of mechanoreceptors in individuals 
with HF and confirm prior observations in animal models of HF (Li et al., 2004; 
Middlekauff et al., 2004; Smith et al., 2003; Smith, Mitchell, et al., 2005; Smith, 
Williams, et al., 2005; Wang et al., 2010).   
2.3.3.3 Exercise pressor reflex and central hemodynamics in heart failure 
Cardiac hemodynamics 
Our current understanding of the influence of the afferent feedback on cardiac 
hemodynamics in HF is unclear (Amann et al., 2014; Piepoli et al., 1999). Observations 
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from several studies in animals with or without HF suggest that the response of cardiac 
hemodynamics in HF is not similar to what could be expected in the non-HF state 
(Ansorge et al., 2005; Hammond et al., 2000; O'Leary et al., 2004; Sala-Mercado et al., 
2007). Briefly, as discussed previously, when Q and SV are permitted to freely adjust in 
proportion to metabolic demand arterial pressure and vascular conductance adjusted in 
parallel. In contrast, when adjustments in Q and SV are restricted during periods of 
increased hemodynamic demand changes in arterial pressure and vascular conductance 
occurred in response to changes in vascular tone as opposed to the influence from cardiac 
hemodynamics (Crisafulli et al., 2011; Ichinose et al., 2010; Spranger et al., 2013).  
Hammond et al. (2000) have demonstrated in a cross-over experiment that the 
metaboreflex did not elicit adjustments in Q and SV in dogs with HF comparable to 
healthy canines (Hammond et al., 2000). Both Q and SV were lower in HF versus non-
HF at rest and during exercise in both the absence and presence of metaboreflex 
stimulation. Although, with metaboreflex activation during exercise, Q and SV responses 
were diminished but in the presence of normal changes in HR and right atrial pressure 
(RAP) in HF compared to no HF (Hammond et al., 2000). Cardiac output and SV 
changes during exercise in HF with metaboreflex activation did not rise above exercise 
values without metaboreflex activation, but HR and RAP did. In contrast, Q, SV, and HR 
during exercise with metaboreflex activation in the absence of HF increased significantly 
versus exercise without metaboreflex activation. Also important, it appeared that 
adjustments in arterial pressure and systemic vascular conductance occurred in a manner 
which reflected adjustments or lack of adjustments in Q and SV in both the non-HF and 
HF condition, respectively (Hammond et al., 2000). These changes in arterial pressure 
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and systemic vascular conductance in HF were mainly due to peripheral vascular 
constriction, whereas changes in the non-HF condition were largely due to increases in 
cardiac hemodynamics. It could be suggested that in the absence of HF, the metaboreflex 
increases HR and cardiac contractility which result in increases in Q and SV that 
contribute to changes in arterial pressure and vascular (Hammond et al., 2000). In 
contrast, in HF, metaboreflex influenced increases in HR are not accompanied by 
increased cardiac contractility (potentially due to ischemic tissue and/or β-receptor 
abnormalities) and therefore Q and SV cannot increase, which attenuates the ability of Q 
to contribute to arterial pressure and vascular conductance. This results in exaggerated 
peripheral vascular constriction in attempts to maintain driving pressure for venous return 
(Sheriff, Augustyniak, & O'Leary, 1998). The observations and interpretations of 
Hammond et al. (2000) are supported by others (Ansorge et al., 2005; O'Leary et al., 
2004; Sala-Mercado et al., 2007; Sala-Mercado et al., 2006; Sheriff et al., 1998).  
In addition to confirming the impaired cardiac hemodynamic response to metaboreflex 
activation in dogs with HF, more recent studies have provided further evidence to suggest 
that there are critical relationships between changes in HR, cardiac contractility, and 
venous return during metaboreflex activation. In healthy dogs, it would appear that 
metaboreflex activation can contribute to increases HR and maintenance of central 
venous pressure which mirror increases in myocardial contractility (similar to an 
inotropic agent) and augmentation of the Frank—Starling mechanism (O'Leary et al., 
2004; Sala-Mercado et al., 2007; Sala-Mercado et al., 2006; Sheriff et al., 1998). In HF, 
because of factors related to abnormal β-receptor function and/or necrotic myocardial 
tissue for example, the ability to increase cardiac contractility either by the metaboreflex 
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and/or Frank—Starling mechanism may be severely limited and, therefore, despite 
maintained central venous pressure via metaboreflex activation, dysfunctional myocardial 
tissue likely prohibits normal increases in Q and SV (Ansorge et al., 2005; O'Leary et al., 
2004; Sala-Mercado et al., 2007). Furthermore, because metaboreflex activation 
contributes to increases in both HR and arterial resistance (i.e. afterload), these factors in 
parallel with blunted cardiac contractility likely exacerbate the attenuated rise of Q and 
SV in HF. 
In contrast to the numerous observations in animal models of HF regarding relationships 
between the EPR and cardiac hemodynamics, there is a considerable gap in the 
understanding of the EPR and cardiac hemodynamics in human HF. Nevertheless, and 
perhaps unexpectedly, it was recently observed by Amann et al. (2014) that by blocking 
group III/IV neural feedback during exercise in HFrEF that Q and SV failed to reach the 
level of Q and SV attained during exercise without inhibition of group III/IV neural 
feedback (Amann et al., 2014). Further, it appeared that HR during exercise was 
negligibly influenced by group III/IV neural feedback blockade in HF; and, despite 
observing blood pressure and vascular conductance responses to inhibition of group 
III/IV neural afferents similar to our recent findings (Olson, Joyner, Eisenach, Curry, & 
Johnson, 2014), these responses were not consistent with adjustments in both Q and SV 
(Amann et al., 2014). During exercise with inhibited group III/IV afferents arterial 
pressure was significantly lower and vascular conductance was significantly higher 
versus exercise without group III/IV afferent neural blockade in HF; which, was 
surprising, given Q and SV were also depressed therefore making it unclear what 
mechanism was driving central venous pressure with exercise in patients (Amann et al., 
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2014). Moreover, it might also be expected that blockade of group III/IV neural afferents 
from exercising muscle would not be sufficient to lower the sympathoexcitation of 
cardiac tissue to a point where contractility but not HR would be influenced. This should 
be considered since it has been observed in patients with HF that significant increases in 
HR occur in parallel with metaboreflex stimulation (Olson, Joyner, & Johnson, 2010). 
Also, despite reported differences in catecholamines between inhibited exercise and non-
inhibited exercise, these differences alone do not indicate uptake and/or sensitization of 
cardiac β-adrenergic receptors (Amann et al., 2014). It is clear that these recent 
observations present controversial evidence regarding relationships between afferent 
feedback and cardiac hemodynamic responses during exercise in HF. Further study is 
warranted to better understand the afferent reflex pathway and cardiac hemodynamics in 
HF.    
Exercise pressor reflex and pulmonary hemodynamics in heart failure 
The influence of metabo- and/or mechano-receptors on pulmonary hemodynamics 
remains undefined. It is hypothesized, that because pulmonary vasculature shares 
anatomical and physiological similarities with the peripheral vasculature that the 
pulmonary hemodynamic response to afferent feedback in HF may be similar to that of 
peripheral hemodynamics (Harrison, Pirages, Robison, & Wintroub, 1969). Presented 
earlier was evidence which suggests adjustments in pulmonary hemodynamics were 
closely related to both metabo- and mechano-receptor activation in healthy individuals 
(Lykidis et al., 2008; White et al., 2013). With the lack of increase in Q and SV in HF, it 
may be possible that afferent feedback mediated adjustments in pulmonary 
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hemodynamics might be aimed at increasing overall pulmonary vascular permeability in 
effort to improve ventilation-perfusion matching.     
Afferent feedback mediated adjustments in pulmonary hemodynamics in HF may also be 
aimed at preventing or attenuating backflow caused by high pressures in the left atria 
(regurgitation into pulmonary vein) in the instance of diastolic dysfunction. Although, 
this response by the pulmonary vasculature over the long-term could result in “mixed” 
PH which may lead to pulmonary congestion and impaired ventilatory function which are 
also known to be common in HF (Butler et al., 1999; Dickstein et al., 2008; Moraes et al., 
2000; Paulus et al., 2007). Thus, it is possible that excessive pulmonary vascular 
pressures (i.e. arterial, venous, or total pressure) in HF are related to an augmented 
afferent feedback system and therefore a contributing cause in the development of PH 
and/or pulmonary congestion. 
Summary 
In summary, although there is ample evidence in animal models which suggest that there 
are close relationships between the dysfunctional EPR and abnormal central 
hemodynamics in HF (Ichinose et al., 2010; Lykidis et al., 2008; O'Leary et al., 2004; 
Spranger et al., 2013; White et al., 2013), there are obvious gaps in our current 
understanding of the impact of locomotor muscle neural feedback on central 
hemodynamics in human HF. It is critical to improve this understanding as these neural 
afferents have been closely linked with dysfunctional ventilation and peripheral 
hemodynamic responses at rest and during exercise in HF; which, more importantly, have 
been associated with symptoms and prognosis in this population (Middlekauff et al., 
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2004; Olson et al., 2014; Olson, Joyner, & Johnson, 2010; Piepoli, 1998; Piepoli et al., 
1996; Piepoli et al., 1999).          
2.4 Clinical implications of central hemodynamic measurement during exercise 
2.4.1 Introduction 
The importance of central hemodynamic assessment during exercise for the clinical 
evaluation of HF cannot be understated. Recent and encouraging observations suggest 
that non-traditional indices, which include CP, CircP, or PVCAP assessed during exercise 
provide robust clinical value for evaluating syndrome severity and survival risk in HF 
(Bhella et al., 2011; Cohen-Solal et al., 2002; Lang et al., 2009; Mahapatra, Nishimura, 
Oh, et al., 2006; Taylor, Olson, et al., 2013; Williams, Jackson, et al., 2005; Williams et 
al., 2001; Williams, Tzeng, et al., 2005). Studies in HF examining the clinical value of 
traditional versus non-traditional cardiac hemodynamic parameters indicate that 
evaluating hydraulic power generation (e.g. CP) is more valuable than simply estimating 
blood flow alone (e.g. Q or SV) (Lang et al., 2009; Williams, Jackson, et al., 2005). 
Moreover, compared to common ventilatory parameters assessed during exercise (i.e. 
VO2), it has recently been suggested that metrics such as CP may be more valuable in the 
clinical classification of HF (Cohn & Rector, 1988; Lang et al., 2009; Williams, Jackson, 
et al., 2005). Thus, although central hemodynamic evaluation using non-traditional 
indices during exercise is still an emerging area of study and not yet commonly agreed 
upon, the observations to date are encouraging and suggest central hemodynamic 
evaluation during exercise is critical at any stage of the evaluation of the HF patient. 
2.4.2 Traditional measurements 
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Assessment of Q and SV, and perhaps even RV and LV EF% provide valuable 
information regarding HF severity. Evaluation of these parameters during exercise offers 
an even greater level of information for the clinical evaluation of HF (Borlaug et al., 
2006; Franciosa et al., 1985; Franciosa, Leddy, Wilen, & Schwartz, 1984; Franciosa et 
al., 1981; Francis et al., 1982; Szlachcic, Massie, et al., 1985). As such, aside from the 
most important consequence of HF which is an increased risk for early mortality, it is 
important to point out that functional impairment (e.g. exercise intolerance) closely 
associated with HF greatly affects these patients which is also associated with prognosis 
(Cleland, Dargie, & Ford, 1987; Cohn & Rector, 1988; Jessup Likoff, Chandler, & Kay, 
1987; Pilote, Silberberg, Lisbona, & Sniderman, 1989; Szlachcic, Massie, et al., 1985). 
Therefore, a better understanding of how cardiac and pulmonary hemodynamic factors 
during exercise are related to exercise intolerance in HF is crucial. 
Early observations from Francis et al. (1982) suggest that there is little direct association 
between resting LV function and exercise capacity in HF (Francis et al., 1982). In support 
of this, Francis et al. (1982) demonstrated that resting QI, SVI, and LV EF% correlated 
poorly with VO2peak in HFrEF (Francis et al., 1982). Benge et al. (1980) similarly 
demonstrated in HFrEF, that despite low resting LV EF%, it could be possible for 
patients to have preserved exercise capacity (i.e. duration) (Benge, Litchfield, & Marcus, 
1980). More recently, Piepoli et al. (1999) observed that resting LV EF% related poorly 
with VO2peak measured during arm or leg exercise in HFrEF (Piepoli et al., 1999). 
Together, these observations indicate that although resting assessment of cardiac 
hemodynamics can be useful for assisting in identifying the presence of impaired cardiac 
function, these measurements at rest do not accurately describe cardiac functional reserve 
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or functional capacity. Hence, resting assessment of cardiac hemodynamics cannot evoke 
the full magnitude of pumping impairment in HF. This is likely due to a multitude of 
factors which are highlighted in this dissertation, which include lack of competition for 
blood flow at rest versus during exercise, depressed contractile capabilities related to 
ischemic/necrotic cardiac tissue, or influence of receptor dysfunction (e.g. β-cardiac 
adrenergic or ergoreceptors) (Bristow et al., 1986; Bristow et al., 1990; Kannengiesser, 
Opie, & van der Werff, 1979; Olson, Joyner, Dietz, et al., 2010; Piepoli et al., 1999). 
In contrast, Szlachcic et al. (1985) observed that exercise capacity (i.e. VO2peak) closely 
correlated with exercise measures of QI, but correlated poorly with resting measures of 
QI, LV or RV EF%, PVR, and mPAP (Szlachcic, Massie, et al., 1985). More importantly, 
Szlachcic et al. (1985) further demonstrated at one-year that patients with a VO2peak <10 
mL/kg/min had a 77% higher mortality versus patients with a VO2peak >10 mL/kg/min, 
suggesting that there could be important clinical implications for the relationship between 
exercise central hemodynamics and exercise capacity in HF (Szlachcic, Massie, et al., 
1985). Similarly, Franciosa et al. (1984) observed in the first of two separate 
investigations, that measurements of QI, SV, and PCWP during exercise significantly and 
closely correlated with exercise capacity (i.e. workload) in HFrEF; and, that maximal QI 
correlated closely with VO2MAX (Franciosa et al., 1984). Further, Franciosa et al. (1985) 
observed that QI assessed during exercise significantly correlated with exercise capacity 
(i.e. VO2MAX) as did total PVR in HFrEF; whereas, relationships were less between 
resting measures of QI and PVR with exercise capacity (Franciosa et al., 1985). Kitzman 
et al. (1991) similarly observed that exercise capacity (i.e. workload performed) 
significantly and closely correlated with changes in SVI from rest to peak exercise in 
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HFrEF (Kitzman et al., 1991). Also, more recently, it was observed that change in Q from 
rest to peak exercise in HFpEF correlated closely with both exercise duration and VO2peak 
(Borlaug et al., 2006). 
Despite observations which suggest that there are important direct associations between 
specific changes in central hemodynamics during exercise and exercise tolerance and 
prognosis, contrasting observations indicate that neither rest nor exercise measurements 
of central hemodynamics are indicative of exercise tolerance or risk stratification in HF 
(Higginbotham et al., 1983; Meiler, Ashton, Moeschberger, Unverferth, & Leier, 1987; 
Willens et al., 1987). However, it may be argued that traditional measurements of central 
hemodynamics (e.g. Q, SV, mPAP) potentially lack diagnostic strength because these 
parameters do not quantify pressure and blood flow relationships, and they do not fully 
describe the integrated anatomy and physiology that pulmonary hemodynamics share 
with cardiac hemodynamics. Thus, it is suggested that non-traditional parameters such as 
CP, CircP, or PVCAP can better describe the hydraulic pump as well as the interaction the 
heart shares with the pulmonary vasculature and, hence, these newer indices may be more 
useful in the clinical classification of HF (Bhella et al., 2011; Cohen-Solal et al., 2002; 
Lang et al., 2009; Mahapatra, Nishimura, Oh, et al., 2006; Mahapatra, Nishimura, 
Sorajja, et al., 2006; Taylor, Olson, et al., 2013; Williams, Jackson, et al., 2005; Williams 
et al., 2001; Williams, Tzeng, et al., 2005). 
2.4.3 Non-traditional measurements   
Assessment of the blood flow and pressure generating capability of the heart describes 
hydraulic power and total pumping capacity. As previously described, parameters such as 
CP or CircP integrate both factors of flow and pressure to quantify the hydraulic power of 
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the heart. Consistent with Q and SV, these non-traditional metrics of cardiac 
hemodynamics are lower at rest and during exercise in HF compared to healthy 
individuals (Bhella et al., 2011; Bromley et al., 2006; Cohen-Solal et al., 2002; Gelberg et 
al., 1979; Hecht et al., 1982; Jakovljevic et al., 2012; Lang et al., 2009; Schlader et al., 
2010; Williams, Jackson, et al., 2005; Williams et al., 2001). However, more importantly, 
non-traditional indices of the pumping capability of the heart have been observed to 
predict prognosis in HF to a greater magnitude than traditional measurements of cardiac 
and ventilatory function (Lang et al., 2009; Williams, Jackson, et al., 2005).  
Although the extent of testing is limited, because PVCAP considers the direct interaction 
of cardiac hemodynamics with pulmonary hemodynamics, it has been suggested that this 
index measured during exercise may be a better indicator of the pulmonary hemodynamic 
response to exercise versus traditional parameters in HF (Mahapatra, Nishimura, Oh, et 
al., 2006; Mahapatra, Nishimura, Sorajja, et al., 2006; Taylor, Olson, et al., 2013). 
Moreover, PVCAP has shown prognostic strength in patients with primary PH (Mahapatra, 
Nishimura, Oh, et al., 2006; Mahapatra, Nishimura, Sorajja, et al., 2006). Pulmonary 
vascular capacitance is important because individuals with HF are at an increased risk for 
the development of passive and/or mixed forms of PH (Aronson et al., 2011; Taylor, 
Mojica, et al., 2013). 
More recent observations by Williams et al. (2001) and Lang et al. (2009) provide 
support for the role of CP in predicting prognosis in HFrEF (Lang et al., 2009; Williams 
et al., 2001). It was demonstrated in HFrEF that peak CP was significantly different in 
survivors versus non-survivors, and that when patients were dichotomized at a peak CP 
cut-off of 1.96 watts, patients above this threshold demonstrated significantly higher 
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survival compared to patients below this threshold (90.5% versus 43.4%, respectively) 
(Williams et al., 2001). Moreover, in both univariate and multivariate hazard models, 
peak CP remained a significant predictor of survival in HF; whereas, peak Q and VO2peak 
failed to significantly predict survival when put into multivariate models (Williams et al., 
2001). Consistent with the observations of Williams et al. (2001) (Williams et al., 2001), 
it has been demonstrated that not only is peak CP related to HF severity, but of all cardiac 
and cardiovascular factors tested during exercise in HF, CP has been observed to 
demonstrate the highest area under the receiver operating curve (Lang et al., 2009). 
Outcomes of the receiver operator curve analyses suggested that a peak CP cut-off of 1.5 
watts was most indicative of event-free survival in HF (>1.5 watts = 94% versus <1.5 
watts = 69%). Lastly, when patients were dichotomized above or below a common VO2 
threshold of 14 mL/kg/min, results of multivariate hazard modeling produced only peak 
CP as a significant predictor of outcome in patients with a VO2 <14 mL/kg/min (Lang et 
al., 2009). 
These recent observations which relate non-traditional measurements of cardiac 
hemodynamics during exercise with prognosis are important and help to strengthen 
earlier observations which suggest that peak CP as well as changes in CP from rest to 
peak exercise are important for the clinical evaluation of HF (Bain, Tan, Murray, Davies, 
& Littler, 1990). It was observed by Bain et al. (1990) that although peak exercise 
measurements of QI correlated with exercise tolerance in HF, peak CP and change in CP 
were the strongest indicators of exercise tolerance in these patients. Peak exercise 
measurements of cardiac hemodynamics all related to exercise tolerance to a greater 
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extent compared to corresponding resting measurements in HF patients (Bain et al., 
1990).  
Similar to outcomes of CP in HF, it has been suggested that CircP may demonstrate 
prognostic value while being able to discriminate surviving from non-surviving patients 
(Cohen-Solal et al., 2002). Cohen-Solal et al. (2002) observed that HF patients who did 
not survive at follow-up demonstrated significantly lower peak CircP (2402 ± 843 versus 
3573 ± 1273 mL/kg/min ∙ mm Hg) versus survivors at time of initial testing, respectively 
(Cohen-Solal et al., 2002). Also, peak measurement of CircP was a significant 
independent predictor of mortality as well mortality or transplantation, and the median 
peak CircP was associated with significantly higher survival in HF with a value above 
3,047 mL/kg/min ∙ mm Hg (Cohen-Solal et al., 2002). These observations by Cohen-
Solal et al. (2002) in parallel with CircP validation testing by Williams et al. (2005) 
suggest that cardiac hydraulic power generating capacity in HF may be estimated using 
cardiovascular-derived factors (i.e. VO2 and MAP or SBP) while also demonstrating 
predictive prognostic strength (Cohen-Solal et al., 2002; Williams, Tzeng, et al., 2005).    
In summary, the use of non-traditional central hemodynamic indices for predicting 
prognosis in HFrEF is supported well by the current evidence. However, secondarily, and 
closely related to predicting prognosis in HF, is the ability to judge the severity of HF 
based on overt symptomology and signs of this syndrome. This is important because 
symptoms such as exercise intolerance and signs related to depressed cardiac 
hemodynamics are commonly considered factors in determining the appropriate course of 
therapeutic treatment.  
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Exercise measurements of cardiac function and pulmonary vascular pressures may relate 
with various parameters of exercise tolerance in HF. In comparison, the body of evidence 
supporting the use of non-traditional measures of central hemodynamics for predicting 
exercise capacity in HF is less in number (Bain et al., 1990). In attempts to better 
understand exercise tolerance as it relates to central hemodynamics, exercise duration 
and/or exercise workload should be compared with cardiac pumping capability. It 
remains unclear what relationships exist between exercise duration and/or exercise 
workload and advanced measures of central hemodynamics in HFrEF and HFpEF.   
2.5 Summary of the review of the literature 
The anatomy and physiology of the heart in both HFrEF and in HFpEF are paradoxical to 
the heart of the healthy individual. To further complicate the understanding of HF, it is 
commonly recognized that differences in heart function between HF and healthy 
individuals are not the only factors which drive the impairment in functional capacity and 
higher risk for mortality in patients. Heart failure is a systemic syndrome which, for 
diagnostic purposes, requires clinical judgment based on a multitude of factors, including 
signs and symptoms common to this illness. Therefore, it is imperative that our 
understanding of the underlying mechanisms leading to the signs and symptoms of HF 
continues to evolve by studying newer non-traditional areas which may also be closely 
related. 
Further, specific research is discussed on non-traditional measurements of cardiac and 
pulmonary hemodynamics which appear to be promising parameters in adding strength to 
the clinical classification of HF. Additionally, continued study of neural feedback 
pathways related to group III and IV sensory nerve fibers appears to be critical in 
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understanding the disconnect between central dysfunction in HF and symptomology. 
Lastly, development of new techniques and metrics to study central hemodynamics has 
resulted in an overall lack of uniformity of measurement techniques and the manner in 
which indices are being reported in the literature. Although not completely prohibitive in 
the study of HF, variability in technique utilization in parallel with reporting of data 
increases the difficulty in interpreting observations across studies in HF.     
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3.1 Acetylene Rebreathe and O2pulse Estimates of Stroke Volume at Peak Exercise 
in HFpEF 
Erik H. Van Iterson1, Thomas P. Olson2, Barry A. Borlaug2, Bruce D. Johnson2, Eric M. 
Snyder1 
1Department of Kinesiology, University of Minnesota, Minneapolis, MN; 2Division of 
Cardiovascular Diseases, Mayo Clinic, Rochester, MN 
Summary 
Purpose: Direct Fick is the gold standard for measurement of stroke volume (SV), but 
this technique is invasive and resource dependent. Therefore, this comparison study was 
designed to examine relationships between non-invasive techniques for estimating SV at 
rest and peak exercise in heart failure patients with preserved ejection fraction (HFpEF). 
We hypothesized that SV via echocardiography (SVECHO), acetylene rebreathe (SVACET), 
and O2pulse would closely relate at peak exercise in HFpEF; and, lung diffusion capacity 
for carbon monoxide (DLCO), nitric oxide (DLNO), alveolar—capillary membrane 
conductance (DM) would not influence SVACET. 
Methods: SVECHO, SVACET, and O2pulse were measured at rest and peak exercise in 18 
HFpEF and 26 control participants. Ventilation and gas-exchange measurements via 
breath-by-breath and 12-lead electrocardiogram were continuous. SVECHO (LV outflow 
diameter×velocity-time integral). SVACET, DLCO, DLNO, and DM were measured using the 
rebreathe technique. O2pulse (oxygen uptake/heart rate) was calculated.   
Results: In HFpEF and controls at rest, SVACET was lower versus SVECHO (p>0.05). In 
HFpEF at peak exercise, SVACET was higher versus SVECHO (p>0.05). In controls at peak 
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exercise, SVACET was lower versus SVECHO (p>0.05). Linearity between SVACET with 
O2pulse or SVECHO was significant at rest (R
2=0.65, 0.28; 0.57, 0.66) and peak exercise 
(R2=0.67, 0.62; 0.33, 0.28) in HFpEF and controls, respectively. DLCO, DLNO, and DM 
were lower at rest and peak exercise in HFpEF versus controls (p<0.05). Linearity 
between SVACET with DLCO, DLNO, and DM (R
2=0.25, 0.23, 0.23; 0.59, 0.48, 0.48, 
respectively; p<0.05) were less at peak exercise in HFpEF versus controls, respectively.  
Conclusion: Independent of lung diffusion capacity, SVACET directly related with 
O2pulse and SVECHO at rest and closer at peak exercise in HFpEF.  
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Introduction 
Patients with heart failure with preserved ejection fraction (HFpEF) have impaired 
cardiac contractility, myocardial relaxation, and loading conditions at rest and during 
exercise (Borlaug, Olson, et al., 2010; Paulus et al., 2007). During physical activity, the 
signs and symptoms of central hemodynamic dysfunction are exacerbated in these 
patients (Borlaug, Olson, et al., 2010; Paulus et al., 2007). More importantly, reduced 
cardiac pumping capacity is closely related to increased mortality in HFpEF (Bhatia et 
al., 2006). Therefore, accurate assessment of cardiac output (Q) and/or stroke volume 
(SV) is critical in these patients. 
The most reliable and valid method for assessing cardiac hemodynamics is the direct Fick 
method which utilizes measures of oxygen uptake (VO2) and systemic arteriovenous 
difference in oxygen (O2) content (Ca-vO2) to estimate Q; yet, because of its invasive 
nature due to the requirement of arterial and mixed venous blood O2 samples, this method 
is time and resource dependent making it impractical for routine use in clinical and 
research settings. Therefore, other less invasive and time consuming methods are critical 
for the rapid assessment of Q in these patients.  
Echocardiography is a non-invasive alternative to the direct Fick technique for measuring 
Q in the clinical or research settings. Results from validation and repeatability studies 
which used direct Fick or thermodilution as standards, indicate that echocardiography can 
be used to measure Q and SV in healthy individuals or in cardiac patients (e.g. HF) 
(Holland, Prasad, & Marwick, 2010; Lewis, Kuo, Nelson, Limacher, & Quinones, 1984; 
Loeppky, Hoekenga, Greene, & Luft, 1984). Importantly, however, as with many 
techniques, important limitations are associated with echocardiography that should not be 
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overlooked which include high user dependence related to image acquisition (e.g. view of 
the heart, sonographer skill, rest vs. exercise, and equipment), reader reliability (e.g. 
inter- and- intra-observer- and- lab variability), and high technology cost related concerns 
to name a few (Marwick, Nemec, Pashkow, Stewart, & Salcedo, 1992). Therefore, less 
user dependent techniques to estimate Q are needed. 
The acetylene uptake method for measurement of Q has also been validated against direct 
Fick at rest and at peak exercise (Hoeper et al., 1999; Johnson et al., 2000). Acetylene, at 
very small concentrations, is a non-toxic and non-physiological gas with low solubility in 
lung tissue but a high Bunsen solubility coefficient in blood (0.740, nearly 20 and 40 
times that of nitric oxide [0.0364] and carbon monoxide [0.0189], respectively) and low 
affinity for hemoglobin (Hb) (Cander, 1959; Grollman, 1929; Roughton & Forster, 1957; 
Tamhane, Johnson, & Hsia, 2001). The acetylene rebreathe technique is considered 
reliable and accurate for resting and exercise assessment of Q (QACET) and SV (SVACET) 
in healthy individuals and patients with cardiac or pulmonary diseases such as HF (Olson, 
Snyder, Beck, & Johnson, 2006), PPH (Hoeper et al., 1999), or cystic fibrosis (Wheatley 
et al., 2011). However, because accurate estimate of Q using acetylene rebreathe is 
potentially dependent on near homogenous ventilation of alveoli in parallel with 
perfusion matching of pulmonary capillaries, as well as the capacity for acetylene gas to 
freely diffuse across the alveolar—capillary membrane barrier at a rate commensurate 
with pulmonary capillary blood flow (VC), it remains unclear if the efficacy of acetylene 
rebreathe for estimating SV is valid in individuals with low capacity for gas transfer 
within lungs such as in HFpEF (Olson et al., 2008).    
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Our group recently demonstrated that measures useful for determining gas transfer 
capacity within lungs, which include pulmonary diffusion capacity for carbon monoxide 
(DLCO), nitric oxide (DLNO), alveolar—capillary membrane conductance (DM), and VC 
increase from rest to peak exercise in HFpEF despite being lower compared to healthy 
individuals (Olson et al., 2008). However, it is unknown of what consequences both low 
Q and lung gas diffusing capacity have on the capacity for the acetylene rebreathe 
technique to estimate Q and SV at rest or at peak exercise in HFpEF.  
Contrasting acetylene rebreathe, the SV estimate O2pulse (quotient of oxygen uptake 
[VO2] with heart rate [HR]) simply requires standard gas-exchange and HR monitoring 
systems. However, for VO2 to remain an estimate for Q, the direct Fick equation (Q = 
VO2/(Ca-vO2)) assumes that Ca-vO2 is invariable during steady-state exercise (Beck et al., 
2006; Crisafulli, Piras, et al., 2007). Accordingly, consistent with previous reports of 
O2pulse in HF with reduced ejection fraction (HFrEF) (Lavie et al., 2004), our group has 
recently validated O2pulse via gas-exchange system with direct Fick measurements of SV 
during submaximal exercise in HFrEF with or without concurrent PH (Taylor, Olson, et 
al., 2013). Moreover, others have also observed that O2pulse closely related to SV 
assessed via carbon dioxide (CO2) rebreathing during submaximal exercise in healthy 
individuals (Bhambhani et al., 1994). 
Because of the potential utility SV and its surrogate O2pulse have for prognosis and 
detection of syndrome severity in HF, specifically during physical activity (Bhatia et al., 
2006; Lavie et al., 2004; Paulus et al., 2007), it is important to identify techniques for SV 
assessment, which are valid, repeatable, non-invasive, and easy to obtain in the clinical 
setting during peak exercise. This study compared non-invasive measurements of SV 
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using acetylene rebreathe, O2pulse, and echocardiography in HFpEF at rest and at peak 
exercise. We hypothesized that acetylene rebreathe and O2pulse would compare 
favorably to echocardiography when measuring SV at rest and at peak exercise in 
HFpEF. Secondarily, we hypothesized that low gas transfer capacity within lungs would 
not directly influence SVACET at peak exercise in HFpEF.  
Methods 
Participants 
Eighteen Caucasian HFpEF patients and 26 Caucasian healthy control participants 
matched for gender and age were recruited for this study (participant demographics, 
Table 1). Patients with elevated BNP or N-terminal prohormone BNP (> 200.0 picograms 
[pg]/milliliters [mL] or  > 220.0 pg/mL), significant coronary artery disease (stenosis 
≥50.0 %), valvular heart disease (any stenosis, > mild regurgitation), hypertrophic or 
infiltrative cardiomyopathy, constrictive pericarditis, exercise-induced PH due to vascular 
disease (mean exercise pulmonary artery pressure >30 millimeters mercury [mm Hg] 
with pulmonary capillary wedge pressure <15 mm Hg (Tolle, Waxman, Van Horn, 
Pappagianopoulos, & Systrom, 2008)), or radiographic pulmonary congestion were 
excluded (Paulus et al., 2007). The Mayo Clinic Heart Failure Service and the 
Cardiovascular Health Clinic were used to recruit HFpEF. Control participants were 
recruited through advertisement in the surrounding community. Control participants had 
normal cardiac function without evidence of exercise-induced ischemia and were without 
history of hypertension, lung disease, or coronary artery disease. The experimental proce-
dures were approved by the Mayo Clinic Institutional Review Board, all participants 
provided written informed consent prior to study, and all aspects of the study were 
performed in accordance with the ethical standards of the Declaration of Helsinki. 
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Protocol 
Upon arrival, participants were fitted with a 12-lead electrocardiogram (Marquette 
Electronics, Milwaukee, WI) to monitor HR. Participants were seated upright on a cycle 
ergometer (Corival Lode B.V., Netherlands) where resting simultaneous measures of Q, 
DLCO, DLNO, VO2, carbon dioxide production (VCO2), respiratory exchange ratio (RER), 
respiratory rate (RR), tidal volume (VT), minute ventilation (VE), and end-tidal partial 
pressure of CO2 (PETCO2) were performed. Measures of Q, DLCO, and DLNO were 
performed at peak exercise, whereas ventilation and gas exchange (Medical Graphics 
CPX/D, St. Paul, MN) were continuously monitored and averaged every three seconds at 
rest and throughout exercise. The incremental exercise testing protocol started at 20 watts 
and increased by 10 watts every three minutes until two of the following occurred: they 
could no longer maintain a pedal rate between 60 and 80 revolutions per minute, a RER 
greater than 1.10, or a rating of perceived exertion (Borg scale) of  ≥17. Ventilatory 
efficiency (VE/VCO2), Ca-vO2 (VO2/QACET/10) (Beck et al., 2006), and O2pulse (VO2/HR) 
were calculated as the average of 30 second intervals at the end of each workload 
(Taylor, Olson, et al., 2013). 
Measures of lung gas transfer, cardiac output, and pulmonary capillary blood volume 
At each work intensity simultaneous measures of Q, DLCO, and DLNO were performed via 
standard rebreathe technique as previously described (Reeves & Park, 1992; Snyder, 
Johnson, & Beck, 2005; Wheatley et al., 2011), and DM and VC were calculated (Reeves 
& Park, 1992; Snyder et al., 2005; Wheatley et al., 2011). Participants breathed into a 
non-rebreathing three-way automatic pneumatic switching valve (Hans Rudolph, Kansas 
City, MO) that was connected to a pneumotachometer (Hans Rudolph, Kansas City, 
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MO), mass spectrometer (Perkin Elmer MGA-1100, Wesley, MA), and NO analyzer (GE 
Instruments, Boulder, CO), which were all integrated with custom analysis software for 
the calculation of Q, DLCO, and DLNO (Snyder et al., 2005). The NO analyzer was 
calibrated prior to each visit using an NO filter and NO gas (45.0 parts per million [ppm]) 
for the zero and second calibration points, respectively. The inspiratory port of the 
switching valve allowed for rapid switching for breathing room air or from a 5.0 liter (L) 
anesthesia rebreathe bag (Hans Rudolph, Kansas City, MO) containing one- to- three L of 
test gas (0.7% acetylene [C2H2], 9.0% helium [He], 0.3% carbon monoxide [C
18O], 
55.0% nitrogen, 40.0 ppm NO (Tamhane et al., 2001), and 35.0% O2) depending on 
initial VT of the subject and the exercise intensity as previously described (Snyder et al., 
2005; Wheatley et al., 2011).  
Serial measurement of gas concentrations with the mass spectrometer starting at end-
expiration of the first breath enabled calculation of measures of lung gas transfer and Q. 
Because acetylene does not bind to hemoglobin and has low lung tissue and high 
solubility in blood (Cander, 1959; Grollman, 1929), acetylene disappears in the blood in a 
linear fashion according to the rate at which a new volume of blood is transported 
through the lungs and the rate of disappearance of acetylene with each breath to 
determine Q is calculated from the slope of the exponential disappearance of acetylene 
with respect to the insoluble gas He (Hsia et al., 1995; Snyder et al., 2005).   
According to the Direct Fick model and modified by Grollman (Grollman, 1929), QACET 
and SVACET using HR can be calculated using C2H2 as follows:  
Q =
𝑉𝑂2  ∙ (𝐶2𝐻2)𝑑𝑖𝑓𝑓
(𝑂2)𝑑𝑖𝑓𝑓  ∙  ?̅?𝐶2𝐻2  ∙ 𝑃𝑏 − 47 ∙ 0.00974
, 𝑎𝑛𝑑 × 
1
𝐻𝑅
= 𝑆𝑉 
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Where 𝑉𝑂2 is determined by a standard gas-exchange system, (𝐶2𝐻2)𝑑𝑖𝑓𝑓  is the amount 
of 𝐶2𝐻2 absorbed per liter of blood during the time of sampling, (𝑂2)𝑑𝑖𝑓𝑓  is the amount 
of O2 absorbed during the time of the sampling, ?̅?𝐶2𝐻2 is the average concentration of 
𝐶2𝐻2  during the time of the sampling, 𝑃𝑏 is barometric pressure, 47 is the assumed vapor 
pressure of water in the lungs (mm Hg), and 0.00974 is a numerical constant derived by 
combining the constants 760 and 100, and 740, the solubility coefficient for 𝐶2𝐻2 in 
blood at body temperature (Grollman, 1929). 
To calculate DM and VC, we used the model of diffusion capacity of the lungs as 
originally described by Roughton and Forster (Roughton & Forster, 1957) and modified 
by Reeves and Park (Reeves & Park, 1992):   
1
𝐷𝐿𝐶𝑂
=
1
𝐷𝑀𝐶𝑂
+
1
𝜃𝐶𝑂  ∙  𝑉𝐶
 
Relative to DLCO, DLNO reflects predominantly diffusive resistance of the tissue-plasma 
barrier in man because of the nearly 300 times greater binding affinity for Hb NO has 
compared to CO, DLNO ≅ DMNO (Roughton & Forster, 1957; Tamhane et al., 2001). 
However, the theoretical DLNO/DMCO ratio (αratio) equal to 1.93 based on the molecular 
weights and Bunsen solubilities of NO and CO in blood is suggested to misrepresent a 
physiological plausible relationship between NO and CO in humans during peak exercise 
(Reeves & Park, 1992; Tamhane et al., 2001). Accordingly, the corrected αratio we applied 
in the calculation of DMCO was the value described by Reeves and Park (Reeves & Park, 
1992) equal to 2.26. Moreover, because of dissimilarities in each subject’s alveolar 
partial pressure of oxygen (PAO2) as well as Hb concentrations which influence the 
resistance to the rate of gas uptake per Torr of pressure gradient by whole blood and 
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binding to hemoglobin ( 
1
𝜃 
 ), we corrected for these differences using the following 
formula (Reeves & Park, 1992): 
1
𝜃𝐶𝑂
= (0.0156 + 0.008 ∙ 𝑃𝐴𝑂2) ∙
14.6
𝐻𝑏
 
Echocardiography 
Echocardiographic assessment of SV (SVECHO) was performed at baseline and peak 
exercise using standard 2-dimensional (2-D) and pulsed wave tissue Doppler imaging 
(TDI-PW) using the GE Vivid 7® echocardiographic system, and stored for off-line 
analysis on the GE EchoPac® software, version 5.0. The echocardiographies were read 
blinded to participant condition (i.e. HFpEF vs. control) and activity state (i.e. rest vs. 
peak exercise). In the present study, we used the same sonographer and the same 
echocardiographic reader for all studies. Both of these individuals had extensive 
experience (>10 years working with stress echocardiography data acquisition and 
interpretation).  
Measurements of SV were obtained according to the methods of Lewis et al. (1984) 
(Lewis et al., 1984) using the left ventricular (LV) outflow method that included views of 
the apical- five- chamber (A5C) and parasternal- long- axis (PLAX) views. Briefly, in the 
PLAX view, the left ventricular outflow tract (LVOT) aimed at the aortic annulus was 
captured using gray-scale 2-D video imaging of five- to- ten consecutive cardiac cycles. 
Cross-sectional area (CSA) of the LVOT—proximal to the aortic valve points of insertion 
of the LVOT was assessed at the time point of maximal separation of aortic valve leaflets 
during systole, with the CSA value used for analysis being the average of five cardiac 
cycles. Because it is assumed the LVOT is circular, CSA = π ∙ r2, where r equals the 
radius of the LVOT.  
95 
 
In the A5C view using TDI-PW imaging, with the pulsed-wave beam focused at the 
depth of the LVOT—proximal to the aortic valve points of insertion of the LVOT, the 
velocity-time integral (VTI) of the flow entering the LVOT during systole was measured 
using integrated software of the GE EchoPac® system, with the average VTI of five 
cardiac cycles used for analysis. Stroke volume was calculated as: 
𝑆𝑉 (𝑐𝑚3) = 𝐶𝑆𝐴 (𝑐𝑚2) × 𝑉𝑇𝐼 (𝑐𝑚) 
Statistical Analyses 
All data are presented at means ± standard error of mean (SEM). Homogeneity of 
variance of data was tested using Levene’s test. Since it was unclear which technique was 
the criterion, to nullify this potential bias in our comparisons, analyses of slopes and 
intercepts between SVECHO, SVACET, and O2pulse were tested using ordinary least 
products univariate linear regression. Ordinary least squares regression was used for all 
other tests of relationships. Specific comparison between groups (i.e. controls vs. HFpEF) 
or conditions (i.e. rest vs. peak exercise) were compared using unpaired and paired two-
tailed Student’s t-tests, respectively. Multiple comparisons for between- and- within 
group differences for rest and peak exercise were tested using two-way analysis of 
variance tests. When the F-statistic was significant for analysis of variance testing, post-
hoc testing using the Bonferroni test was used to identify between which comparisons 
significance occurred. An alpha of 0.05 was set to determine statistical significance. All 
analyses were conducted using SAS statistical software, version 9.4 (SAS Institute, Cary, 
North Carolina). 
Results 
Participant characteristics 
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Participant characteristics are presented in Table 1. Age, height, weight, and BSA were 
not significantly different between groups, although HFpEF had a greater BMI versus 
controls (p <0.05). Ejection fraction percentage was within normal limits for HFpEF 
(range = 50.0 – 68.0%). However, HFpEF demonstrated significantly lower exercise 
capacity (VO2peak, predicted percentage range = 30.0 – 95.3% vs. 50.3 – 137.0%). 
Patients were all of ischemic etiology and on standard optimum pharmacological therapy. 
Exercise intensity, symptomology, ventilation, and gas-exchange 
Presented in Table 2 are measures of exercise intensity, symptomology, ventilation, and 
gas-exchange. Overall, HFpEF exercised at a lower workload and duration (17.7 ± 1.0 
and 21.3 ± 1.2 minutes; p <0.05) compared to controls despite similar RPE (p >0.05). For 
baseline measures of ventilation and gas-exchange, there were no differences between 
HFpEF and controls (p >0.05). At peak exercise, HFpEF generally demonstrated lower 
function versus controls for ventilation and gas-exchange, showing significance for VO2, 
VCO2, RER, VE, and VT.  
Not presented in Table 2, linear regression coefficient of determination (R2) estimates 
between VO2 and Ca-vO2 at rest and at peak exercise in HFpEF were negligible (R
2 = 0.04 
and 0.00, respectively; p >0.05), which were similar to controls at baseline and at peak 
exercise (R2 = 0.09 and 0.10, respectively; p >0.05).  
Heart rate, blood pressure, and cardiac hemodynamics 
Presented in Table 3 are baseline and peak exercise HR, blood pressure, and cardiac 
hemodynamics. At baseline no significant differences were present between groups 
except for DBP which was less in HFpEF (p <0.05). At peak exercise, HFpEF 
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demonstrated overall lower HR, blood pressure, and cardiac hemodynamic function 
versus controls; although, only HR, SBP, DBP, Q, and VC reached significance.  
Not shown in Table 3, linear regression at peak exercise between O2pulse and QACET was 
similar for HFpEF and controls (R2 = 0.41 vs. 0.43; p <0.05).   
Relationships between techniques for estimating SV 
Presented in Figures 1 – 3 (A – D) are linear regression relationships between SVECHO, 
SVACET, and O2pulse in HFpEF and in controls at rest and at peak exercise. Overall, 
HFpEF demonstrated a greater magnitude of linearity between techniques at peak 
exercise versus rest. Linearity between techniques at rest versus peak exercise appeared 
to be similar in controls.  
Figure 1 shows regression equations between SVACET and SVECHO in HFpEF and in 
controls. The common regression equation (i.e. entire sample for rest and at peak 
exercise) was f(x) = 0.99x – 4.75, p <0.05; and goodness of fit for the data was R2 = 0.44, 
95% confidence limits (CL) for R2 was 0.31, 0.54. The 95% CL for the slope (0.85, 1.17) 
and intercept (-17.8, 8.3) indicated the presence of overall fixed bias between SVACET and 
SVECHO in the entire sample, which is supported by goodness of fit lines in panels A, C, 
and D showing SVACET consistently underestimated SV versus SVECHO. 
Next, Figure 2 shows regression equations between O2pulse and SVECHO in HFpEF and 
in controls. The common regression equation was f(x) = 0.15x – 4.67, p <0.05; and 
goodness of fit for the data was R2 = 0.36, 95% CL for R2 was 0.22, 0.46. The 95% CL 
for the slope (0.13, 0.18) and intercept (-6.8, -2.5) indicated the presence of overall fixed 
and proportional bias between O2pulse and SVECHO in the entire sample. This suggests, 
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depending on the sample, although O2pulse may consistently over (HFpEF)- or under 
(controls)-estimate SV in comparison to SVECHO, these differences may progressively 
change as SV increases.  
Lastly, presented in Figure 3 are regression equations between O2pulse with SVACET in 
HFpEF and in controls. The common regression equation was f(x) = 0.16x – 3.93, p 
<0.05; and goodness of fit for the data was R2 = 0.55, 95% CL for R2 was 0.43, 0.63. 
Similar to Figure 2, the 95% CL for the slope (0.13, 0.18) and intercept (-5.6, -2.2) 
suggests the presence of overall fixed and proportional bias between O2pulse and SVACET 
in the entire sample. Similar to Figure 2, this suggests that although O2pulse may 
consistently over (HFpEF)- or under (controls)-estimate SV in comparison to SVACET, 
these differences may progressively change as SV increases.          
Relationships between cardiac hemodynamics with gas-exchange 
Linear regression between QACET and VO2 at rest and peak exercise were significant in 
HFpEF (R2 = 0.59 and 0.61, respectively). In comparison, linear regression between 
QACET and VO2 was lower at rest and at peak exercise in controls (R
2 = 0.25 and 0.57, 
respectively). Linear regression at peak exercise between Ca-vO2 and SVACET was 
significant for HFpEF (R2 = 0.47) but not significant for controls (R2 = 0.08). Linear 
regression between O2pulse and Ca-vO2 (R
2 = 0.04 vs. 0.06; p >0.05) was similar for 
HFpEF versus controls at peak exercise, respectively. Lastly, linear regression between 
Ca-vO2 and QACET at peak exercise in HFpEF (R
2 = 0.29, p <0.05) and controls (R2 = 0.10, 
p >0.05) was less than expected in HFpEF.  
Measures of gas transfer capacity within lungs 
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We have previously reported that HFpEF demonstrate reduced gas transfer in the lungs at 
rest and at peak exercise (Olson et al., 2008). Briefly, at baseline, DLCO, DLNO, and DM 
were less in HFpEF versus controls (p <0.05). These significant differences at baseline 
persisted at peak exercise for DLCO, DLNO, and DM in HFpEF in comparison to controls. 
Also, consistent with DLCO, DLNO, and DM at baseline and at peak exercise, the increases 
from baseline to peak exercise in DLCO (6.3 ± 0.5 vs. 10.3 ± 0.8 mL ∙ min-1 ∙ mm Hg-1), 
DLNO (19.2 ± 1.3 vs. 31.8 ± 1.5 mL ∙ min-1 ∙ mm Hg-1), and DM (8.4 ± 0.5 vs. 14.0 ± 0.7 
mL ∙ min-1 ∙ mm Hg-1) were significantly less for HFpEF compared to controls, 
respectively.  
Despite significant differences in DLCO, DLNO, and DM between HFpEF and controls at 
baseline and at peak exercise, the rate of change for DLCO (0.4 ± 0.1 vs. 0.6 ± 0.1), DLNO 
(1.3 ± 0.2 vs. 1.9 ± 0.3), and DM (0.8 ± 0.1 vs. 0.6 ± 0.1) were of similar magnitude 
between HFpEF and controls (p >0.05), respectively. Also, the quotient of DLNO with 
DLCO was not different between HFpEF and controls at rest or at peak exercise (p >0.05), 
which was consistent with the direct relationships between DLNO and DLCO at peak 
exercise for HFpEF (R2 = 0.83) and controls (R2 = 0.90) (p < 0.05).  
At peak exercise, although significant for HFpEF and controls, the following 
relationships between DLCO and SVACET
 (R2 = 0.25 vs. 0.59), DLNO and SVACET
 (R2 = 
0.23 vs. 0.48), or DM and SVACET (R
2 = 0.23 vs. 0.48) were less in HFpEF versus 
controls, respectively. Whereas, linear regression between DM and VC
 were not 
significant nor directly related in HFpEF (R2 = -0.05) or in controls (R2 = -0.01). Finally, 
despite significance for both HFpEF and controls, linear regression between O2pulse and 
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DLCO (R
2 = 0.19 vs. 0.34), DLNO (R
2 = 0.23 vs. 0.39), or DM (R
2 = 0.23 vs. 0.39) at peak 
exercise was less in HFpEF versus controls, respectively. 
Discussion 
This study compared three non-invasive techniques for assessing SV at rest and at peak 
exercise in HFpEF patients and in healthy individuals. Our main observations indicate 
that SV measured using acetylene rebreathe compared favorably with O2pulse and 
echocardiography at rest and to a greater magnitude at peak exercise in participants; but, 
although linear, the strength of relationships between O2pulse and echocardiography was 
less in comparison to relationships between O2pulse and acetylene rebreathe at rest and at 
peak exercise in participants. These data also revealed the presence of potential bias 
associated with these techniques which appeared to be influenced by condition (i.e. 
HFpEF versus healthy) as well as exercise intensity (i.e. rest versus peak exercise). Our 
observations indicated the strongest relationships between non-invasive techniques 
occurred at peak exercise in HFpEF.    
A cost-effective, repeatable, and reliable measurement of SV is desirable to clinicians 
given the dynamic nature of cardiac hemodynamics during exercise. This has important 
clinical implications since HFpEF demonstrate impaired cardiac function at rest that is 
exacerbated during exercise, and because the assessment of cardiac function during 
exercise has been demonstrated to be an excellent measure of syndrome severity and 
prognosis in these individuals (Bhatia et al., 2006; Lavie et al., 2004; Paulus et al., 2007). 
Therefore, to the best of our knowledge, the present study is the first to evaluate 
relationships between SVACET, O2pulse, and SVECHO at rest and at peak exercise in 
HFpEF. In addition to demonstrating close relationships between SVACET with O2pulse 
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and SVECHO at peak exercise in HFpEF and in healthy individuals; perhaps, it is of equal 
importance that the present findings identify SVACET or O2pulse as non-invasive, yet 
reliable techniques for measuring SV at rest and at peak exercise in HFpEF. These data 
support, while also extend, previous observations which indicate inert gas rebreathing or 
gas-exchange are valid techniques for assessing cardiac hemodynamics at rest and during 
exercise in patients with cardiopulmonary abnormalities (Agostoni, Cattadori, Bianchi, & 
Wasserman, 2003; Olson et al., 2008; Saur et al., 2010; Smith et al., 1999; Taylor, Olson, 
et al., 2013).    
Echocardiography in HFpEF  
Although SV can be measured using echocardiography, accurate image capture at rest 
can be challenging and these difficulties are markedly amplified even during bouts of 
moderate-intensity exercise (Marwick et al., 1992). Further complicating this technique, 
irrespective of rest or exercise, no commonly agreed upon protocol or technology (e.g. 
motion-mode, 2-D, TDI-PW, TDI-continuous wave, or 3-dimensional) has been 
established and, hence, inconsistencies in the assessment of cardiac hemodynamics are 
persistent (Christie et al., 1987; Lewis et al., 1984; Marwick et al., 1992). Distortion of 
the SV jet commonly occurs as a result of calculations which are dependent on image 
capture (e.g. 2-D and TDI-PW images), heart views (e.g. PLAX vs. A5C), and 
measurement (e.g. depth in relation to the aortic valve and influence of chest cavity size) 
which can be variable depending on the sonographer (Christie et al., 1987; Lewis et al., 
1984; Marwick et al., 1992). Nevertheless, despite the proposed limitations which may 
influence the efficacy of echocardiography for SV measurement, these sources of error 
may potentially be marginalized by an experienced sonographer in combination with a 
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skilled echocardiographic reader (Christie et al., 1987; Lewis et al., 1984; Marwick et al., 
1992; Rowland, Melanson, Popowski, & Ferrone, 1998), and therefore echocardiography 
can be useful for detecting other potential sources of error in the SV measure such as 
valvular regurgitation that is suggested to influence techniques such as thermodilution 
(Christie et al., 1987; Lewis et al., 1984; Marwick et al., 1992; Rowland et al., 1998).  
Acetylene rebreathe in HFpEF 
Recently it was observed by our group that HFpEF demonstrate low DLCO at rest and at 
peak exercise which was attributable to a combined attenuation in DM and VC both at rest 
and at peak exercise (Olson et al., 2008). Although demonstrated in HFrEF but still 
unconfirmed in HFpEF, it is possible that reductions in DM and VC could be related to the 
presence of pulmonary shunt (e.g. exercise-independent interstitial pulmonary edema or 
obstructive disease) or exercise-related interstitial pulmonary edema (Agostoni et al., 
2003; Barbera, Peinado, & Santos, 2003; Friedman, Wilkins, Rothfeld, & Bromberg, 
1984; Oelberg et al., 1998; Smith et al., 1999; Tolle et al., 2008), which could potentially 
influence the accuracy of SVACET since the rebreathe technique is dependent on the free 
diffusion acetylene gas across the alveolar–capillary membrane barrier. However, despite 
lower lung diffusion in comparison to controls, we observed in the present study that lung 
gas transfer capacity (e.g. DLCO, DLNO, and VC) was not only higher at peak exercise 
versus rest in HFpEF, but the magnitude in the rate of increase was comparable to 
controls (Olson et al., 2008). Hence, these data suggest that low DLCO, DLNO, and VC 
demonstrated previously in HFpEF were more likely to be associated with mechanisms 
influencing the alveolar—capillary membrane relationship related to the pathophysiology 
of HFpEF and not directly related to lung sarcoidosis, interstitial pulmonary fibrosis, 
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pulmonary shunt (e.g. exercise-independent interstitial pulmonary edema or obstructive 
disease), or extrapulmonary restriction for example (Barbera et al., 2003; Friedman et al., 
1984; Hughes, Lockwood, Jones, & Clark, 1991; Oelberg et al., 1998; van der Lee, 
Zanen, Stigter, van den Bosch, & Lammers, 2007). Also, and perhaps equally important, 
we demonstrate in the present study that despite a lower ratio of DM, DLCO, and DLNO 
with SVACET at peak exercise in HFpEF versus controls, there appears to be a negligible 
direct influence of lung gas transfer capacity within lungs on SVACET at peak exercise in 
HFpEF.  
Although we demonstrated direct relationships for measures of SV between SVACET with 
O2pulse or SVECHO at peak exercise in HFpEF, it is noteworthy that the agreement 
between these techniques appeared to be influenced by various factors of proportional or 
systematic bias. As examples of this, the magnitude of relationships between SVACET and 
SVECHO were clearly influenced by exercise intensity (i.e. rest versus peak exercise) in 
HFpEF but not in controls, whereas exercise intensity did not appear to be influential in 
the regression of SVACET with O2pulse in either group. It is likely that the variability in 
the comparisons between SVACET with O2pulse or SVECHO could partially be explained by 
differences in cardiac function (e.g. low cardiac reserve in HFpEF) between groups, in 
addition to the influence of physiological adjustments which occur during exercise such 
as pulmonary capillary recruitment and alveoli unfolding, and hence a potential for a rise 
in alveoli—pulmonary capillary surface area which might influence SVACET and O2pulse 
similarly, while having no influence of SVECHO.    
Comparison of inert gas rebreathing studies 
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Our current findings most closely support the observations of Saur et al. (2010) (Saur et 
al., 2010) which demonstrated that lung diffusing capacity did not significantly influence 
estimates of Q measured using inert gas rebreathing in patients with pulmonary disease. 
Additionally, previous validation studies of Hoeper et al. (1999) (Hoeper et al., 1999) 
(acetylene), Snyder et al. (2005) (Snyder et al., 2005) (acetylene), McLure et al. (2011) 
(McLure et al., 2011) (N2O), and Trinkmann et al. (2009) (Trinkmann et al., 2009) (N2O) 
in healthy individuals or in patients with cardiac and/or pulmonary disease further 
support the present study regarding the use of acetylene rebreathe for the measurement of 
SV during exercise in HFpEF.  
O2pulse in HFpEF  
Despite the recent findings from our group and from others (Bhambhani et al., 1994; 
Crisafulli, Piras, et al., 2007; Lavie et al., 2004; Lim et al., 2005; Taylor, Olson, et al., 
2013), O2pulse during exercise as a surrogate for SV may lose accuracy in the presence 
of conditions that violate assumptions regarding the relationship of Q with VO2 or Ca-vO2 
during exercise. Persons with unexpected variability in the relationship between cardiac 
hemodynamics and ventilation and gas-exchange might include clinical patients (e.g. HF, 
pulmonary disease, mitral valve dysfunction, anemia, and skeletal muscle disorders) 
(Katz et al., 2000; Lewis & Haller, 1989; Lim et al., 2005; Oelberg et al., 1998; Taylor, 
Olson, et al., 2013), highly-trained endurance athletes (Beck et al., 2006; Bhambhani et 
al., 1994; Crisafulli, Piras, et al., 2007), or obese individuals (Lavie et al., 2004). 
Aberrant variability in Ca-vO2 during exercise could influence the accuracy of O2pulse by 
minimizing the direct relationship between VO2 and Q, and thus misrepresent the 
quotient of VO2 with HR as an estimate of SV. Nevertheless, our findings are consistent 
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with observations from studies examining O2pulse measures in individuals with the 
potential for variability in Ca-vO2 and relationships between Q and VO2 during exercise. 
These samples included diastolic dysfunction, pulmonary disease, valvular regurgitation, 
and systolic HF patients (Barbera et al., 2003; Katz et al., 2000; Lim et al., 2005; Taylor, 
Olson, et al., 2013).   
The direct relationships between O2pulse and SVACET at peak exercise reported in the 
present study correspond closely to a recent validation study by our group which 
demonstrated robust relationships between O2pulse and direct Fick measurements of SV 
during submaximal exercise in HFrEF (Taylor, Olson, et al., 2013). However, the 
relationships we demonstrated currently between O2pulse and SVECHO suggest low- to- 
moderate linearity, and appeared to be heavily influenced by proportional or systematic 
biases associated with either the techniques, exercise status, or differences in participants. 
Oxygen pulse measurements appeared to consistently overestimate SV in comparison to 
SVECHO and SVACET at rest and at peak exercise in HFpEF, whereas O2pulse generally 
underestimated SV at peak exercise in controls.  
Several mechanisms may account for differences in SV estimation using O2pulse 
between HFpEF and controls. Although HFpEF demonstrated overall low cardiovascular 
function at rest, it is likely that O2pulse consistently overestimated SV during exercise 
because the relative rise in total ventilation or gas-exchange (i.e. VO2 ~267%) markedly 
surpassed the relative increase in cardiac function (i.e. SVACET ~30%, SVECHO ~8.0%, and 
HR ~73%) from rest to peak exercise. Whereas, in healthy individuals who are assumed 
to have normal cardiac function (i.e. both SV and HR), it is likely that because the 
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relative increase in HR (~106%) was greater than either SVACET (~33%) or SVECHO 
(~44%), an ensuing underestimation of SV via O2pulse occurred.  
Clinical Implications 
The data presented in the current study suggests that inert gas rebreathing (i.e. acetylene 
rebreathe) and other non-invasive gas-exchange (i.e. O2pulse) techniques can be safely 
used to reliably estimate SV at rest and during exercise in HFpEF (Hoeper et al., 1999; 
McLure et al., 2011; Saur et al., 2010; Taylor, Olson, et al., 2013). With these cost-
effective, non-invasive, and low user dependent systems available, surrogate estimates of 
SV during submaximal and/or peak exercise protocols may be readily available to 
quickly grade disease severity and response to therapy.        
Limitations 
Although we suggest that exercise-related interstitial pulmonary edema could have 
occurred but was non-influential to SV measurements in HFpEF, the presence of 
interstitial pulmonary edema was not directly measured in HFpEF. However, measures of 
the capacity of lungs for gas transfer (e.g. DLCO, DLNO, and DM) which are sensitive to 
the accumulation of interstitial pulmonary edema did not indicate the occurrence of 
unexpected adjustments in pulmonary vascular hemodynamics at peak exercise (Agostoni 
et al., 2003; Olson et al., 2006; Smith et al., 1999). Also, our clinical sample included 
only HFpEF without known pulmonary disease, and despite the close association of this 
syndrome with secondary pulmonary hypertension, more studies are needed to validate 
O2pulse and acetylene rebreathe estimates of SV at peak exercise in patient populations. 
Conclusion 
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In summary, the observations from the present study indicate that there is acceptable 
agreement between echocardiography, acetylene rebreathe, and O2pulse as non-invasive 
techniques for measurement of SV at rest in HFpEF; which, more importantly, increases 
at peak exercise in these patients. However, because of confounding influences of the 
pathophysiology of HFpEF concurrent with potential biases associated with these 
techniques at rest or at peak exercise, these factors should be considered prior to 
interpreting estimates of SV via these techniques. Nevertheless, we suggest that because 
of the low user dependence and reliability associated with acetylene rebreathe or O2pulse, 
these non-invasive techniques have the capacity to be readily available and efficacious 
for quick measurement of SV in research or clinical settings.  
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Tables 
  
 
  
Table 1: Participant characteristics    
 CTL HFpEF 
Demographics   
Age, years 65±2 69±2 
Gender, male/female  9/17 5/13 
Height, m 1.67±0.02 1.65±0.02 
Weight, kg 82.0±3.6 93.1±4.9 
BMI, kg∙m-2 29.2±1.1 34.0±1.6* 
BSA, m2 1.9±0.1 2.1±0.1 
VO2peak, predicted (%) 92.4±4.2 58.4±4.4* 
Left ventricular ejection fraction (%)   62.2±1.3 
Heart failure etiology (ischemic)   18 
Medications   
ACE inhibitor   8 (44) 
Angiotensin II receptor blockers  6 (33) 
β-blocker  12 (66) 
Digitalis   0 (0) 
Aspirin   7 (39) 
Diuretics  14 (78) 
Data presented as means ± SEM or count (n) and percentage (%). CTL = healthy controls; 
HFpEF = heart failure with preserved ejection fraction; BMI = body mass index; BSA = body 
surface area, VO2peak = peak oxygen consumption; *p  < 0.05. 
 1 
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Table 2: Exercise intensity, symptomology, ventilation, and gas-exchange  
 Baseline Peak exercise 
Exercise intensity and symptomology   
Work performed (watts)   
CTL - 93.8±5.3 
HFpEF - 52.2±5.4* 
RPE (Borg 6-20)   
CTL 6.0±0.0 16.1±0.4† 
HFpEF 6.0±0.0 15.9±0.4† 
Ventilation and gas exchange  
VO2, L∙min-1   
CTL 0.3±0.0 1.5±0.1† 
HFpEF 0.3±0.0 1.1±0.1*† 
VCO2, L∙min-1   
CTL 0.2±0.0 1.6±0.1† 
HFpEF 0.2±0.0 1.2±0.1*† 
RER   
CTL 0.76±0.0 1.1±0.0† 
HFpEF 0.81±0.0 1.0±0.0*† 
VE, L∙min-1   
CTL 8.5±0.4 56.7±2.8† 
HFpEF 9.5±0.6 42.9±2.9*† 
VT, L∙min-1   
CTL 0.6±0.0 1.6±0.1† 
HFpEF 0.7±0.1 1.2±0.1*† 
RR, breaths∙min-1   
CTL 14.3±0.6 36.8±1.2† 
HFpEF 15.1±0.9 36.4±2.1† 
VE/VCO2   
CTL 38.6±1.0 34.7±0.7† 
HFpEF 40.1±1.5 36.7±1.2 
PETCO2, mm Hg   
CTL 36.5±0.7 35.2±0.6 
HFpEF 34.8±0.7 34.2±1.1 
Ca-vO2, mL∙100 mL-1   
CTL 7.1±0.3 13.2±0.4† 
HFpEF 7.3±0.3 12.2±0.5† 
Ca-vO2, slope   
CTL - 23.8±1.2 
HFpEF - 23.7±1.7 
Data presented as means ± SEM. CTL = healthy controls; HFpEF = heart failure with preserved ejection 
fraction; RPE = rate of perceived exertion; VO2 = oxygen uptake; VCO2 = carbon dioxide production; RER = 
respiratory exchange ratio; VE = minute ventilation; VT = tidal volume; RR = respiratory rate; VE/VCO2 = 
ventilatory equivalent for CO2; PETCO2 = end-tidal partial pressure CO2; arteriovenous difference in oxygen 
content = Ca-vO2; Slope = rate of change from baseline to peak exercise; *HFpEF vs. CTL, p < 0.05. 
†Baseline vs. peak exercise, p < 0.05. 
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Table 3: Heart rate, blood pressure, and cardiac hemodynamics 
 Baseline Peak exercise 
HR, beats∙min-1   
CTL 70.0±2.1 143.9±3.9† 
HFpEF 68.4±3.0 118.5±5.2*† 
SBP, mm Hg   
CTL 133.3±3.1 193.8±5.0† 
HFpEF 128.8±4.4 158.1±6.5* 
DBP, mm Hg   
CTL 77.0±1.4 88.2±3.5† 
HFpEF 68.8±2.1* 76.2±2.8* 
MAP, mm Hg   
CTL 88.2±5.4 108.7±8.4† 
HFpEF 88.6±2.1 103.2±3.6 
Cardiac output (acetylene), L∙min-1 
CTL 4.2±0.2 11.6±0.6† 
HFpEF 4.2±0.3 9.6±0.6*† 
VC, mL  
CTL 65.3±5.5 101.3±7.1† 
HFpEF 50.8±5.5 75.3±9.3*† 
Stroke volume (ECHO), mL  
CTL 63.4±3.4 91.6±4.3† 
HFpEF 74.1±4.9 80.0±5.9 
Stroke volume (acetylene), mL   
CTL 61.8±3.5 82.1±4.7† 
HFpEF 63.4±4.6 82.7±5.9† 
O2pulse, mL∙beat-1   
CTL 4.5±0.2 10.7±0.6† 
HFpEF 4.3±0.3 9.8±0.5† 
Data presented as means ± SEM. CTL = healthy controls; HFpEF = heart failure with preserved ejection 
fraction; HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; MAP = mean 
arterial pressure; VC = pulmonary blood volume; ECHO = echocardiography; O2pulse = oxygen pulse; 
*HFpEF vs. CTL, p < 0.05; †Baseline vs. peak exercise, p < 0.05. 
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Figure Captions 
Figure 1. HFpEF = heart failure with preserved ejection fraction; CTL = healthy 
controls. Solid line represents the line of best fit, dotted line represents the line of 
identity. Ordinary least product regression equation shown with goodness of fit for the 
data expressed as the coefficient of determination (R2). The common regression equation 
(i.e. combined rest and peak exercise) for the method comparison between SVACET and 
SVECHO in HFpEF was f(x) = 1.05x – 8.13, p < 0.05; R2 = 0.46, 95% confidence limits 
(CL) (0.24, 0.59). The 95% CL for the slope (0.82, 1.36) and intercept (-30.0, 13.7) 
indicates the presence of fixed bias between SVACET and SVECHO. (A) Linear regression 
between echocardiographic and acetylene measures of stroke volume (mL) at rest in 
HFpEF with 95% CL for R2 (0.02, 0.50) (B) Linear regression between 
echocardiographic and acetylene measures of stroke volume (mL) at peak exercise in 
HFpEF with 95% CL for R2 (0.31, 0.75). In panels A and B, 95% CL for the slope at rest 
(0.61, 1.45) was similar to peak exercise (0.72, 1.37) in HFpEF which suggests there is 
fixed bias between SVACET and SVECHO at rest and at peak exercise. The 95% CL for the 
intercept at rest (-38.9, 26.4) was similar to peak exercise (-23.9, 30.3) in HFpEF, which 
indicates no proportional bias was present between techniques at rest or peak exercise. 
The common regression equation (i.e. combined rest and peak exercise) for CTL was f(x) 
= 0.96x – 2.56, p < 0.05; R2 = 0.43, 95% CL (0.25, 0.55). The 95% CL for the slope 
(0.78, 1.19) and intercept (-19.4, 14.3) indicate the presence of overall fixed bias between 
SVACET and SVECHO in CTL. (C) Linear regression between echocardiographic and 
acetylene measures of stroke volume (mL) at rest in CTL with 95% CL for R2 (0.09, 
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0.51), (D) Linear regression between echocardiographic and acetylene measures of stroke 
volume (mL) at peak exercise in CTL with 95% CL for R2 (0.06, 0.48). In panels C and 
D, 95% CL for slope at rest (0.72, 1.42) and at peak exercise (0.76, 1.53) suggests that 
there was fixed bias between SVACET and SVECHO. The 95% CL for intercept at rest (-
26.4, 20.3) and at peak exercise (-52.7, 20.0) indicate that there was no proportional bias 
between techniques at rest or at peak exercise in CTL. 
Figure 2. HFpEF = heart failure with preserved ejection fraction; CTL = healthy 
controls. Solid line represents the line of best fit, dotted line represents the line of 
identity. Ordinary least product regression equation shown with goodness of fit for the 
data expressed as the coefficient of determination (R2). The common regression equation 
(i.e. combined rest and peak exercise) for HFpEF is f(x) = 0.14x - 3.49, p < 0.05; R2 = 
0.13, 95% confidence limits (CL) (0.01, 0.30). The 95% CL for the slope (0.10, 0.19) and 
intercept (-7.15, 0.17) indicate the presence of overall fixed bias between O2pulse and 
SVECHO in HFpEF. (A) Linear regression between echocardiographic (mL) and O2pulse 
(mL/beat) measures of stroke volume at rest in HFpEF with 95% CL for R2 (0.05, 0.55). 
(B) Linear regression between echocardiographic (mL) and O2pulse (mL/beat) measures 
of stroke volume at peak exercise in HFpEF with 95% CL for R2 (0.00, 0.43). In panels A 
and B, 95% CL for slope at rest (0.04, 0.08) and at peak exercise (0.05, 0.13) both 
suggest the presence of fixed bias between O2pulse and SVECHO in HFpEF. The 95% CL 
for intercept at rest (-1.5, 2.2) and peak exercise (-0.12, 6.52) suggests no presence of 
proportional bias between techniques at rest or at peak exercise in HFpEF. 
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The common regression equation (i.e. combined rest and peak exercise) for CTL was f(x) 
= 0.16x – 5.30, p < 0.05; R2 = 0.52, 95% CL (0.35, 0.63). The 95% CL for the slope 
(0.14, 0.20) and intercept (-7.9, -2.7) suggests the presence of overall fixed and 
proportional bias between O2pulse and SVECHO in CTL. (C) Linear regression between 
echocardiographic (mL) and O2pulse (mL/beat) measures of stroke volume at rest in CTL 
with 95% CL for R2 (0.11, 0.54). (D) Linear regression between echocardiographic (mL) 
and O2pulse (mL/beat) measures of stroke volume at peak exercise in CTL with 95% CL 
for R2 (0.07, 0.49). In panels C and D, the 95% CL for slope at rest (0.05, 0.09) and at 
peak exercise (0.10, 0.20) indicate the presence of fixed bias between O2pulse with 
SVECHO. The 95% CL for intercept at rest (-1.24, 1.62) and at peak exercise (-7.0, 2.4) 
suggests no evidence of proportional bias was present between techniques at rest or at 
peak exercise. 
Figure 3. HFpEF = heart failure with preserved ejection fraction; CTL = healthy 
controls. Solid line represents the line of best fit, dotted line represents the line of 
identity. Ordinary least product regression equation shown with goodness of fit for the 
data expressed as the coefficient of determination (R2). The common regression equation 
(i.e. combined rest and peak exercise) for HFpEF was f(x) = 0.13x – 2.43, p < 0.05; R2 = 
0.53, 95% confidence limits (CL) (0.32, 0.65). The 95% CL for the slope (0.10, 0.17) and 
intercept (-4.80, -0.02) indicate the presence of fixed and proportional bias between 
O2pulse and SVACET in HFpEF. (A) Linear regression between acetylene (mL) and 
O2pulse (mL/beat) measures of stroke volume at rest in HFpEF with 95% CL for R
2 
(0.35, 0.76). (B) Linear regression between acetylene (mL) and O2pulse (mL/beat) 
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measures of stroke volume at peak exercise in HFpEF with 95% CL for R2 (0.38, 0.78). 
In panels A and B, 95% CL for slope at rest (0.04, 0.08) and at peak exercise (0.06, 0.11) 
both suggest fixed bias between O2pulse and SVACET in HFpEF. The 95% CL for 
intercept at rest (-0.54, 1.94) and at peak exercise (0.76, 5.12) both suggest no presence 
of proportional bias between O2pulse and SVACET in HFpEF. 
The common regression equation (i.e. combined rest and peak exercise) for CTL was f(x) 
= 0.17x – 4.86, p < 0.05; R2 = 0.58, 95% CL (0.42, 0.67). The 95% CL for the slope 
(0.14, 0.21) and intercept (-7.3, -2.5) indicate the presence of overall fixed and 
proportional bias between O2pulse and SVACET in CTL. (C) Linear regression between 
acetylene (mL) and O2pulse (mL/beat) measures of stroke volume at rest in CTL with 
95% CL for R2 (0.32, 0.70). (D) Linear regression between acetylene (mL) and O2pulse 
(mL/beat) measures of stroke volume at peak exercise in CTL with 95% CL for R2 (0.44, 
0.76). In panels C and D, 95% CL for slope at rest (0.05, 0.08) and at peak exercise (0.10, 
0.17) both indicate fixed bias between O2pulse and SVACET. The 95% CL for intercept at 
rest (-0.74, 1.50) and at peak exercise (-2.9, 2.6) suggests that there was no proportional 
bias between O2pulse with SVACET at rest or at peak exercise. 
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Summary 
Background: An impaired metaboreflex is associated with abnormal ventilatory and 
peripheral vascular function in heart failure (HF), whereas its influence on cardiac 
function or pulmonary vascular pressure remain unclear. This study investigated whether 
stimulating metabolite-sensitive neural feedback (metaboreflex) from locomotor muscles 
via post-exercise regional circulatory occlusion (RCO) would attenuate non-invasive 
estimates of central hemodynamics in HF patients. 
Methods: Eleven HF patients (NYHA class: I/II; ages, 51±15; EF: 32±9%) and 11 age 
and gender matched controls (ages, 43±9) completed three cycling sessions (four-
minutes, 60% VO2peak). Session one: control trial with normal recovery (NR). Sessions 
two or three: bilateral upper-thigh pressure tourniquets inflated suprasystolic at end-
exercise (RCO) for two-minutes recovery with or without inspired CO2 (RCO+CO2) 
(randomized). Mean arterial pressure (MAP), HR, and VO2 were continuously measured. 
Estimates of central hemodynamics; circulatory power (CircP=(VO2×MAP)/weight), 
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oxygen pulse index (O2pulseI=(VO2/HR)/BSA), and pulmonary vascular capacitance 
(GXCAP= O2pulseI×PETCO2) were calculated.  
Results: At rest and end-exercise, CircP and GXCAP were lower in HF versus controls 
(P<0.05), but no between treatment differences (P>0.05). At two-minutes recovery, 
GXCAP was lower during RCO versus NR in HF and controls (72±23 versus 98±20 and 
73±34 versus 114±35 mL∙beat-1∙mm Hg∙m-2, respectively; P<0.05); whereas, CircP did 
not differ between recovery treatments (P>0.05). O2pulseI at rest, end-exercise, or two-
minutes recovery for HF or controls did not differ across treatments (P>0.05).  
Conclusion: The present observations suggests metaboreflex stimulation did not 
influence CircP or O2pulseI in HF or controls. Whereas, metaboreflex stimulation may 
have evoked decreases in GXCAP (increased pulmonary vascular pressures) in these same 
individuals. 
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Introduction 
Patients with chronic heart failure (HF) frequently develop pulmonary system 
abnormalities which are commonly associated with symptoms of dyspnea and exercise 
intolerance (Guazzi et al., 2005; Kleber et al., 2000; Olson et al., 2014; Olson, Joyner, & 
Johnson, 2010; Rubin & Brown, 1984). Recently it has become evident that measures of 
both cardiac and ventilatory function are clear markers of syndrome severity and 
prognosis in HF patients, especially during physical activity when signs and symptoms of 
HF are exacerbated (Guazzi et al., 2005; Kleber et al., 2000; Lang et al., 2009; Lavie et 
al., 2004; Rubin & Brown, 1984). Further, abnormalities of pulmonary vascular 
hemodynamics related to increases in pulmonary vascular pressures and pulmonary 
vascular resistance (i.e. pulmonary hypertension [PH]) are common to HF patients 
(Aronson et al., 2011; Butler et al., 1999; Moraes et al., 2000; Taylor, Olson, et al., 
2013); and, also closely linked to increased mortality (Aronson et al., 2011; Moraes et al., 
2000). 
Recent evidence in support of the “muscle hypothesis” suggests that neural feedback 
from group III/IV skeletal muscle afferents contributes to altered arterial pressure and 
ventilatory control during exercise in HF (Keller et al., 2014; Olson et al., 2014; Olson, 
Joyner, & Johnson, 2010; Piepoli et al., 1999; Scott, Francis, Coats, & Piepoli, 2003). 
Post-exercise regional circulatory occlusion (RCO) is a validated non-invasive technique 
used to selectively stimulate metabolite-sensitive neural feedback from skeletal muscle 
(i.e. metaboreflex) in both humans and animals (Scott, Francis, et al., 2003; Spranger et 
al., 2013). Activation of the metaboreflex leads to sympathetically mediated 
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vasoconstriction and increased arterial pressure as well as augmented ventilation leading 
to ventilatory inefficiency in HF (Keller et al., 2014; Olson, Joyner, & Johnson, 2010). 
Although generally believed to be a favorable mechanism for improving peripheral 
vascular conductance and ventilatory and cardiac function during exercise in healthy 
individuals (Amann et al., 2011; Crisafulli et al., 2011; Crisafulli et al., 2006; Crisafulli et 
al., 2003; Fisher et al., 2010), recent observations suggest that the metaboreflex may 
contribute to unexpectedly high mean pulmonary arterial pressure (mPAP) during and 
following exercise in healthy individuals (Lykidis et al., 2008; White et al., 2013). 
However, it is unclear whether this mechanism contributes to secondary PH frequently 
observed in HF.  
Consistent with the beneficial influences of the metaboreflex observed in healthy 
individuals (Amann et al., 2011; Crisafulli et al., 2011; Crisafulli et al., 2006; Crisafulli et 
al., 2003; Fisher et al., 2010), invasive studies in healthy canines help confirm that the 
metaboreflex evokes increases in cardiac function (e.g. heart rate [HR], stroke volume 
[SV], and cardiac output [Q]) during and immediately following submaximal exercise 
(Ichinose et al., 2010; Sala-Mercado et al., 2006; Spranger et al., 2013). Further, as a 
result of these observations it has been suggested that increases in arterial pressure during 
or following exercise are primarily facilitated by metaboreflex-mediated increases in 
cardiac hemodynamics; and, that the metaboreflex does not provoke significant 
peripheral vasomotor pressor responses when maintenance of arterial pressure is flow-
mediated via adjustments in myocardial contractility and SV (Ichinose et al., 2010; Sala-
Mercado et al., 2006; Spranger et al., 2013). In contrast, extended studies in canines with 
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HF indicate that the metaboreflex contributes to augmented arterial pressure but does so 
primarily in the absence of contributions from increases in cardiac function during 
exercise (Hammond et al., 2000; Ichinose et al., 2008; Ichinose et al., 2010; Iellamo et 
al., 2007; O'Leary et al., 2004; Sala-Mercado et al., 2007; Sala-Mercado et al., 2006; 
Spranger et al., 2013). 
Encouraging observations suggest that cardiac power, the product of Q and mean arterial 
pressure (MAP), determined invasively or with inert-gas breathing is a robust index of 
cardiac function and prognosis in HF (Lang et al., 2009; Tan, 1986). More recently, it has 
been demonstrated that the indirect estimate of cardiac power, circulatory power (CircP), 
closely correlates with cardiac power and similarly shows prognostic strength in HF 
(Cohen-Solal et al., 2002; Williams, Tzeng, et al., 2005). Moreover, our group recently 
demonstrated that oxygen pulse (O2pulse) during exercise strongly related with invasive 
determination of SV in HF patients with or without secondary PH; and, equally 
noteworthy, it was also shown that mPAP was related to end-tidal partial pressure of CO2 
(PETCO2) (Taylor, Olson, et al., 2013). Together, we previously demonstrated that the 
indirect determination of pulmonary vascular capacitance (PVCAP), which shows 
prognostic power in PH patients (Mahapatra, Nishimura, Sorajja, et al., 2006), using 
O2pulse and PETCO2 (i.e. GXCAP) closely associated with invasive determination of 
PVCAP (Taylor, Olson, et al., 2013).     
Therefore, because it is known that systolic HF patients are afterload sensitive and that 
there is an association between metaboreflex activation with increased systemic arterial 
pressure in these patients (Keller et al., 2014; Piepoli et al., 1999); the aim of this study 
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was to examine the influence of the skeletal muscle metaboreflex, via post-exercise RCO, 
on central hemodynamics estimated using CircP and GXCAP in HF. We hypothesized that 
stimulation of the skeletal muscle metaboreflex during post-exercise recovery would 
attenuate both CircP and GXCAP in HF patients.  
Methods 
Subjects 
Eleven HF patients were recruited through the Mayo Clinic Heart Failure Service and the 
Cardiovascular Health Clinic. Eleven healthy control participants were recruited through 
advertisement in the surrounding community with attempts to match the HF group for 
age and gender (participant demographics, Table 1). Inclusion criteria for HF patients 
included diagnosis of ischemic or dilated cardiomyopathy with duration of HF symptoms 
>one-year; stable HF symptoms (>three-months); left ventricular (LV) ejection fraction 
percentage (EF%) ≤35% (from clinical records within three months); body mass index 
(BMI) <35.0 kg/m2 (at enrolment); and current non-smokers with a past smoking history 
<15 pack-years (at enrolment). All HF patients were on standard optimum 
pharmacological therapy at the time of the study. Control participants had normal cardiac 
function without evidence of exercise-induced ischemia and were without history of 
hypertension, lung disease, or coronary artery disease. The Mayo Clinic Institutional 
Review Board approved all experimental procedures. Prior to study, all participants 
provided written informed consent, and all aspects of the study were performed in 
accordance with the ethical standards of the Declaration of Helsinki. 
Protocol Overview 
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The study consisted of two separate days of exercise testing procedures, in an 
environmentally controlled physiological laboratory, separated by ≥48-hours. For all 
study visits, participants were asked to avoid strenuous physical activity for 24-hours and 
refrain from eating or consuming caffeine for three hours prior to arrival at the 
physiological laboratory for testing. Day one of testing consisted of a peak exercise test 
to volitional fatigue (peak oxygen consumption [VO2peak]). Day two consisted of three 
separate and randomized submaximal exercise sessions at 60% of the previously 
determined VO2peak.   
For each testing day, upon arrival, participants were fitted with a 12-lead 
electrocardiogram (Marquette Electronics, Milwaukee, WI) to monitor heart rate (HR) 
and rhythm. Participants were seated on a recumbent cycle ergometer and fitted with a 
nose clip and standard mouthpiece attached to a PreVent Pneumotach (Medical Graphic, 
St Paul, MN) connected to a metabolic measurement system (MedGraphics CPX/D; 
Medical Graphics) which was calibrated for volume (3.0 liter [L] syringe) and gases 
immediately prior to each test (Olson, Joyner, & Johnson, 2010). Resting simultaneous 
measures of gas-exchange and ventilation included: VO2, carbon dioxide production 
(VCO2), respiratory exchange ratio (RER), respiratory rate (RR), tidal volume (VT), 
minute ventilation (VE), ventilatory equivalent for carbon dioxide production (VE/VCO2), 
and end-tidal partial pressure of CO2 (PETCO2) were performed. Blood pressure was 
measured via manual sphygmomanometer at rest and the end of each stage during peak 
exercise testing and each minute during constant-load submaximal exercise sessions. For 
all exercise testing, measures of gas-exchange and flow analysis as well as HR and 
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oxygen saturation were continuously monitored and averaged every three-seconds at rest 
and throughout exercise sessions. For analysis and data reporting, at rest we averaged the 
entire three min period for all measures, for exercise we averaged the final 30-seconds of 
each exercise stage. During recovery, data were averaged in 10-second intervals. 
Additional calculations included the SV estimate O2pulse adjusted for body surface area 
(BSA) (VO2/HR)/BSA) (Taylor, Olson, et al., 2013), the non-invasive surrogate for 
PVCAP (GXCAP = O2pulseI×PETCO2) (Taylor, Olson, et al., 2013), and cardiac power 
estimated by CircP (VO2/weight)×MAP) (Cohen-Solal et al., 2002; Scharf et al., 2002; 
Williams, Tzeng, et al., 2005). We calculated O2pulseI, GXCAP, and CircP at rest, end-
exercise, and at two-minutes (min) post-exercise. 
During day two of testing, each participant performed three separate and randomized 
bouts of constant-load submaximal exercise at 60% of VO2peak (measured on day one of 
testing). Each of the three exercise sessions were identical in procedure and consisted of 
three-min of resting data collection, followed by four-min of constant-load cycle 
ergometry, and five-min of passive recovery which was randomized between cuffing 
conditions. Session one was the control trial which included a normal recovery at end-
exercise (NR). Sessions two and three were randomized and included, immediately at 
cessation of exercise, RCO via inflation of bilateral upper-thigh pressure tourniquets to 
≈20 mm Hg above peak exercise arm systolic blood pressure (SBP) measured during the 
VO2peak test conducted on day one. Session two or three also included addition of CO2 
(RCO+CO2) to the inspired air to clamp end-exercise PETCO2 in attempt to account for 
reduced venous return of CO2 due to RCO and its potential influence on central 
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chemoreceptor activity. The cuffing protocol has been validated in HF and has not been 
indicated to induce significant pain or discomfort associated with biasing measures of 
cardiovascular function (Olson, Joyner, & Johnson, 2010; Scott, Francis, et al., 2003).  
Statistical Analyses 
No dropouts or test failures occurred during the collection of study data and all data were 
included in the analyses. Where appropriate, all data are presented at means±standard 
deviation (SD). Normality of data was tested using Levene’s test. Two-tailed Student’s t-
tests were conducted for comparison between groups. Multiple comparisons for between- 
and- within group differences for treatment condition as well as control vs. HF were 
tested using the repeated measures one-way analysis of variance test. When the F-test 
statistic was significant from the analysis of variance test, Bonferroni post-hoc analysis 
was used to correct for multiple comparisons and to identify between which comparisons 
significance occurred. Statistical significance was determined using an alpha level of 
0.05. All computations were made using SAS statistical software, v.9.4 (SAS Institute, 
Cary, NC). 
Results 
Participant demographics 
Participant characteristics are presented in Table 1. The age range for participants was 
22- to- 69 years with males accounting for 64% in each group. Heart failure patients 
weighed approximately 10% more than controls (P>0.05); however, the lack of 
difference in height resulted in non-significant differences in BSA between groups.   
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End-exercise intensity and symptomology; and, basic cardiovascular measures at 
baseline, end-exercise, and two-minutes post-exercise  
Presented in Table 2 is exercise intensity and symptomology at end-exercise. Heart 
failure patients did not perceive their level of exertion to be significantly different versus 
controls despite a significantly less workload at end-exercise.  
Our laboratory has previously demonstrated HR, blood pressure, ventilation, and gas-
exchange responses for HF and controls at baseline, end-exercise, and at two-min post-
exercise with or without RCO (Keller et al., 2014; Olson, Joyner, & Johnson, 2010). 
Therefore, for the purposes of the aims of the present study, only HR, VO2, PETCO2, and 
MAP at baseline, end-exercise, and at two-min post-exercise are presented in Table 2 
because these metrics are directly related to the estimation of central hemodynamics.  
Briefly, previous data indicated that overall HR and blood pressure (mm Hg) were 
reduced at baseline, end-exercise, and at two-min post-exercise in HF versus controls 
(P>0.05) (Keller et al., 2014). No significant between treatment differences were present 
at baseline or end-exercise for HF or controls. Although, at two-min post-exercise with 
RCO or RCO+CO2 in HF, absolute differences for SBP (12.7±0.5 or 14.7±5.0, both 
P>0.05), diastolic blood pressure (DBP) (10.2±2.9 or 10.9±2.0, both P<0.05), and MAP 
(11.0±2.2 and 12.2±0.1, both P>0.05) were elevated compared to NR, respectively. Also, 
during RCO or RCO+CO2 in HF, absolute differences for SBP (5.2±3.2 or 4.9±4.0, 
P>0.05) and MAP (6.5±0.2 or 6.5±0.1, P>0.05) were greater at two-min post-exercise 
compared to end-exercise measures, respectively.  
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For measurements related to ventilation or gas-exchange at baseline or end-exercise, no 
significant within group differences were present; but, overall, HF demonstrated 
significantly worse ventilation and gas-exchange versus controls.(Olson, Joyner, & 
Johnson, 2010) Significant differences at end-exercise (i.e. VE, VT, VE/VCO2, or PETCO2) 
between HF and controls persisted to two-min post-exercise. Also, within group 
differences were demonstrated for both HF and controls at two-min post-exercise. For 
HF, VE (RCO+CO2 higher vs. NR), VE/VCO2 (RCO+CO2 higher vs. NR or RCO), and 
PETCO2 (RCO lower vs. NR or RCO+CO2) were different (all P<0.05). For controls, VE 
(RCO lower vs. NR or RCO+CO2), VE/VCO2 (RCO+CO2 higher vs. NR or RCO), and 
PETCO2 (RCO lower vs. NR or RCO+CO2) differed (all P<0.05).    
Estimates of central hemodynamics at baseline, end-exercise, and two-minutes post-
exercise 
Indices directly related to the estimation of central hemodynamics including O2pulseI, 
CircP, and GXCAP at baseline, end-exercise, and at two-min post-exercise are presented in 
Table 3. At baseline, no significant between treatment condition differences were present 
for HF or controls. Circulatory power was less in HF versus controls at baseline 
(P>0.05), and reached significance during the RCO+CO2 session. At baseline, lower 
O2pulseI for RCO and RCO+CO2 sessions in HF contributed to significantly lower 
GXCAP versus controls.  
For all treatment conditions at end-exercise, lower O2pulseI and PETCO2 contributed to 
significantly lower GXCAP in HF versus controls. However, at end-exercise there were no 
between treatment condition differences present for O2pulseI, CircP, or GXCAP in HF or 
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controls (P>0.05). Consistent with lower VO2 (P<0.05) and MAP (P>0.05) at end-
exercise for all treatment conditions, CircP was significantly lower in HF versus controls 
for all treatment conditions.   
At two-min post-exercise despite no differences in O2pulseI between or within groups, 
because of significantly lower PETCO2 in RCO versus NR in both HF and controls, GXCAP 
was also lower in both HF and controls in RCO versus NR by magnitudes of -26.1±2.5 
and -41.1±0.7 mL/beat ∙ mm Hg/m2, respectively; P<0.05. Whereas, consistent with no 
between or within group differences for VO2 and MAP at two min post-exercise 
(P>0.05), CircP did not differ between or within groups at two min post-exercise 
(P>0.05).  
Taking into consideration the elevation of O2pulseI, CircP, and GXCAP at end-exercise in 
controls versus HF, but the attenuation of these differences at two min post-exercise in 
controls versus HF, there was a lower rate of reduction from end-exercise to two-min 
post-exercise for these measures in all three treatments in HF versus controls (Table 3, 
P<0.05 for all). Also, in comparing the slopes (i.e. rate of change, end-exercise to two-
min post-exercise) for O2pulseI, CircP, or GXCAP between RCO and NR for each in HF 
versus controls, the absolute difference in slopes (i.e. RCO minus NR) for O2pulseI in HF 
was lower versus controls (3.3±2.0 and 5.7±4.7 mL/beat/m2, respectively); for CircP, HF 
was lower versus controls (8.8±26.4 and 136.7±76 mL/kg/min ∙ mm Hg, respectively), 
and GXCAP, HF was lower versus controls (10.3±0.1 and 23.5±5.7 mL/beat ∙ mm Hg/m2, 
respectively) (all P>0.05). 
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Absolute change in CircP and GXCAP from end-exercise to two-min post-exercise are 
shown in Figure 1 (A and B), respectively. Figure 2 (A and B) shows CircP and GXCAP at 
two-min post-exercise as a percentage of CircP and GXCAP at end-exercise, respectively. 
Absolute mean values from rest to end-exercise to two-min post-exercise for CircP and 
GXCAP are presented in Figure 3 (A and B), respectively. 
Discussion 
The main findings of this study suggests that metabolically mediated neural feedback 
from skeletal muscle, which is increased during constant-load submaximal exercise and 
maintained during post-exercise RCO, contributes to reductions in GXCAP in HF patients 
and healthy individuals. In contrast, CircP or O2pulse were not appreciably altered by 
metaboreflex stimulation or by decreased GXCAP suggesting that there was a direct 
influence of the metaboreflex on the pulmonary vasculature perhaps related to increased 
pulmonary vascular pressures.  
Physical activity results in increased autonomic nervous system activity and augmented 
adrenergic drive to cardiac and peripheral tissues in an attempt to maintain or restore 
hemodynamic homeostasis by increasing perfusion while also matching oxygen supply 
with demand (O’Leary, Augustyniak, Ansorge, & Collins, 1999); however, the “muscle 
hypothesis” suggests that the mechanisms of this pathway are deranged in HF (Keller et 
al., 2014; O'Leary et al., 2004; Olson et al., 2014; Olson, Joyner, & Johnson, 2010; 
Piepoli et al., 1999). The unencapsulated nerve endings of group III/IV neural afferents 
are dispersed within skeletal muscle and are sensitized by mechanical and/or chemical 
stimuli (Adreani & Kaufman, 1998; Piepoli et al., 1995; Scott, Wensel, et al., 2003; 
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Smith, Williams, et al., 2005). It is suggested that neural feedback from group III/IV 
skeletal muscle afferents influences changes in arterial pressure via primary adjustments 
in cardiac function in healthy individuals and animals (Amann et al., 2011; Crisafulli et 
al., 2011; Sala-Mercado et al., 2006; Spranger et al., 2013). Whereas, it is unclear 
whether neural feedback from skeletal muscle group III/IV fibers evokes adjustments in 
central hemodynamics in HF patients (Amann et al., 2014; Coutsos et al., 2013; O'Leary 
et al., 2004; Sala-Mercado et al., 2007).  
Stimulation of the metaboreflex using RCO or comparable muscle ischemia techniques 
have been validated for use in promoting neural feedback from skeletal muscle group IV 
fibers during or immediately following exercise in HF and healthy models (Crisafulli et 
al., 2011; Sala-Mercado et al., 2007; Scott, Francis, et al., 2003; Spranger et al., 2013). 
The RCO technique during post-exercise is particularly useful for examining metabolite-
sensitive neural feedback from skeletal muscle and its influence on inotropy and SV since 
central command and mechanical deformation from muscle are not present at this time, 
and because increases in HR (i.e. chronotropy) are not present during post-exercise RCO 
likely due to a robust baroreflex effector presence in response to pronounced 
metaboreflex sensitization (Crisafulli et al., 2011; Iellamo et al., 2007; Sala-Mercado et 
al., 2006). However, recent observations would suggest that although activation of the 
metaboreflex during or immediately following exercise in HF or healthy models 
contributes to increased arterial pressure (Crisafulli et al., 2011; Ichinose et al., 2010; 
Sala-Mercado et al., 2006; Spranger et al., 2013), it is likely that the mechanisms 
underlying these adjustments in peripheral vascular hemodynamics are not similar in HF 
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patients compared to healthy individuals. For example, based on the observations of 
Ichinose et al. (2010) and Spranger et al. (2013) in healthy canines (Ichinose et al., 2010; 
Spranger et al., 2013), it could be suggested that if hemodynamics generated from 
metaboreflex mediated increases in myocardial contractility cannot adequately overcome 
parallel sympathetically mediated increases in afterload, the metaboreflex could be 
expected to provoke substantial lowering of systemic vascular conductance and increased 
vascular resistance to compensate for the low contribution of cardiac hemodynamics to 
the generation of arterial pressure. Thus, because HF patients are known to have severely 
depressed cardiac reserve related to impaired inotropy, the observations in the present 
study indicate that stimulation of the metaboreflex likely influenced adjustments in 
GXCAP via pressor responses in pulmonary vascular tone with little contribution from the 
recruitment of myocardial contractile reserve and SV as indicated by null adjustments in 
CircP and O2pulse in these patients (Cohen-Solal et al., 2002; Keller et al., 2014; Lang et 
al., 2009; O'Leary et al., 2004; Sala-Mercado et al., 2007). 
Although it has been demonstrated by us and others previously that hyperpnea concurrent 
with attenuated gas-exchange function occur during exercise in HF in comparison to 
healthy individuals (Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999), the parallel 
impairment of both ventilation and gas-exchange demonstrated during exercise amongst 
our three treatment conditions in HF compared to controls did not persist at two-min 
post-exercise recovery. As noted by our present and previous observations (Olson, 
Joyner, & Johnson, 2010), at two-min post-exercise there were marked differences in 
gas-exchange (i.e. PETCO2) in the absence of ventilation (i.e. VE, RR, and VT) and other 
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gas-exchange (i.e. VO2) in RCO versus NR in HF; whereas, during exercise these 
measures were similar between RCO and NR. This is important as it suggests that 
although ventilation – perfusion mismatch concordant with attenuated Q and increased 
afterload could have occurred during exercise in HF as has been demonstrated previously 
(Buller & Poole-Wilson, 1990; Reindl et al., 1998), our post-exercise observations of 
changes in PETCO2 during RCO in comparison to NR were not likely due to mechanical 
adjustments in ventilatory function or ability to deliver blood to the pulmonary 
circulation caused by RCO-metaboreflex activation. Indeed, because others have 
demonstrated that increased VE/VCO2 slope may be related to increased mPAP during 
exercise in HF (Reindl et al., 1998), and because we have previously demonstrated an 
association between PETCO2 and mPAP during exercise in HF (Taylor, Olson, et al., 
2013), we suggest that attenuated PETCO2 observed at two-min post-exercise during RCO 
in HF was the consequence of increased mPAP related to metaboreflex stimulation. 
Moreover, although the adjustments in PETCO2 and GXCAP in response to metaboreflex 
sensitization were similar between HF and controls, these data are consistent with 
previous observations which suggested that metaboreflex activation leads to increased 
mPAP during and following exercise in healthy individuals (Lykidis et al., 2008; White 
et al., 2013). However, the present observations extend these previous findings by being 
the first to examine this mechanism in HF and by demonstrating that the metaboreflex 
influence on GXCAP was independent of adjustments in the SV estimate O2pulse in both 
controls and HF (Lykidis et al., 2008; Taylor, Olson, et al., 2013; White et al., 2013).  
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We did observe that CircP and O2pulse were comparable at two-min post-exercise with 
RCO or RCO+CO2 versus NR in controls which was similar to the pattern shown in HF. 
This finding occurred despite preserved cardiac function in controls, in addition to 
previous observations which suggested that the metaboreflex contributed to increased 
cardiac function (e.g. Q and SV) in healthy individuals (Amann et al., 2011; Crisafulli et 
al., 2011; Crisafulli et al., 2003). However, it is important to point out that HR responses 
in the present study were consistent with previous observations of HR during post-
exercise recovery with RCO in healthy individuals (Crisafulli et al., 2011). Also, it is of 
interest that Coutsos et al. (2013) recently demonstrated in both canines with or without 
HF during exercise with metaboreflex stimulation that Q but not HR or MAP were 
significantly higher with alpha adrenergic (α1) receptor blockade versus without (Coutsos 
et al., 2013). As such, it is important to consider, although augmented cardiac adrenergic 
drive is known to stimulate myocardial beta adrenergic (β1,2) receptors which 
subsequently leads to increased myocardial metabolic activity and metabolite mediated 
hyperemia within coronary arteries, coronary vascular α1 receptors associated with a 
vasoconstrictor capabilities are also stimulated. Thus, in the event that α1 reserves 
exceeded β1,2 reserves; or, β1,2 receptors had a blunted sensitivity compared to α1 
receptors in individuals of the present study, it is possible that a restrained coronary 
arterial vasodilatory ability could attenuate myocardial perfusion and inotropy despite the 
presence of augmented cardiac adrenergic drive facilitate by RCO-metaboreflex 
activation (Coutsos et al., 2013; O'Leary et al., 2007). Moreover, this mechanism could 
be further exacerbated in HF when combined with additional myocardial abnormalities 
such as an exhausted Frank—Starling mechanism, as well as dysfunctional cardiac β1,2 
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receptors (e.g. attenuated reuptake or degradation of catecholamines at cardiac β1,2 
receptor sites (Eisenhofer et al., 1996; Rose, Burgess, & Cousineau, 1983)) which may 
also help to explain the attenuated return of CircP to baseline levels during recovery with 
or without RCO in HF patients.  
Lastly, that the present study suggests a potential synergistic interaction between 
feedback from central chemoreceptors with feedback from ergoreceptors as GXCAP 
responses during RCO+CO2, although not significantly different versus RCO, were 
noticeably higher in HF and in controls. Thus, reaffirming the critical role of the regions 
within the dorsal medulla (e.g. caudal nucleus tractus solitarius) in receiving, organizing, 
and integrating neural feedback from the viscera of central and peripheral origins.        
Clinical Implications 
While cardiac and pulmonary system abnormalities are most evident during physical 
activity in HF, to date, controversy remains regarding the specific mechanisms 
underlying the etiology of exertional symptoms and functional limitation of these 
patients. The present study suggests neural feedback from metabolite-sensitive skeletal 
muscle afferents may partially explain chronic increases in pulmonary vascular pressures 
which contribute to impaired pulmonary vascular reactivity and permeability and 
pulmonary vascular resistance in HF. This is critically important because common 
complications of HF includes ventilatory dysfunction, dyspnea, and exercise intolerance 
which may be related to tonic increases in pulmonary vascular resistance (Butler et al., 
1999; Moraes et al., 2000; Taylor, Olson, et al., 2013); but, perhaps more importantly due 
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to the relationship between increased pulmonary vascular pressures and increased 
mortality risk (Aronson et al., 2011; Moraes et al., 2000).   
Limitations 
Although the post-exercise RCO technique has been well validated in multiple 
populations (Scott, Francis, et al., 2003), our current study did not directly measure 
intramuscular metabolite concentration and thus it was not possible to identify specific 
metabolites that mediated stimulation of metaboreceptors. Further, we did not assess α- 
or β-adrenergic receptor density or function within the heart or vasculature and therefore 
our conjecture regarding α- and β-adrenergic receptors is aimed to be thought provoking. 
Lastly, we did not directly measure Q or mPAP and therefore do not know whether there 
was unanticipated bias that accompanied our surrogate estimates. Nevertheless, CircP, 
O2pulse, and GXCAP have been well validated as accurate surrogates for their respective 
invasive counterparts (Cohen-Solal et al., 2002; Lavie et al., 2004; Scharf et al., 2002; 
Taylor, Olson, et al., 2013; Williams, Tzeng, et al., 2005), and therefore use of indirect 
estimates of central hemodynamics were considered adequate as the intent of this study 
design was to assess relative changes in central hemodynamics in response to 
metaboreflex augmentation, not absolute measurements. 
Summary 
Administrating RCO immediately at cessation of submaximal constant-load exercise in 
HF patients and healthy individuals facilitates stimulation of metabolite-sensitive neural 
feedback from skeletal muscle nerve fibers. This neural feedback pathway contributes to 
decreased GXCAP (i.e. increased pulmonary vascular pressures) in low- to- moderate 
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severity HF patients and in older healthy individuals; whereas, because of null changes in 
CircP and O2pulse, it is unlikely that this pathway influences adjustments in cardiac 
function in these same individuals. 
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Tables 
 
 
  
Table 1. Participant Characteristics 
 Healthy Control Heart Failure P 
Demographics    
Age, years 43 ± 9 51 ± 15 0.21 
Gender, male/female 7/4 7/4 1.00 
Height, m 1.76 ± 0.06 1.73 ± 0.08 0.35 
Weight, kg 78.3 ± 10.9 87.4 ± 18.5 0.18 
BMI, kg ∙ m-2 25.2 ± 3.6 29.1 ± 6.1 0.10 
BSA, m2 2.0 ± 0.1 2.0 ± 0.2 0.33 
VO2peak, mL ∙ kg-1 ∙ min-1 36.3 ± 9.2 17.5 ± 4.8 <0.001 
LVEF, %  32.1 ± 9.2  
HF etiology 
(ischemic/idiopathic)  
 4/7  
NYHA class  1.6 ± 0.5  
I  4  
II  7  
Medications    
ACE inhibitor  6 (55)  
Angiotensin II receptor blockers  4 (36)  
β-blocker  10 (91)  
Digitalis  4 (36)  
Aspirin  7 (64)  
Diuretics  7 (64)  
Data are mean ± SD or as n. BMI, body mass index; BSA, body surface area; LVEF, left 
ventricular ejection fraction; NYHA, New York Heart Association; ACE, angiotensin 
converting enzyme. 
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Table 2: Workload, symptomology, heart rate, VO2, PETCO2, and MAP 
 NR  RCO  RCO+CO2  
Baseline    
HR, beats ∙ min-1    
CTL 64±13 68±11 68±11 
HF 76±14 77±14 77±14 
VO2, L ∙ min-1    
CTL 0.4±0.1 0.4±0.2 0.5±0.1 
HF 0.4±0.1 0.4±0.1 0.4±0.1* 
PETCO2, mm Hg    
CTL 36.6±4.3 35.7 ± 3.8 36.0±3.6 
HF 34.1±3.3 33.7 ± 4.0 33.5±3.7 
MAP, mm Hg    
CTL 90±12 93±12 92±10 
HF 91±14 91±15 92±14 
End-exercise    
Workload (watts)    
CTL 115±16 - - 
HF 36±7* - - 
RPE (Borg 6-20)    
CTL 11.4±1.2 11.4±1.4 11.2±1.7 
HF 10.7±1.8 11.3±1.8 11.6±2.0 
Dyspnea (Borg 0-10)    
CTL 1.8±1.2 1.7±1.1 1.6±1.1 
HF 1.9±1.0 2.1±1.1 2.5±0.8 
HR, beats ∙ min-1    
CTL 116±10 115±11 117±13 
HF 105±16 104±15 106±16 
VO2, L ∙ min-1    
CTL 1.7±0.4 1.8±0.5 1.8±0.5 
HF 1.0±0.3* 1.0±0.3* 1.1±0.3* 
PETCO2, mm Hg    
CTL 41.4±5.2 40.6±4.3 40.3±3.8 
HF 35.4±4.7* 35.3±4.7* 34.7±4.8* 
MAP, mm Hg    
CTL 111±14 112±14 111±14 
HF 99±14 100±13 101±16 
Post-exercise (2 min)    
HR, beats ∙ min-1    
CTL 75±14 77±11 76±11 
HF 80±16 87±18 85±17 
VO2, L ∙ min-1    
CTL 0.4±0.1 0.3±0.1 0.4±0.1 
HF 0.5±0.1 0.4±0.1 0.4±0.1 
PETCO2, mm Hg    
CTL 36.4±4.0 33.2±4.9† 38.4±3.9‡ 
HF 33.8±4.5* 30.2±3.4† 34.8±4.0*‡ 
MAP, mm Hg    
CTL 98±12 97±34 108±13 
HF 96±15 107±13 108±16 
Data are mean ± SD. NR, normal recovery; RCO, regional circulatory occlusion; RCO+CO2, added CO2 during RCO; 
HF, heart failure; CTL, control; RPE, rate of perceived exertion; HR, heart rate; VO2, oxygen uptake; PETCO2, end-tidal 
partial pressure CO2; MAP, mean arterial pressure; *p<0.05 compared to CTL after Bonferroni correction; †p<0.05 
compared with NR after Bonferroni correction; ‡p<0.05 compared with RCO after Bonferroni correction. 
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Table 3: Estimates of central hemodynamics   
 NR  RCO  RCO+CO2  
Baseline    
O2pulseI, mL/beat/m
2   
CTL 3.3±0.8 3.4±1.6 3.6±1.1 
HF 2.5±0.5* 2.6±0.8 2.4±0.5* 
CircP, mL/kg/min ∙ mm Hg   
CTL 465±102 510±199 542±105 
HF 391±76 418±152 397±87* 
GXCAP, mL/beat
 ∙ mm Hg/m2   
CTL 122±38 122±59 128±43 
HF 84±16* 88±30 80±15* 
End-exercise    
O2pulseI, mL/beat/m
2   
CTL 7.6±1.6 7.9±1.7 7.8±1.7 
HF 4.9±1.1* 4.8±1.0* 5.0±1.2* 
CircP, mL/kg/min ∙ mm Hg   
CTL 2451±572 2579±750 2527±673 
HF 1217±367* 1187±323* 1241±301* 
GXCAP, mL/beat
 ∙ mm Hg/m2   
CTL 318±86 323±86 315±79 
HF 175±51* 170±43* 172±50* 
Post-exercise (2 min)    
O2pulseI, mL/beat/m
2   
CTL 3.1±0.9 2.2±0.8‡ 2.6±1.0‡ 
HF 2.9±0.7 2.4±0.7 2.5±0.7 
CircP, mL/kg/min ∙ mm Hg   
CTL 557±132 453±233 510±189 
HF 505±83‡ 492±138 520±105‡ 
GXCAP, mL/beat
 ∙ mm Hg/m2   
CTL 114±35 73±34†‡ 100±47 
HF 98±20 72±23† 86±22 
Slope    
O2pulseI, mL/beat/m
2   
CTL 16.1±3.1 21.8±7.8 19.3±6.3 
HF 12.5±6.6 15.8±4.6* 16.1±5.4 
CircP, mL/kg/min ∙ mm Hg   
CTL -947±263 -1084±339 -1009±289 
HF -356±187* -348±161* -361±134* 
GXCAP, mL/beat
 ∙ mm Hg/m2   
CTL -102±28 -125±34 -108±25 
HF -39±24* -49±24* -43±19* 
Data are mean±SD. CTL, control; CircP, circulatory power; GXCAP, pulmonary vascular capacitance; HF, 
heart failure; NR, normal recovery; O2pulseI, oxygen pulse indexed to body surface area; RCO, regional 
circulatory occlusion; RCO+CO2, added carbon dioxide during RCO; Slope, rate of change from end-exercise 
to 2-min post-exercise; *p<0.05, compared to CTL after Bonferroni correction; †p<0.05, RCO compared to 
NR; ‡p<0.05, compared to baseline. 
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Figure captions 
Figure 1. Data presented as means±SD. (A) Circulatory power (CircP) absolute change 
(Δ) from end-exercise to two-min post-exercise. (B) Pulmonary vascular capacitance 
(GXCAP) absolute Δ from end-exercise to two-min post-exercise. *Significant between 
groups, heart failure vs. control (P<0.05). 
Figure 2. Data presented as means±SD. (A) Circulatory power (CircP) at two-min post-
exercise as a percentage (%) of CircP at end-exercise. (B) Pulmonary vascular 
capacitance (GXCAP) at two-min post-exercise as a % of GXCAP at end-exercise. 
†Significant across control conditions NR vs. RCO or RCO+CO2 (P<0.05). *Significant 
between groups, heart failure vs. control (P<0.05). 
Figure 3. Data presented as means±SD. (A) CircP at rest, end-exercise, two-min post-
exercise. At rest, CircP was less in heart failure for RCO+CO2 compared to controls 
(P<0.05). Heart failure showed less of an increase in CircP compared to control at end-
exercise for all conditions (P<0.05). At two-min post-exercise no significant differences 
were present between or within groups. (B) GXCAP at rest, end-exercise, and two-min 
post-exercise. At rest GXCAP was significantly less in heart failure for NR and RCO+CO2 
compared to controls. At end-exercise GXCAP was significantly less for heart failure 
compared to controls for all conditions. At two-min post-exercise, RCO differed 
compared to NR for heart failure and controls (P<0.05). CircP=circulatory power, 
GXCAP=pulmonary vascular capacitance, NR=normal recovery, RCO=regional 
circulatory occlusion, RCO+CO2=regional circulatory occlusion+carbon dioxide. 
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3.3 Intrathecal fentanyl blockade of neural feedback from skeletal muscle during 
exercise in heart failure patients: Influence on circulatory power and pulmonary 
vascular capacitance 
Erik H. Van Iterson1, Eric M. Snyder1, Michael J. Joyner2, Bruce D. Johnson2, Thomas P. 
Olson2  
1Department of Kinesiology, University of Minnesota, Minneapolis, MN; 2Division of 
Cardiovascular Diseases, Mayo Clinic, Rochester, MN 
 
Summary 
Background: Secondary pulmonary hypertension is common in heart failure (HF) 
patients. We hypothesized that inhibition of neural feedback from locomotor muscle 
group III/IV neurons contributes to reduced pulmonary vascular pressures independent of 
changes in cardiac function during exercise in HF.  
Methods: 9 HF patients (ages, 60±2; EF, 26.7±1.9%; New York Heart Association class, 
I-III) and 9 age/gender matched controls (ages, 63±2) completed five-minutes of 
constant-load cycling (65% Workloadpeak) with intrathecal fentanyl or placebo, on 
separate days (randomized). Mean arterial pressure (MAP), heart rate (HR), end-tidal 
partial pressure of CO2 (PETCO2), and oxygen consumption (VO2) were measured at rest 
and exercise. Non-invasive surrogates for cardiac power (circulatory power, 
CircP=VO2×MAP), stroke volume (oxygen pulse, O2pulse=VO2/HR), and pulmonary 
arterial pressure (GXCAP=O2pulse×PETCO2) were calculated.  
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Results: At rest and end-exercise, differences between fentanyl versus placebo were not 
significant for CircP in HF or controls. Differences between fentanyl versus placebo for 
GXCAP were not significant at rest in HF or controls. At end-exercise, GXCAP was 
significantly higher with fentanyl versus placebo in HF (691±59 versus 549±38 
mL/beat×mm Hg), but not controls (536±59 versus 474±43 mL/beat×mm Hg). Slopes 
(rest to end-exercise) for GXCAP were significantly higher with fentanyl versus placebo in 
HF (95.1±9.8 versus 71.6±6.0 mL/beat×mm Hg), but not controls (74.3±9.5 versus 
60.8±6.5 mL/beat×mm Hg). CircP slopes did not differ between fentanyl versus placebo 
in HF or controls (p>0.05).  
Conclusion: We conclude that neural feedback from locomotor muscle group III/IV 
neurons may evoke increased pulmonary vascular pressures independent of changes in 
cardiac function during exercise in HF. 
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Introduction 
Secondary pulmonary hypertension (PH) is a frequent consequence of chronic heart 
failure (HF) (Abramson et al., 1992; Aronson et al., 2011; Ghio et al., 2001; Moraes et 
al., 2000; Taylor, Olson, et al., 2013). Initially, the elevation in pulmonary pressures 
(mPAP) is caused by passive hemodynamic backup due to increased left ventricular 
and/or left atrial pressures because of impaired left ventricular output (passive PH) (Galie 
et al., 2009). In some cases, however, despite reduction in the hemodynamic volume of 
the pulmonary circulation, the transpulmonary gradient between mPAP and pulmonary 
capillary wedge pressure remain elevated (i.e. >15 mm Hg) and high pulmonary vascular 
resistance (PVR) persists (Galie et al., 2009; Rich & Rabinovitch, 2008). The latter form 
of secondary PH has been termed “reactive” or “mixed” although the pathogenic 
mechanisms are not fully understood (Aronson et al., 2011; Butler et al., 1999; Galie et 
al., 2009).  
Another debilitating consequence of HF is a dysregulated autonomic nervous system 
(ANS) with chronically elevated sympathetic nervous system activity. 
Sympathoexcitation contributes to increased vascular resistance in the periphery (Amann 
et al., 2014; Keller et al., 2014; O'Leary et al., 2004); although, its contribution to the 
pulmonary vascular system remains unclear in HF. Because of the close link between 
secondary PH in HF and increased morbidity and mortality it is critical to improve the 
understanding of mechanisms linking elevated adrenergic drive, impaired cardiac 
function, and pulmonary vascular health in these patients (Aronson et al., 2011; Butler et 
al., 1999; Ghio et al., 2001; Moraes et al., 2000). 
147 
 
Recently, it has been suggested that a major contributor to sympathoexcitation during 
exercise in HF originates from mechanically (group III mechanoreceptors) and/or 
metabolically (group IV metaboreceptors) sensitive skeletal muscle neurons (Amann, 
Proctor, Sebranek, Pegelow, & Dempsey, 2009; O’Leary et al., 1999; Olson et al., 2014; 
Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999). Group III/IV unencapsulated nerve 
fibers are embedded near venules, capillaries, and within collagenous tissue of skeletal 
muscle and have been shown to influence both peripheral cardiovascular and ventilatory 
control in humans (Amann et al., 2009; Coote et al., 1971; McCloskey & Mitchell, 1972; 
O’Leary et al., 1999; Olson et al., 2014; Piepoli et al., 1999). In healthy individuals, an 
ample body of evidence now suggests that neural feedback from group III/IV nerve fibers 
contributes to favorable adjustments in ventilation, cardiac function, and hemodynamic 
circulation which leads to improved homeostatic regulation during exercise (Amann et 
al., 2009; Crisafulli et al., 2011; Fisher et al., 2010). In contrast, observations in HF 
suggest that neural feedback from skeletal muscle group III/IV nerve fibers contribute to 
impaired ventilatory and increased peripheral vascular resistance which are closely 
associated with reduced functional capacity and exertional symptoms (Keller et al., 2014; 
Olson et al., 2014; Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999).  
Assessment of the influence of neural feedback from group III/IV nerve fibers during 
exercise in humans remains challenging. However, μ-opioid receptors which can be 
found superficially located on the lumbar dorsal horn of the spinal cord where group 
III/IV nerve fibers synapse represent a feasible target for pharmacological manipulation 
of afferent neural signaling (Besse, Lombard, & Besson, 1991; Besse, Lombard, Zajac, 
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Roques, & Besson, 1990; Meintjes, Nobrega, Fuchs, Ally, & Wilson, 1995; Pomeroy, 
Ardell, & Wurster, 1986). Inhibition of group III and IV neural transmission via a 
selective μ-opioid receptor agonist has been shown to inhibit the cortical projection of 
group III/IV neural feedback in human and animal models (Amann et al., 2011; Amann et 
al., 2009; Meintjes et al., 1995). Indeed, intrathecal administration of fentanyl at the 
lower-lumbar level prior to exercise in healthy individuals has been associated with 
reduced exercise ventilation, improved ventilatory efficiency, and reduced vascular 
resistance without affecting efferent neuromuscular control or the force-generating 
capacity of skeletal muscle related to central command (Amann et al., 2011; Amann et 
al., 2009).  
Intrathecal injection of fentanyl at the lower-lumbar level prior to submaximal exercise 
has been shown to improve minute ventilation (VE), respiratory rate (RR), the ventilatory 
equivalent for carbon dioxide production (VE/VCO2), and mean arterial pressure (MAP) 
in HF (Amann et al., 2014; Olson et al., 2014). While the influence of locomotor muscle 
neural feedback inhibition during exercise on peripheral vascular function and ventilatory 
control appear clear, it’s influence on cardiac hemodynamics in human HF remains open 
to question (Amann et al., 2014); and, the influence of locomotor muscle neural 
inhibition during exercise on pulmonary vascular pressures (i.e. GXCAP)(Taylor, Olson, et 
al., 2013) has not been investigated previously in this population. 
A number of studies have suggested that non-invasive gas-exchange based  indices 
including oxygen pulse (O2pulse) (Taylor, Olson, et al., 2013), circulatory power (CircP) 
(Scharf et al., 2002; Williams, Tzeng, et al., 2005), and GXCAP(Taylor, Olson, et al., 
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2013) are robust surrogates of direct measures of stroke volume, cardiac power, and 
pulmonary vascular pressures during exercise in HF, respectively. In particular, cardiac 
power has shown to be a robust indicator of cardiac hemodynamic and pressure 
generating capability during exercise in HF (Lang et al., 2009). In contrast, pulmonary 
vascular capacitance describes the interaction between pulmonary vascular pressures and 
hemodynamics (Taylor, Olson, et al., 2013), and when measured during exercise has 
been shown to discriminate between HF patients with and without secondary PH.   
The present study sought to test the hypothesis that selective μ-opioid inhibition of neural 
feedback from group III/IV nerve fibers using intrathecal fentanyl at the lower-lumbar 
level during submaximal constant-load exercise would improve CircP (Scharf et al., 
2002; Williams, Tzeng, et al., 2005) and GXCAP (Taylor, Olson, et al., 2013) in HF 
patients. 
Methodology 
Participants 
Nine Caucasian systolic HF patients along with nine Caucasian healthy control 
participants matched for gender and age were recruited and participated in this study 
(participant demographics, Table 1). Inclusion criteria for HF patients included diagnosis 
of ischemic or dilated cardiomyopathy with duration of HF symptoms >one year; stable 
HF symptoms (>three months); left ventricular ejection fraction percentage ≤35.0% 
(from clinical records within three months); body mass index (BMI) <35.0 
kilograms/meter2 (at enrolment); and current non-smokers with a past smoking history 
<15 pack-years (at enrolment). All patients were on standard optimum pharmacological 
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therapy for HF at the time of the study. Heart failure patients were recruited through the 
Mayo Clinic Heart Failure Service and the Cardiovascular Health Clinic. Control 
participants were recruited through advertisement in the surrounding community. Control 
participants had normal cardiac function without evidence of exercise-induced ischemia 
and were without history of hypertension, lung disease, or coronary artery disease. The 
experimental procedures were approved by the Mayo Clinic Institutional Review Board, 
all participants provided written informed consent prior to study, and all aspects of the 
study were performed in accordance with the ethical standards of the Declaration of 
Helsinki. Parts of these data have been reported previously (Olson et al., 2014); however, 
the data presented in the current manuscript represent a new analysis based on an a priori 
novel hypothesis. 
Protocol Overview 
Each participant underwent three days of testing, separated by ≥48-hours, in an 
environmentally controlled physiology laboratory. For all study visits, participants were 
asked to avoid strenuous physical activity for 24-hours prior to the visit and refrain from 
eating or consuming caffeine for three hours prior to arrival at the physiological 
laboratory for testing. Upon arrival, participants were fitted with a 12-lead 
electrocardiogram (Marquette Electronics, Milwaukee, WI) to continuously monitor heart 
rate (HR) and rhythm. Participants were seated on a recumbent cycle ergometer and fitted 
with a nose clip and mouthpiece attached to a PreVent Pneumotach (Medical Graphics, St 
Paul, MN) connected to a breath-by-breath gas-exchange system (MedGraphics CPX/D; 
Medical Graphics), which was calibrated for volumes (3.0 liter [L] syringe) and gases 
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immediately prior to each protocol (Olson, Joyner, & Johnson, 2010). Resting measures 
of oxygen uptake (VO2), VCO2, respiratory exchange ratio (RER), breathing frequency 
(fB), tidal volume (VT), VE, and PETCO2 were performed. Blood pressure was measured 
using manual sphygmomanometry at rest and near the end of each stage during the peak 
exercise test and continuously by indwelling radial artery catheter during constant-load 
submaximal exercise sessions. Measures of all gas-exchange and flow analysis as well as 
HR and oxygen saturation were continuously monitored and averaged every three 
seconds at rest and throughout exercise sessions. Oxygen pulse was calculated as, 
O2pulse = VO2/HR (Taylor, Olson, et al., 2013); and the non-invasive surrogate for 
pulmonary vascular capacitance was calculated as, GXCAP = O2pulse×PETCO2 (Taylor, 
Olson, et al., 2013). 
The first study day included a peak exercise test beginning at 20 watts (W) and increased 
by 20 W (HF) and 40 W (controls) every three min while maintaining a cadence of 65 
repetitions per minute (rpm) until volitional fatigue (i.e. rating of perceived exertion ≥17 
[Borg Scale = 6–20] or RER of ≥1.10). Study days two- and- three were randomized to 
either intrathecal injection of fentanyl at the lumbar level (fentanyl) to produce blockade 
of neural feedback from locomotor muscles or sham injection (placebo) in a single-blind 
fashion, where each exercise session then consisted of constant-load exercise at 65% of 
previously determined peak work. 
Study days two- and- three, irrespective of randomization order, were identical except for 
intrathecal injection of fentanyl or placebo. Briefly, within two- to- three min following 
placement of the radial intra-arterial catheter and intrathecal injection techniques 
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(described below), participants were seated on a recumbent cycle ergometer and 
ventilation and gas-exchange measures were collected for five min at rest with the last 
min being used for analysis. Immediately following rest, at a cadence of 65 rpm 
participants cycled at their previously determined 65% of peak workload for five min. 
Non-active post-exercise recovery commenced for five min immediately following each 
exercise session. After recovery, but within ten min following cessation of exercise, 
assessment of central chemoreceptor sensitivity using a CO2 rebreathe technique occurred 
(described below). 
Radial intra- arterial blood pressure and gases assessment 
During study days two- and- three, blood pressures and blood gases were measured using 
radial intra-arterial catheterization. Briefly, a 20-guage Teflon catheter (FA-04020; 
Arrow International Inc., Reading, PA) was placed into a radial artery after induction of 
local anesthesia (1.0% lidocaine). Real-time blood sampling and measurement of arterial 
pressure was recorded from a pressure transducer (PXMK099; Edwards Lifesciences, 
Irvine, CA) and exported to a digital oscilloscope for offline analysis of SBP, diastolic 
blood pressure (DBP), and MAP. Partial pressure of arterial oxygen (PaO2) and CO2 
(PaCO2) were also measured from anaerobically drawn arterial blood samples from the 
same catheter over a period of 10–15 seconds at rest and immediately before cessation of 
exercise (ABL825 Flex Blood Gas/CO-ox analyzer; Radiometer America Inc., Westlake, 
OH). From these blood pressure measures with our ventilatory gas-exchange measures 
we calculated the non-invasive estimate of cardiac power (Lang et al., 2009), circulatory 
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power, adjusted for body weight as, CircP = VO2×MAP/weight (Cohen-Solal et al., 2002; 
Scharf et al., 2002; Williams, Tzeng, et al., 2005). 
Intrathecal injection to influence neural feedback from locomotor muscles, fentanyl 
versus placebo 
The following approach used in the present study was similar to the approach used in a 
variety of clinical anesthesiology settings and research laboratories, as described 
previously (Amann et al., 2009; Olson et al., 2014). Briefly, on study days two- and- 
three participants were seated in an upright position. Immediately following arterial 
catheter placement, using aseptic technique, the skin and subcutaneous tissue were 
anaesthetized at the L3—L4 vertebral interspace with 2.0–4.0 milliliters (mL) of 1.0% 
lidocaine. A 22-guage Whitaker needle was advanced to the subarachnoid space between 
L3—L4, with placement confirmed by visualization of free-flowing cerebrospinal fluid 
1.0 mL of fentanyl (0.05 milligram/mL) was injected into the subarachnoid space 
following aspiration of a small amount of cerebrospinal fluid. The participants remained 
seated in the upright position to minimize cephalad migration of fentanyl. During the 
placebo visit, with the exception of the advancement of the 22-guage Whitaker needle 
into the subarachnoid space for fentanyl injection, all procedures were identical to the 
fentanyl injection visit. 
Central chemosensitivity assessment 
To assess for cephalad migration of fentanyl in the cerebrospinal fluid we measured 
central chemosensitivity using a CO2 rebreathing method optimally timed within ten min 
following cessation of exercise. This timing, as opposed to immediately following 
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injection, was chosen because if cephalad migration in cerebrospinal fluid was to occur it 
would be most readily detectable post-exercise when sufficient time for migration had 
elapsed.  
In brief, participants breathed into a non-rebreathing three-way pneumatic switching 
valve (Hans Rudolph, Kansas City, MO) that was connected to a pneumotachometer 
(Hans Rudolph, Kansas City, MO) and gas-exchange system (MedGraphics CPX/D; 
Medical Graphics). The inspiratory port of the switching valve allowed for rapid 
switching from breathing room air to the 6.0 L anesthesia rebreathe bag (Hans Rudolph, 
Kansas City, MO) containing a gas-mixture volume of 5.0% CO2 and 95.0% O2 
depending on initial VT of the subject. Participants breathed room air for two min that 
was followed by a slow maximal expiration to residual volume where the participants 
were then switched into the rebreathe bag. Participants began with a maximal full 
inspiration of rebreathe bag air that was followed with relaxed breathing for four min.  
Continuous measures of PETCO2, end-tidal partial pressure of oxygen (PETO2), and VE 
occurred. The test was stopped prior to the conclusion of the four min maneuver period if 
one of the following occurred: PETCO2 of 65.0 mm Hg; PETO2 of 160.0 mm Hg; VE of 
100 L/min; or participant wished to stop. The sensitivity to CO2 was assessed using the 
slope of the relationship between measures of VE and PETCO2. On study days two- and- 
three, the CO2 rebreathe test was performed three separate times with three- to- five min 
of exposure to room air to allow VE and PETCO2 to return to baseline between measures. 
Statistical analysis 
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All data are presented at means ± standard deviation (SD). Normality and homogeneity of 
variance of the data was assessed and met using Levene’s test. Specific comparison 
between groups (i.e. controls vs. HF) or conditions (i.e. rest vs. exercise or fentanyl vs. 
placebo) were compared using unpaired and paired two-tailed Student’s t-tests, 
respectively. Multiple comparisons for time, group, and condition effects were tested 
using the repeated measures two-way analysis of variance test. In the occurrence of a 
significant F-test statistic, a correction for multiple comparisons using the post-hoc 
Bonferroni test was used to identify significance between specific comparisons. The 
alpha level was set at 0.05 to determine significance. Computations were made using 
SAS statistical software, v.9.4 (SAS Institute, Cary, NC). 
Results 
Participant characteristics 
Participant characteristics are presented in Table 1. Participants were predominantly male 
in both groups with an overall age range of 52- to-73. Height did not differ between 
groups, whereas controls weighed on average ~18.0% less than HF which contributed to 
the differences in BMI and body surface area between groups. Ejection fraction 
percentage was characteristic of systolic HF (range = 20.0–35.0%). Exercise capacity was 
significantly reduced in HF compared to controls (peak oxygen consumption [VO2peak], 
range = 14.0–23.1 vs. 22.0–36.7 mL/kg/min, respectively; P<0.05). Heart failure patients 
were of New York Heart Association (NYHA) classification range I–III, ischemic or 
idiopathic etiology, and optimally medicated for HF using standard pharmacological 
therapy. 
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Baseline ventilation and hemodynamics 
Baseline measures of ventilation and hemodynamics for both groups and experimental 
conditions are presented in Table 2. There was no difference in VE, VT, fB, or PETCO2 
between HF and controls (P>0.05, for all). Heart rate did not differ significantly between 
or within groups, whereas SBP, DBP, and MAP were lower in HF versus controls 
(P<0.05, for all). Because of the predominately lower blood pressure in HF, CircP was 
significantly lower in HF versus controls. 
Exercise ventilation and hemodynamics 
Exercise intensity, ventilation, and hemodynamic measures averaged over the final 30 
seconds of exercise for both groups and experimental conditions are presented in Table 3. 
Although there was a significant difference in exercise workload between groups, 
percentage of VO2peak between groups was not different (P>0.05). Lack of significant 
differences between groups and experimental conditions for VO2 and VCO2 were also 
reflected in RER. This lack of difference demonstrates that the groups were well matched 
for metabolic intensity. Whereas, although no significant differences appeared for VCO2 
and VT, there were significant differences for VE in HF with fentanyl versus controls with 
fentanyl. The average difference for PETCO2 between experimental conditions for HF was 
7.2±0.1 mm Hg (P<0.05), whereas the average difference for controls was 2.1±0.8 mm 
Hg (P>0.05).  
The significantly lower HR for HF versus controls contrasted non-significant differences 
in O2pulse, but shared a similar pattern for significant differences in CircP before 
adjustment for workload. Although, differences in O2pulse at end-exercise were 
157 
 
consistent with baseline O2pulse differences between HF and controls (P>0.05). 
Significant reductions in SBP and DBP in HF with fentanyl versus placebo likely 
contributed to significant reductions in MAP in this same comparison. Unexpectedly, 
after adjustment for workload, CircP was similar across groups and experimental 
conditions (P>0.05). Whereas, O2pulse and GXCAP for HF were greater versus controls 
after adjustment for workload (P<0.05). Differences in unadjusted CircP for HF between 
experimental conditions was 48±76 mL/kg/min ∙ mm Hg (P>0.05), and in controls was 
247±55 mL/kg/min ∙ mm Hg (P>0.05). Unadjusted differences in GXCAP between 
experimental conditions in HF was 142±62 mL/beat ∙ mm Hg (P<0.05), and in controls 
this difference was 62±47 mL/beat ∙ mm Hg (P>0.05). The significantly greater PETCO2 
in HF with fentanyl versus placebo appeared to contribute to the baseline to end-exercise 
rate of change difference for GXCAP in HF with fentanyl versus placebo (P<0.05). There 
was no significant rate of change difference for GXCAP between experimental conditions 
in controls. 
The absolute change (∆) from baseline to end-exercise for CircP and GXCAP comparing 
groups and experimental conditions are shown in Figure 1 (A and B). The percentage 
increase from baseline to end-exercise for CircP and GXCAP comparing groups and 
experimental conditions are shown in Figure 2 (A and B). Presented in Figure 3 (A and 
B) are the averages for CircP and GXCAP during the exercise period in 30 second 
intervals, while also comparing group differences as well as differences between 
experimental conditions for HF and controls. 
Discussion 
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In this randomized, single-blind, placebo-controlled crossover study, it was observed that 
inhibition of centrally projecting neural feedback from locomotor muscle group III/IV 
nerve fibers using intrathecal fentanyl during constant-load submaximal exercise 
improved GXCAP (i.e. pulmonary vascular pressures) (Taylor, Olson, et al., 2013) in HF. 
In contrast, despite an apparent influence on both pulmonary and peripheral vascular 
pressures, inhibition of neural feedback from locomotor muscle group III/IV nerve fibers 
during exercise did not appear to evoke increases in myocardial contractility and/or 
hemodynamics (i.e. O2pulse and CircP) (Cohen-Solal et al., 2002; Scharf et al., 2002; 
Taylor, Olson, et al., 2013; Williams, Tzeng, et al., 2005) in HF.   
In an attempt to restore or maintain central hemodynamic homeostasis during exercise, 
the cardiovascular system relies on the ANS for augmented adrenergic drive. This acute 
feedback response of the sympathetic nervous system during times of hemodynamic 
instability is influenced by neural feedback from group III/IV nerve fibers found 
dispersed within skeletal muscle, and observed to contribute to the sustained maintenance 
of cardiac and cardiovascular function during exercise in healthy individuals (Amann et 
al., 2011; Amann et al., 2009; Crisafulli et al., 2011; Fisher et al., 2010). In HF, this 
integrated physiology regulating the interaction between neural feedback from group 
III/IV nerve fibers and the ANS is impaired and contributes to persistently elevated 
adrenergic drive at rest which is exacerbated during exercise (Amann et al., 2014; Keller 
et al., 2014; Olson et al., 2014; Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999). 
Moreover, and of clinical significance, our group and others have demonstrated that this 
impaired neural feedback pathway contributes to detrimental changes in ventilatory and 
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peripheral vascular control in patients with HF (Amann et al., 2014; Keller et al., 2014; 
Olson et al., 2014; Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999). To date, 
however, limited data exists on the impact of neural feedback from skeletal muscle group 
III/IV nerve fibers on changes in central hemodynamics during exercise in human HF 
(Amann et al., 2014). Therefore, a major finding of the present study suggests that GXCAP 
(i.e. pulmonary vascular pressures) (Taylor, Olson, et al., 2013) is improved by neural 
inhibition during exercise in HF. This extends findings from two previous studies which 
demonstrate neural feedback from skeletal muscle contribute to increased mPAP during 
and immediately following submaximal exercise in healthy individuals (Lykidis et al., 
2008; White et al., 2013). 
Because of close relationships that pulmonary blood flow shares with mixed venous CO2 
content, mPAP, PVR, and PETCO2 (Shibutani et al., 1994; Taylor, Olson, et al., 2013), the 
present observations in HF suggest that exercise with intrathecal fentanyl decreased 
mPAP as reflected by an increase in PETCO2 measured with gas-exchange. The higher 
GXCAP observed during exercise with intrathecal fentanyl in HF during the present study 
was likely attributable to attenuations in both mPAP and PVR since O2pulse (i.e. product 
of stroke volume and arteriovenous oxygen difference) (Cohen-Solal et al., 2002; Taylor, 
Olson, et al., 2013) remained unchanged compared to the placebo condition. In further 
support of this mechanism in HF, occurring in parallel with increases in PETCO2 during 
exercise with intrathecal fentanyl were significant reductions in systemic arterial 
pressure.  
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Although healthy individuals in the present study did not demonstrate a change in GXCAP 
during exercise with intrathecal fentanyl similar to the observations of Lykidis et al. 
(2008) and White et al. (2013) during exercise in healthy individuals, it is important to 
point out that the techniques utilized in these previous studies differed considerably from 
the current study (Lykidis et al., 2008; White et al., 2013). Lykidis et al. (2008) and 
White et al. (2013) stimulated neural feedback responses from group IV (and perhaps 
group III) afferents during exercise using regional circulatory occlusion (RCO) of 
exercising limbs (Lykidis et al., 2008; White et al., 2013). Additionally, previous studies 
comparing mPAP responses between exercise with RCO versus RCO not associated with 
exercise (either during or after), with the latter condition known to not generate a 
significant pressor response (Lykidis et al., 2008; White et al., 2013). In contrast, the 
present cross-over study used neural feedback inhibition during exercise which were 
compared to a matched exercise session with placebo. Hence, comparing the influence of 
neural feedback from locomotor muscle afferents on vascular responses between RCO 
with exercise and RCO independent of exercise may overestimate the influence of neural 
feedback from skeletal muscle group III/IV nerve fibers on vascular pressures relative to 
the observations of the present study (Lykidis et al., 2008; White et al., 2013). 
Nevertheless, observations during post-exercise+RCO by Lykidis et al. (2008) and White 
et al. (2013) are consistent with the present exercise+placebo hemodynamic circulatory 
findings (Lykidis et al., 2008; White et al., 2013), in addition to recently reported 
evidence by our group which suggests that stimulation of the metaboreflex using RCO 
immediately following exercise in HF patients contributes to increased peripheral arterial 
pressure (Keller et al., 2014). 
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Although not measured directly, we assume based on the observations from other studies 
of HF during exercise that peripheral vascular reactivity and permeability was not 
completely impaired in the present HF sample (Wilson, Martin, Schwartz, & Ferraro, 
1984; Zelis, Mason, & Braunwald, 1969). It is likely that increased vascular conductance 
and decreased systemic vascular resistance during exercise with intrathecal fentanyl lead 
to a reduction in afterload and mPAP in HF. These changes would be expected to 
facilitate an improvement in cardiac output and contribute to the maintenance of arterial 
pressure. However, inhibition of locomotor muscle neural feedback did not influence 
significant inotropic and/or chronotropic increases which is suggested by null increases in 
O2pulse (Cohen-Solal et al., 2002; Taylor, Olson, et al., 2013), CircP (Scharf et al., 2002; 
Williams, Tzeng, et al., 2005), or HR during exercise in HF; which, also considering 
blood pressure responses (i.e. ↓ afterload) further suggests that myocardial contractile 
reserve is not influenced by neural feedback from locomotor muscle group III/IV nerve 
fibers in patients. The comparable O2pulse between HF and control participants at 
baseline was likely caused by the presence of larger ventricular cavities related to dilated 
cardiomyopathy, and not because of preserved cardiac function since patients also 
demonstrated significantly attenuated CircP at rest and at end-exercise as well as reduced 
HR at end-exercise in comparison to control participants.  
Cardiac pumping capacity is impaired in HF at rest and during exercise despite 
heightened cardiac adrenergic drive (Bristow et al., 1982; Dickstein et al., 2008; Lang et 
al., 2009). This is suggested to be related to impaired mechanisms intrinsic to HF such as 
a failing Frank—Starling mechanism (related to ischemic wall segments and/or 
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dysfunctional cardiac β-adrenergic receptors) (Bristow et al., 1982; Eisenhofer et al., 
1996; Komamura et al., 1993; Rose et al., 1983; Schwinger et al., 1994). Therefore, 
because HF patients are commonly regarded as being afterload dependent (i.e. limited 
myocardial contractile reserve), this suggests that augmented afterload associated with 
exercise should attenuate the ability of cardiac hemodynamics to contribute to the 
increase of systemic arterial pressure. However, our present findings suggest cardiac 
function is less dependent on the response of the systemic vasculature to the influences of 
neural feedback from locomotor muscle group III/IV nerve fibers during exercise in HF. 
The lack of increase in cardiac hemodynamics despite a decrease in afterload during 
exercise with intrathecal fentanyl was likely related to mechanisms associated with 
limited myocardial contractile reserve in HF, which could also explain why elevated 
adrenergic drive associated with neural feedback from locomotor muscle group III/IV 
nerve fibers had little influence on inotropy and SV during exercise.  
Clinical Implications 
The present findings suggest that neural feedback from locomotor muscle group III/IV 
nerve fibers contributes to pulmonary vascular pressures independent of cardiac 
hemodynamic status during submaximal exercise in HF; and, perhaps more importantly, 
may provide further insight into the mechanisms contributing to exertion-related 
symptomology at work intensities equivalent to those of daily living. These observations 
are also important because it is well-accepted that HF patients commonly develop 
secondary PH which is closely linked to increased morbidity and mortality (Abramson et 
al., 1992; Aronson et al., 2011; Ghio et al., 2001; Moraes et al., 2000). The current 
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findings extend those of others by highlighting a novel contributory mechanism of 
secondary PH in HF.  
Limitations 
The patients in the present study are characterized as NYHA class I-III, whereas NYHA 
class IV patients exhibit more severe cardiac and/or pulmonary impairment in parallel 
with diminished vascular health which are commonly associated with signs and 
symptoms at rest and during low-level activity. Therefore, while it might be expected that 
the findings of the present study would be exacerbated in patients exhibiting increased 
exertional symptoms, these data are only generalizable to the patients studied. Further 
research is necessary to confirm our findings in a larger patient population. Also, 
although we did not directly assess sympathetic nervous system activity during exercise, 
the intrathecal fentanyl technique has been used previously to inhibit group III/IV neural 
feedback during exercise in healthy individuals and HF patients (Amann et al., 2009; 
Amann et al., 2014; Olson et al., 2014). Finally, although O2pulse is a validated surrogate 
of SV (Taylor, Olson, et al., 2013), and CircP for cardiac power in HF (Scharf et al., 
2002; Williams, Tzeng, et al., 2005), we did not directly measure SV or Q in the current 
study. Nevertheless, cardiac power and its estimate CircP are suggested to be robust 
indicators of cardiac hemodynamic function (Cohen-Solal et al., 2002; Lang et al., 2009; 
Scharf et al., 2002; Williams, Tzeng, et al., 2005), and therefore it is important to point 
out that our use of indirect indices were adequate to address our study objectives since we 
aimed to study relative changes in central hemodynamics between experimental 
conditions as opposed to absolute capacities. 
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Conclusion 
In conclusion, the findings of the present study suggest that inhibition of neural feedback 
from group III/IV nerve fibers originating within locomotor muscles using intrathecal 
fentanyl during submaximal exercise improves pulmonary vascular pressures 
independent of changes in cardiac function. 
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Tables 
 
  
Table 1: Participant characteristics   
 Healthy Control Heart Failure P 
Demographics    
Age, years 63±8 60±6 0.37 
Gender, male/female 7/2 7/2 1.00 
Height, cm 175.7±9.8 175.9±9.5 0.97 
Weight, kg 80.1±12.4 97.8±9.2 0.003 
BMI, kg/m2 25.9±3.4 31.9±4.4 0.005 
BSA, m2 2.0±0.2 2.2±0.1 0.02 
VO2peak, mL/kg/min 26.8±5.2 18.4±2.8 0.001 
LVEF, %  26.7±5.7  
Etiology (ischemic/idiopathic)  5/4  
NYHA class  1.9±0.8  
I  3  
II  3  
III  3  
Medications    
ACE inhibitor  6 (67)  
Angiotensin II receptor 
blockers 
 3 (33)  
β-blocker  9 (100)  
Aspirin  5 (56)  
Diuretics  6 (67)  
Data are mean±SD or as n (%).ACE, angiotensin converting enzyme; BMI, body mass index; 
BSA, body surface area; LVEF, left ventricular ejection fraction; NYHA, New York Heart 
Association. 
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Table 2: Resting measures    
 Healthy Control Heart Failure 
 Placebo Fentanyl Placebo Fentanyl 
Ventilation and gas exchange    
VO2, L/min 0.34±0.03 0.33±0.07 0.36±0.03 0.38±0.05 
VCO2, L/min 0.31±0.03 0.30±0.05 0.34±0.04 0.36±0.05 
RER 0.87±0.08 0.85±0.04 0.94±0.09 0.94±0.09* 
VE, L/min 12±2 12±2 14±2 13±2 
VT, L 0.76±0.11 0.72±0.14 0.74±0.12 0.75±0.07 
fB, breaths/min 17±3 18±4 19±2 18±2 
PETCO2, mm Hg 34.9±2.2 35.2±3.0 36.5±8.2 38.8±4.5 
Hemodynamics     
HR, beats/min 73±13 72±9 70±10 70±17 
SBP, mm Hg 148±17 145±18 122±9* 115±8* 
DBP, mm Hg 68±10 64±8 59±8* 57±9* 
MAP, mm Hg 95±11 91±10 80±6* 76±8* 
O2pulse, mL/beat 4.9±1.1 4.7±1.2 5.3±0.8 5.6±1.1 
CircP, mL/kg/min ∙ mm Hg 411±70 381±80 299±38* 300±53* 
GXCAP, mL/beat ∙ mm Hg 170±41 165±45 191±47 216±35* 
Data are presented as means±SD. CircP, circulatory power; DBP, diastolic blood pressure; 
VO2, oxygen consumption; fB, breathing frequency; GXCAP, pulmonary vascular capacitance; 
HR, heart rate; MAP, mean arterial pressure; O2pulse, oxygen pulse; PETCO2, end-tidal partial 
pressure CO2; RER, respiratory exchange ratio; SBP, systolic blood pressure; VCO2, carbon 
dioxide production; VE, minute ventilation; VT, tidal volume. *p<0.05 compared with control 
after Bonferroni correction. 
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Table 3: End-exercise measures    
 Healthy Control Heart Failure 
 Placebo Fentanyl Placebo Fentanyl 
Exercise intensity     
Workload (watts) 120±37 - 78±23* - 
Percent of VO2peak 77±13 77±13 82±14 84±15 
Ventilation and gas exchange    
VO2, L/min 1.7±0.4 1.7±0.5 1.5±0.3 1.5±0.3 
VCO2, L/min 2.0±0.5 2.0±0.5 1.5±0.3 1.6±0.3 
RER 1.09±0.06 1.08±0.05 1.05±0.02 1.04±0.04 
VE, L/min 63±16 63±19 51±9 45±10* 
VT, L 2.1±0.6 2.1±0.6 1.7±0.4 1.7±0.3 
fB, breaths/min 30±4 30±5 33±12 26±5 
PETCO2, mm Hg 37.1±2.7 39.2±3.5 36.3±3.6 43.5±3.7*† 
Hemodynamics     
HR, beats/min 131±15 125±21 99±19* 97±21* 
SBP, mm Hg 239±20 225±26 161±24* 152±29*† 
DBP, mm Hg 75±9 66±6 62±9* 56±11*† 
MAP, mm Hg 130±6 119±8 95±11* 88±15*† 
O2pulse, mL/beat 12.8±3.5 13.9±4.9 15.1±2.5 16.0±4.3 
O2pulse, watts
-1 0.11±0.02 0.11±0.02 0.22±0.1* 0.22±0.06* 
CircP, mL/kg/min ∙ mm Hg 2721±618 2475±673 1413±257* 1365±333* 
CircP, watts-1  23.3±6.0 21.0±4.2 20.0±8.4 19.9±9.4 
GXCAP, mL/beat ∙ mm Hg 474±130 536±177 549±115 691±176† 
GXCAP, watts
-1  3.9±0.6 4.3±0.8 7.9±3.4* 9.5±3.0* 
Slope 
O2pulse, mL/beat 1.59±0.53 1.83±0.80 1.96±0.39 2.08±0.66 
CircP, mL/kg/min ∙ mm Hg 462±125 419±127 223±50* 212±66 
GXCAP, mL/beat ∙ mm Hg 61±19 74±29 72±18 95±30† 
Data are presented as means±SD. CircP, circulatory power; DBP, diastolic blood pressure; 
VO2, oxygen consumption; fB, breathing frequency; GXCAP, pulmonary vascular capacitance; 
HR, heart rate; MAP, mean arterial pressure; O2pulse, oxygen pulse; PETCO2, end-tidal partial 
pressure CO2; RER, respiratory exchange ratio; SBP, systolic blood pressure; VCO2, carbon 
dioxide production; VE, minute ventilation; VT, tidal volume; slope = rate of change baseline 
to end-exercise; *p<0.05 compared with control after Bonferroni correction; †p<0.05 
compared with placebo after Bonferroni correction. 
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Figure Captions 
Figure 1: Data are presented as means±SD (A) Absolute change (Δ) circulatory power 
(CircP) from rest to end-exercise. *Significant between groups, heart failure vs. control, 
p<0.05. (B) Δ in GXCAP from rest to end-exercise. *Significant between fentanyl and 
placebo for heart failure, p<0.05. 
Figure 2: Data are presented as means±SD. (A) Circulatory power (CircP) at end-exercise 
as a percentage (%) of CircP at baseline.  *Significant between groups, heart failure vs. 
control, p<0.05. (B) Pulmonary vascular capacitance (GXCAP) at end-exercise as a % of 
GXCAP at baseline. *Significant between fentanyl and placebo for control, p<0.05.  
Figure 3: Data are presented as means±SD. (A) HF, heart failure; CTL, control. Pattern of 
change for circulatory power (CircP) as increments of 30 second averages from rest to 
end-exercise. *p<0.05, HF-Fentanyl vs. CTL-Fentanyl and HF-Placebo vs. CTL-Placebo. 
(B) Pattern of change for pulmonary vascular capacitance (GXCAP) as increments of 30 
second averages from rest to end-exercise *p<0.05, HF-Fentanyl vs. CTL-Fentanyl. 
†p<0.05, HF-Fentanyl vs. HF-Placebo. 
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Chapter 4  
Overall discussion 
Heart failure is a debilitating syndrome that influences all organ systems and is overtly 
expressed with both signs and symptoms unique to this illness. Importantly, this 
syndrome is associated with an increased risk for morbidity and premature mortality 
(Dickstein et al., 2008; Paulus et al., 2007; Roger et al., 2012). The consequences of HF 
are multifactorial and complicated. Included amongst the generally recognized symptoms 
of HF are dyspnea and fatigue, whereas objective signs of HF include abnormal cardiac 
hemodynamics (e.g. low Q and SV) (Dickstein et al., 2008; "Heart Failure Society of 
America (HFSA) practice guidelines. HFSA guidelines for management of patients with 
heart failure caused by left ventricular systolic dysfunction--pharmacological 
approaches," 1999; Paulus et al., 2007; Remme, Swedberg, Task Force for the, & 
Treatment of Chronic Heart Failure, 2001). However, despite the current knowledge of 
HF, it remains unclear what primarily mediates exercise intolerance, as well as the 
magnitude of relationships between cardiac pumping capability and syndrome severity 
and prognosis in HF. As such, although it is known that no single factor mediates the 
signs, symptoms, or prognosis in HF, a more comprehensive understanding of specific 
factors (e.g. exercise intolerance and central hemodynamics) pertaining to their 
contribution to the clinical classification of HF is critical because of the impact this 
knowledge could have on diagnosis and therapeutic regimen of patients. Accordingly, the 
measurement of central hemodynamic function during exercise provides invaluable 
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information about the magnitude of impairment of cardiac pumping capability as well as 
overall functional capacity in HF; but, equally important, this information is closely 
related to prognosis in these patients (Bain et al., 1990; Franciosa et al., 1981; Lang et al., 
2009; Szlachcic, Massie, et al., 1985; Williams, Jackson, et al., 2005).  
The first of several objectives outlined in this dissertation was to provide a 
comprehensive review of the traditional and non-traditional measurements used to 
describe central hemodynamics in humans. There is considerable variability in the body 
of literature concerning how to best describe the blood flow and pressure generating 
capability of the heart, which is also closely related to the issue of how to describe the 
hemodynamic relationship the heart shares with pulmonary vasculature. Due to of the 
complexity of factors known to influence human central hemodynamics, many efforts 
were made to identify and study those that are not only influential in adjusting central 
hemodynamics, but also functionally contrasting in HF compared to healthy individuals. 
Thus, it could be concluded that although each index is not without its own assumptions, 
non-traditional parameters of central hemodynamics add valuable information about the 
blood flow and pressure generating capability of the heart in HF and in healthy 
individuals (Bain et al., 1990; Cohen-Solal et al., 2002; Jakovljevic et al., 2012; Lang et 
al., 2009; Taylor, Olson, et al., 2013; Williams, Tzeng, et al., 2005). Non-traditional 
central hemodynamic indices appear to be sensitive to the integrative influence that 
hemodynamics share with pressure and loading of the central and peripheral circulation 
in HF, particularly during exercise. 
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Because less is known about the usefulness of certain techniques in HFpEF compared to 
HFrEF, the aim of the first project sought to examine specific non-invasive techniques for 
the quantification of cardiac hemodynamics during exercise in HFpEF. Observations 
from this project suggested that SV measured using ECHO, acetylene rebreathe, and 
O2pulse methods could be adequately accomplished during peak exercise testing in 
HFpEF. Moreover, because the efficacy of the acetylene rebreathe technique is 
potentially dependent on the ability of acetylene gas to diffuse freely across the alveolar-
capillary membrane barrier, and because HFpEF demonstrate low gas transfer capacity 
within lungs (Olson et al., 2008), we sought to study relationships between gas transfer 
capacity within lungs and acetylene rebreathe measurements of SV in these patients. We 
observed that there was no direct association between gas transfer capacity within lungs 
and acetylene rebreathe measurements of SV at peak exercise in HFpEF. These were 
important observations because of the information that can be garnered from exercise 
cardiac hemodynamics for the clinical classification of HF; and, because of the clinical 
implications that non-invasive techniques have in terms of offering widely available and 
reliable methods for cardiac hemodynamic assessment in both clinical and research 
settings.        
The second and third projects in Chapter three of this dissertation focused in on the 
“Muscle Hypothesis” in HF (Piepoli, 1998; Piepoli et al., 2008; Piepoli et al., 1999). The 
“Muscle Hypothesis” suggests that peripheral neural factors are highly influential in 
contributing to abnormal ANS function and ventilatory and peripheral hemodynamic 
control and, hence, exercise intolerance in HF (Middlekauff et al., 2004; Olson et al., 
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2014; Olson, Joyner, & Johnson, 2010; Piepoli et al., 1999; Scott, Davies, et al., 2002). 
However, while the evidence is convincing that neural feedback from group III and IV 
sensory fibers could be responsible for ventilatory inefficiency and hypertension during 
exercise in HF, it is controversial whether this peripheral neural feedback pathway 
contributes to exacerbated central hemodynamic function during exercise in these 
patients (Amann et al., 2014; Ansorge et al., 2005; O'Leary et al., 2004).  
We observed using two separate but previously used techniques for manipulating neural 
feedback from skeletal muscle ergoreceptors (i.e. RCO or intrathecal fentanyl) that the 
cardiac hemodynamic response to this peripheral neural mechanism was in contrast to 
previous observations of cardiovascular responses to skeletal muscle ergoreceptor 
activation in HF (Amann et al., 2011; Amann et al., 2014; Olson et al., 2014; Olson, 
Joyner, & Johnson, 2010; Piepoli et al., 1996; Piepoli et al., 2008; Scott, Francis, et al., 
2003). As such, the observations from projects 3.2 and 3.3 suggest that 
sympathoexcitation associated with the activation of skeletal muscle metabo- or 
mechano-reflexes are not facilitatory in the cardiac hemodynamic responses observed 
during exercise in HF.  
However, it is conceivable that the perceived lack of response of cardiac hemodynamics 
to ergoreceptor-mediated sympathoexcitation was not necessarily absent altogether. The 
ergoreceptor pathway may have influenced cardiac function at the onset of exercise and 
assisted in maintaining cardiac function throughout the remainder of exercise as well as 
during recovery in HF. The myocardium likely was still receiving ergoreceptor-mediated 
sympathetic drive, but because of cardiac impairment that is common to HF such as 
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failure of the Frank—Starling mechanism (attributable to a combination of cardiac β-
adrenergic receptor dysfunction as well as ischemic/necrotic tissue), the heart was 
incapable of increasing pumping capability beyond its intrinsic reserve capacity 
irrespective of augmented cardiac adrenergic drive (Bristow et al., 1982; Bristow et al., 
1986; Kitzman et al., 1991; O'Leary et al., 2004). Although it also suggested that 
energetics of the myocardium are inefficient and potentially influential in lowering the 
working capacity of the heart in HF (Eichhorn et al., 1990), there is no strong support to 
suggest that acute augmentation of adrenergic drive to the heart (e.g. via EPR or inotropic 
therapy) would lower cardiac pumping capability in patients (Maskin, Forman, 
Sonnenblick, Frishman, & LeJemtel, 1983; O'Leary et al., 2004). Lastly, although still 
unclear amongst scientists, it remains possible that metaboreceptor sensitivity is not 
blunted in HF (Li et al., 2004; Smith et al., 2003; Smith, Williams, et al., 2005); but, in 
contrast, metaboreceptors may be hyper-excitable and could explain the elevated CircP 
during normal recovery in HF patients in project 3.2 (Piepoli et al., 1996; Piepoli et al., 
2008; Piepoli et al., 1999). Whereas, similarities in CircP during exercise with or without 
intrathecal fentanyl in project 3.3 likely occurred because of the influence of tonic 
sympathoexcitation that is native to HF. Thus, for reasons mentioned previously, 
blocking neural feedback from locomotor muscles likely had little influence on global 
cardiac adrenergic drive in HF, which is supported by observations of null differences in 
HR between exercise conditions as well.   
Based on the pulmonary hemodynamic responses demonstrated by HF and healthy 
individuals in projects 3.2 and 3.3 we suggest that peripheral neural feedback from group 
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IV and perhaps also group III afferents are be instrumental in adjusting pulmonary 
hemodynamics during exercise in humans.  However, despite HF and healthy individuals 
demonstrating adjustments in GXCAP, it was unclear based on these observations what the 
functional purpose was of the ergoreceptor pathway potentially influencing increases in 
pulmonary pressures (e.g. mPAP). Although, increases in pulmonary pressures due to 
activated ergoreceptors could possibly be protective to pulmonary vasculature since these 
vessels are known to have high compliance in healthy individuals (e.g. ↓ vessel 
loading/distention) (Lykidis et al., 2008; White et al., 2013).  
Lastly, the pulmonary hemodynamic response to exercise with intrathecal fentanyl as 
well as during post-exercise recovery with RCO suggests that there may be an important 
synergistic interaction between neural feedback from ergoreceptors with neural feedback 
from central chemoreceptors as suggested previously by observations in healthy 
individuals during ergoreceptor activation concurrent with hypercapnia (Bruce & White, 
2012; Lykidis, Kumar, Vianna, White, & Balanos, 2010). Minor hypocapnia which may 
occur during exercise or RCO without clamping PETCO2 could be enough to attenuate the 
activity of the central chemoreflex that in-turn could augment the influence of neural 
feedback from ergoreceptors on reflexes of the entire pulmonary system (i.e. ventilation 
and hemodynamics) (Keller et al., 2014; Olson, Joyner, & Johnson, 2010). This could 
help to support observations suggesting that the sensitivity of skeletal muscle 
metaboreceptors are blunted in HF and hence require an integrating influence from other 
mechanisms in order to contribute to abnormal cardiovascular responses (Sterns et al., 
1991). Thus, given the anatomical and physiological relationship that terminating neural 
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feedback from chemoreceptors and ergoreceptors share within the NTS region of the 
medullary center this may well be a conceivable relationship (Donoghue, Felder, Jordan, 
& Spyer, 1984; Nattie & Li, 2002; Paton, Deuchars, Li, & Kasparov, 2001; Potts et al., 
1999). The potential synergistic relationship between central chemoreceptors and muscle 
ergoreceptors is supported currently by the post-exercise recovery GXCAP response 
during RCO+CO2 (versus NR and RCO) as well as during exercise with intrathecal 
fentanyl in both HF and healthy individuals. Although the magnitude of influence that 
neural feedback from central chemoreceptors would appear less in healthy individuals 
versus HF, it is reasonable to suggest that even a slight elevation in the activity of central 
chemoreflex could have profound effects on the influence of neural feedback from 
ergoreceptors on pulmonary ventilatory and hemodynamic function in HF. 
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Chapter 5  
Limitations 
5.1 Introduction 
The research encompassing dissertation requires highly technical methodology in 
addition to in-depth knowledge of unique factors related to human physiology and 
pathophysiology. Accordingly, during the course of research and interpretation of data a 
number of standard assumptions were made which may have influenced the outcomes of 
this dissertation. However, every attempt was made to minimize the influence of known 
and unknown confounding factors which could have had an impact on the results the 
three studies included in this dissertation. Nevertheless, several of the factors which could 
potentially limit the applicability and/or generalizability of the present findings may be 
related to the participants tested in these studies. For each of these studies we did not 
include in the experimental sample HF from all four NYHA class groups (i.e. NYHA I/II 
display no or limited symptomology during low- to- moderate levels of physical activity 
compared to NYHA III/IV patients who exhibit more severe signs and symptoms at rest 
and during exercise), nor did we include both HFrEF and HFpEF in each study. These 
shortcomings influence the generalizability of the present observations across all HF 
conditions and therefore future study designs should consider this limitation.   
Other considerations that could have influenced the interpretability of the present 
findings are more specific to each study and/or methodology utilized to test study 
objectives. Still, despite potential limitations unique to each study, it was believed that 
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during inception of individual study designs and during execution of each protocol that 
all considerations were made in order to minimize imposing challenges to the 
interpretability of resulting observations.   
5.2 Validity of non-traditional indices 
The observations from studies which have tested non-traditional indices of central 
hemodynamics during exercise are encouraging that these metrics are indeed robust 
indicators of cardiac pumping capability (Bain et al., 1990; Bhella et al., 2011; Cohen-
Solal et al., 2002; Jakovljevic et al., 2012; Lang et al., 2009; Williams, Tzeng, et al., 
2005). However, despite promising findings in both healthy individuals and in HF, there 
is currently a limited body of evidence to support consistent agreement that these indices 
are the best descriptors of cardiac hemodynamics in HF. Therefore it is unclear if 
measurements such as CP or CircP are valid indicators of cardiac pump function in this 
population. 
Pertinent to projects 3.2 and 3.3 in HFrEF, although it has been demonstrated that CircP 
could be an estimate for CP (and CP relates closely with Q) (Williams, Tzeng, et al., 
2005), based on the availability of resources, we did not perform more direct assessments 
of cardiac hemodynamics such as Q, SV, or CP in these individuals. Therefore, it cannot 
be ascertained with certainty whether CircP in these studies was indeed descriptive of 
cardiac pumping capability in HF and in healthy individuals. However, the relative and 
absolute differences that we observed between HF and healthy individuals suggest that 
CircP is descriptive of cardiovascular function in these patients; and, perhaps cardiac 
pump function as well. 
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Apart from the single study from our group which tested the non-invasive measurement 
of PVCAP (Taylor, Olson, et al., 2013), it is relatively unknown whether GXCAP 
consistently serves as a robust surrogate estimate for PVCAP in HF. However, if the basic 
assumptions of the factors underlying this measure are consistent (Baraka et al., 2004; 
Isserles & Breen, 1991; Maslow et al., 2001; Taylor, Olson, et al., 2013), it is reasonable 
to suggest that GXCAP is indeed a good estimate PVCAP at rest and during exercise. More 
testing of GXCAP and PVCAP is necessary to better understand the potential value of these 
measurements in describing the health of the heart–lung hemodynamic interaction during 
exercise in HF.  
5.3 Central hemodynamic techniques 
5.3.1 Echocardiography 
Although it was demonstrated in the present dissertation and by others that ECHO can be 
used to measure SV at rest and during exercise in HF, accurate and precise image capture 
at rest can be challenging and these difficulties are markedly amplified during moderate-
intensity bouts of exercise (Dittmann, Voelker, Karsch, & Seipel, 1987; Grothues et al., 
2002; Lu et al., 1992; Marwick et al., 1992). Also, there is no commonly agreed upon 
protocol or technology (e.g. M-mode, 2-D, P-wave TDI, C-wave TDI, or 3-dimensional) 
and inconsistencies in the assessment of cardiac hemodynamics are persistent (Christie et 
al., 1987; Lewis et al., 1984; Marwick et al., 1992). Mismatches of image capture, heart 
views (e.g. PLAX versus A5C), and measurement (e.g. depth in relation to the aortic 
valve and influence of chest cavity size) commonly influence the calculation of the 
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product of CSA and VTI that results in a distortion of the SV jet (Christie et al., 1987; 
Lewis et al., 1984; Marwick et al., 1992). 
Nevertheless, for studies in this dissertation, both the sonographer and ECHO reader had 
extensive experience (>10 years working with stress echocardiography data acquisition 
and interpretation) and were the same for all ECHO analyses. As such, it is suggested that 
experience and a high level of technical skill can overcome the proposed limitations 
influential to the efficacy of ECHO for SV measurement (Christie et al., 1987; Lewis et 
al., 1984; Marwick et al., 1992; Rowland et al., 1998).  
5.3.2 Acetylene rebreathe 
The use of acetylene rebreathe to assess cardiac hemodynamics during exercise has the 
potential for superiority versus ECHO because it is less user dependent and can be 
performed easily by the participant during high-levels of exercise. Still, this technique is 
not without limitations, which if not fully understood can influence the accuracy and 
reproducibility of the technique. The main concerns of this technique have to do with the 
homogenous mixing of acetylene gas within the lungs, the ability of acetylene gas to 
diffuse freely across the alveolar-capillary membrane barrier, and the potential presence 
of pulmonary shunt (e.g. exercise-independent interstitial pulmonary edema or 
obstructive disease) (Barbera et al., 2003; Friedman et al., 1984; Oelberg et al., 1998). 
These factors may have an impact on perfusion of acetylene gas into pulmonary arterial 
blood and thus lead to misrepresentation of the disappearance of acetylene gas. Also 
potentially influential to this technique would be the presence of exercise-related 
interstitial pulmonary edema which is suggested to occur in HFrEF (Agostoni et al., 
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2003; Smith et al., 1999; Tolle et al., 2008). This occurrence could influence alveolar-
capillary recruitment via abnormal VC and DM and hence prohibit the ability for acetylene 
gas to diffuse freely across the alveolar—capillary membrane barrier. 
Nonetheless, the HFpEF patients in the present dissertation were without diagnosed 
pulmonary disease and demonstrated no signs which would indicate the presence of 
pulmonary shunt or exercise-related interstitial pulmonary edema. Moreover, it was also 
demonstrated in the present dissertation that gas transfer capacity within lungs influence 
acetylene rebreathe measurements of SV at peak exercise in HFpEF.   
5.3.3 Oxygen pulse 
As discussed, the accuracy of O2pulse is highly dependent on the physiology of the 
cardiovascular system meeting specific assumptions at rest and during exercise. Most 
notably, based on the direct Fick equation, if there is considerable variability in Ca-vO2 
during steady state exercise then it is likely that VO2 could not be assumed to be a direct 
estimate of Q. This is a potential concern in a certain subset of individuals including 
clinical patients (e.g. HF, pulmonary disease, mitral valve dysfunction, anemia, and 
skeletal muscle disorders) (Katz et al., 2000; Lewis & Haller, 1989; Lim et al., 2005; 
Oelberg et al., 1998; Taylor, Olson, et al., 2013), highly-trained endurance athletes (Beck 
et al., 2006; Bhambhani et al., 1994; Crisafulli, Piras, et al., 2007), or obese individuals 
(Lavie et al., 2004). However, no observations were made in the present studies which 
suggested that the relationships depicted in the direct Fick equation were violated in HF. 
Moreover, it was observed in the first project (3.1) of this dissertation that O2pulse at 
peak exercise demonstrated close relationships with acetylene rebreathe measurements of 
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SV in HFpEF. Others before us and our group have also previously demonstrated that 
O2pulse closely relates with invasive and non-invasive measurements of SV in healthy 
individuals and HF during exercise (Bhambhani et al., 1994; Crisafulli, Piras, et al., 2007; 
Lavie et al., 2004; Lim et al., 2005; Taylor, Olson, et al., 2013).  
5.4 Manipulation of neural feedback from skeletal muscle afferents 
The influence of skeletal muscle afferents on efferent sympathetic activity has been 
demonstrated repeatedly; however we did not directly assess MSNA nor did we measure 
blood or plasma catecholamine levels in participants. Nevertheless, it has been observed 
in numerous animal and human HF studies that both the metabo- and mechano-reflexes 
are associated with abnormal firing of these neural afferents which are closely associated 
with sympathoexcitation (Amann et al., 2014; Dibner-Dunlap & Thames, 1992; Negrao 
et al., 2001; Silber et al., 1998; Sterns et al., 1991).   
5.4.1 Intrathecal fentanyl injection 
The intrathecal fentanyl injection technique used in project 3.3 has been used previously 
by our group and others in HF and in healthy individuals (Amann et al., 2010; Amann et 
al., 2008; Amann et al., 2009; Amann et al., 2014; Olson et al., 2014). Therefore, 
assumptions were made in the present study based on observations of others.  
Multiple methods have been used to block neural feedback from skeletal muscle 
including opiate narcotics and Caine anesthetics (Amann et al., 2010, 2011; Amann et al., 
2009; Besse et al., 1991; Meintjes et al., 1995; Schadt, McKown, McKown, & Franklin, 
1984). However, Caine anesthetics have been shown to reduce neuromuscular facilitation 
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whereas opiates do not appear to have an impact of efferent neuromuscular control 
(Amann et al., 2010; Amann et al., 2008; Amann et al., 2009). Thus, we suggest that 
intrathecal fentanyl (μ-opioid agonist) blocked group III and IV neural feedback to the 
brainstem without influencing central motor command associated with skeletal muscle 
force production. 
5.4.2 Regional circulatory occlusion 
The RCO technique used in project 3.3 has been used in HF and in healthy individuals 
during and immediately following exercise in these individuals (Crisafulli et al., 2011; 
Crisafulli et al., 2006; Olson, Joyner, & Johnson, 2010). Moreover, the RCO technique 
has been tested for validity in HF and in healthy individuals and it is suggested to 
adequately stimulate the metaboreflex in humans (Scott, Francis, et al., 2003). However, 
even when using RCO during static recovery in humans, it remains unclear to what 
magnitude that metabolite-specific factors stimulate metaboreceptors versus 
mechanoreceptors. Also unclear, despite the identification of numerous metabolites 
associated with sensitization of metaboreceptors (e.g. H+, pH, capsaicin, bradykinin, 
prostaglandins, K+, lactic acid, or arachidonic acid) (Clark et al., 1995; Hanna et al., 
2002; Kaufman et al., 1982; Kaufman et al., 1983; Kaufman & Rybicki, 1987; Kaufman, 
Rybicki, et al., 1984; Li & Sinoway, 2002; McCord et al., 2009; Piepoli et al., 1995; 
Rotto et al., 1989; Rybicki et al., 1984; Scott, Wensel, et al., 2003; Scott, Wensel, et al., 
2002; Stebbins et al., 1986; Victor et al., 1988), which metabolites are directly 
responsible for stimulating the metaboreflex in humans. Accordingly, in the present 
study, we did not study specific metabolic factors that could have contributed to the 
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stimulation of metaboreceptors nor did we quantify the activity of group III versus IV 
afferents in these individuals. Nevertheless, based on observations from our group and 
others previously (Crisafulli et al., 2011; Crisafulli et al., 2006; Negrao et al., 2001; 
Olson, Joyner, & Johnson, 2010; Scott, Wensel, et al., 2003; Sterns et al., 1991), the 
present observations indicate that it was primarily the metaboreflex that was activated 
during post-exercise recovery with RCO.  
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Chapter 6  
Future directions and concluding remarks 
Future directions 
The observations from the projects included in this dissertation although providing useful 
information regarding factors pertaining to the importance of central hemodynamic 
evaluation during exercise in HF, also indicate that there is clearly more opportunity to 
expand our understanding of this area of study. It would appear critical to proceed with 
continued testing of non-traditional indices of central hemodynamics using non-invasive 
techniques during exercise in HFrEF and HFpEF. Further, it would be useful in 
strengthen our understanding of the value of hydraulic power measurements  their impact 
on converting venous return into hydraulic and subsequently mechanical power in HF. 
Closely related to this would be to use this additional information to better understand 
relationships between cardiac hemodynamics and pulmonary vascular hemodynamics, 
particularly during exercise in HF. The concept of PVCAP has demonstrated usefulness in 
the clinical evaluation of PH (Mahapatra, Nishimura, Oh, et al., 2006; Mahapatra, 
Nishimura, Sorajja, et al., 2006), and based on the findings from this dissertation and 
observations from our group previously it would appear that non-invasive measurement 
of PVCAP may demonstrate value in HF (Taylor, Olson, et al., 2013). Accordingly, for the 
highest impact, it is important that the next direction for the concepts outlined and studied 
in this dissertation be aimed at the clinical and risk stratification (i.e. morbidity and 
mortality) of a large sample of HFrEF and HFpEF (NYHA class I-IV). This information, 
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although critical for all HF, could be particularly valuable in HFpEF since less is known 
about the relationships between central hemodynamics and mortality risk in this 
population. 
Our observations from projects 3.2 and 3.3 provided thought provoking ideas for 
mechanistic studies which could potentially help us and others to better understand 
relationships between neural feedback from skeletal muscle ergoreceptors and central 
hemodynamics during exercise in HF. We suggest that in future studies using the 
techniques used currently that additional conditions of exercise and recovery be added to 
potentially elucidate influences of group III versus IV neural feedback as well as 
potential influences from neural feedback from chemoreceptors on central hemodynamics 
in HF.  
Additional study conditions which might help to address questions left by the present 
observations would be to include separate clamped conditions of normoxia and 
hypercapnia, exercise with and without concurrent RCO of contractile-active 
musculature, and intra-arterial injection of sodium bicarbonate or saline during exercise 
with intrathecal fentanyl. In addition to these added factors to the current ergoreceptor 
specific techniques, hemodynamic assessment could potentially be improved by adding 
ECHO in order to non-invasively but directly estimate pulmonary hemodynamics and 
pressures. Lastly, it could be valuable to have participants perform exercise bouts of 
constant-load as well as progressive loading under the above conditions. 
The above added study conditions could strengthen our understanding of the impact of 
afferent neural feedback on central hemodynamics in HF. First, clamping PETCO2 in 
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normoxic and hypercapnic exercise conditions would help to address the potential 
influence of the central chemoreflex on the strength that the ergoreflex could possibly 
have on pulmonary hemodynamics. Second, with RCO during exercise concurrent with 
hypercapnia or normoxia, because of the possible augmentation of the metaboreflex in 
the presence of the chemoreflex, this could potentially help to quantify the contribution of 
mechanical versus metabolic specific neural feedback on pulmonary function (i.e. 
hemodynamic and ventilatory). Third, intra-arterial injection of sodium bicarbonate 
(because it is a buffer and lowers H+) versus saline could help to better understand the 
role of H+ in sensitizing ergoreceptors. Fourth, it is possible that we might get a better 
understanding of whether the sensitivity of metaboreceptors are indeed heightened in HF, 
or whether the influence of the central chemoreflex charges neural feedback from 
metaboreceptors upon integration within the medulla at the NTS. Fifth, having 
participants perform a progressive exercise test under these conditions could allow us to 
examine hemodynamic responses at anaerobic threshold, which with blood sampling 
could improve our understanding of the association of certain metabolites (e.g. lactic acid 
and H+) and the EPR in HF. Lastly, if these conditions persisted into post-exercise 
recovery, with the elimination of the mechanoreflex and central command, it is possible 
for further clarification of the possible relationship between the metaboreflex and the 
central chemoreflex on pulmonary hemodynamics. 
Concluding remarks 
In summary, observations from the projects in this dissertation suggest that non-invasive 
assessment of central hemodynamics during exercise in HF is feasible yet also adequate 
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to provide additional value to the process of the clinical evaluation of these patients. It 
could also be suggested now more than ever before that the common assessment of 
central hemodynamic function using Q, SV, and mPAP should be complemented with 
non-traditional measurements of central hemodynamics including CP, CircP, or GXCAP 
which can be assessed non-invasively while also potentially being of high prognostic 
value in HF. Finally, it is also apparent that although possibly influential in contributing 
to abnormal pulmonary hemodynamics and exercise intolerance via pathways of 
ventilatory inefficiency and hypertension in HF, the aberrant metabo- and mechano-
reflex pathways that HF patients generally demonstrate do not appear to readily influence 
adjustments in cardiac hemodynamics associated with exercise in HFrEF.       
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